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ABSTRACT

In recent years, there has been an emergence or re-emergence of Chikungunya virus
(CHIKV), a member of the alphavirus. The virus is one of the arboviruses, and it is
classified as a neglected tropical disease in more than 55 different countries in the
world, including many African and Asian countries, Europe, Americas, and Australia.
In 2008, it was listed in the US National Institute of Allergy and Infectious Disease
(NIAID) category C priority pathogen due to its morbidity and mortality rates. In
addition to damaging global health, the virus also imposes a huge economic burden on
affected countries. However, there is currently no licensed vaccine or effective drug to
combat the disease. Up to now, there have been few studies focusing on finding
potential inhibitors of CHIKV. Taking advantage of all available data about CHIKV and
a combination of different computational methods, this study aimed to discover and
develop an approach leading to identifying inhibitors against this virus. The study
targeted the non-structural proteins, nsP3 macrodomain and nsP2 protease, which play
crucial roles in the viral replication and transcription (Chapter 2 and Chapter 3), and the
envelope glycoprotein complexes responsible for virus entry and attachment (Chapter
4). Initially, this study searched for potential binding pockets of the CHIKV protein
structures. A combination of computational tools including molecule docking, virtual
screening, molecule dynamics simulations, and binding free energy calculations were
used in this approach. A number of lead compounds to fight CHIKV disease were
identified. The insights into the interactions between CHIKV inhibitors and their targets
were elucidated. Our findings open a way which would be helpful for the further
research on antiviral rational drug design, especially design of inhibitors for CHIKV
and also contribute to the guidelines for the drug discovery and development.
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CHAPTER 1.

INTRODUCTION

1.1 OVERVIEW OF CHIKUNGUNYA VIRUS
1.1.1

GLOBAL EXPANSION OF CHIKUNGUNYA DISEASE

Chikungunya disease is caused by the chikungunya virus (CHIKV), one of the
arthropod-borne viruses (arboviruses, or virus spread by mosquitoes) that has emerged1-2
or re-emerged3-4 in recent years. This virus is considered a neglected tropical disease; in
2008, it was listed as a category C priority pathogen by the US National Institute of
Allergy and Infectious Diseases (NIAID) due to its morbidity and mortality rates.5 The
CHIKV produces a dengue-like illness, which may lead to misdiagnosis. The disease is
non-fatal,6 however its debilitating symptoms such as fever, rash, headache, myalgia
(muscle pain), and arthralgia cause enormous health problems,7 affecting millions of
people in nearly 55 different countries around the world.8 Importantly, the
polyarthralgia can exist in some infected patients for months.7, 9-10 The history of the
virus shows the first recorded case was in Tanganyika, Africa, in 1952.11 An
explanation for the name CHIKV is that it was derived from a local dialect, meaning
“that which bends up”11 in order to describe the stooped posture of patients who suffer
from joint pains for weeks to years.6, 11 The virus has been largely neglected due to its
sporadic re-emergence,4,

6

however it has recently attracted interest given a rise in

epidemics occurring since 2006 in different countries; from Africa to Asia, Europe,
Americas, and Australia, spread by infected travellers.6, 10, 12 The expansion of the virus
has drawn global attention with the prevalence listed in Table 1.1 and Figure 1.1. Some
extensive and expanding epidemics occurred in some large cities, affecting potentially
millions of people. However, there is currently no cure for the CHIKV.
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Figure 1.1. Global expansion of CHIKV (taken from the website of Centers for Disease
Control and Prevention (http://www.cdc.gov/chikungunya/geo/index.html) with
countries and territories where chikungunya cases have been reported with endemic or
epidemic, updated 24th of February, 2015).
Table 1.1. Prevalence of CHIKV in terms of year and infected countries.
Year
1950s
1960s
1970s
1980s
1990s

2001-2003
2004
2005-2006

Infected countries or regions
Tanganyika,11, 13 Uganda,14 Thailand,15
Phillipines16
India, Sri Lanka, Myanmar and Thailand,17
Cambodia,18 Vietnam, Laos,19 Pakistan,
Malaysia,20 Taiwan,6 and Phillipines15
India and Southeast Asia15
Thailand, Philippines, and Indonesia21
Malaysia22-24 (514,271 cases),
Congo25 (50,000 cases)
Indonesia, Cambodia, Vietnam, Myanmar,
Pakistan, Thailand,15 the Indian Ocean islands of
the Mauritius, Mayotte, Seychelles, Madagascar,
and La Reunion22
Comoros5 (5,000 cases)
The Indian Ocean islands of the Mauritius (15,760
cases), Mayotte (6,346 cases), Seychelles, and La
Reunion (244,000 cases/total population of
770,000),26 Indonesia,19 Guinea,27 India,28-29 US30

Outbreak

≥ 100,000 cases
and caused 200
dealths

Indian Ocean
(300,000 cases
with 237 deaths)
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Year

2006-2007

2008-2009
2010

Infected countries or regions
Europe, US, Australia,31 Maldives (11,879 cases),
Gabon (48,000 cases)32, Mayotte (6,346 cases,
Mauritius (15,760 cases), Italy (248 cases), Sri
Lanka (40,000 cases), Indonesia (15,000 cases),33
Cameroon,34 India29, 35
India (95,000 cases in 2008; 68,000 cases in
2009), Singapore (1,033 cases),36 Thailand,37-38
Malaysia39 (7,000 cases), Taiwan,40 US,41-42
Indonesia,33 Bangladesh43
France44, China,45 Thailand,17 Canada, Myanmar33

2013

India, Cambodia18
Australia46, Bhutan,47 Canada, Cambodia,18 Papua
New Guinea48
Caribbean, Canada, Thailand49

2014

France,50 Europe, US, Caribbean51

2015

US52

2011
2012

1.1.2

Outbreak
India
(1.4-6.5 million)

THE SPREAD OF CHIKV

CHIKV is transmitted from human-mosquito-human (urban cycle) or animal-mosquitohuman (sylvatic cycle) by the bite of infected mosquitoes.22 The virus is classified into
three genotypes: the Asian, West African, and East Central South African (ECSA).6
Genetic analyses revealed that the CHIKV originated in Africa and expanded to Asia.
The spread of CHIKV from Asian and African countries to other areas is due to an
association of various factors; namely worldwide distribution of the transmission
vectors, climatic conditions, and inadequate mosquito control. The global expansion of
this disease is solely primarily due to an increase in international travel, with disease
transportation from infected travellers.1-3, 22 The mosquito species, Aedes aegypti was a
principal vector in many outbreaks, while Aedes albopictus, the Asian tiger mosquito,
has been considered a primary re-emergence factor since 2005.5-6, 22 The vector switch
was found to be a result of reduced populations of Aedes aegypti, meaning that viral
transmission was primarily caused by the larger Aedes albopictus population.3
Furthermore, a number of adaptive mutations have allowed for exploitation of the new
epidemic vector.53 In particular, a mutation in the E1 envelope protein, Ala226Val, was
responsible for a dramatic increase in CHIKV infectivity for Aedes albopictus since
3
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2005 in Africa and Asia.54-56 In addition, a substitution of lysine by glutamic acid at the
position 211 of the E1 resulted in adaption of the virus to the Aedes albopictus.5, 22, 53
Recently, the E2-Ile211Thr substitution was shown to help the virus adapt to Aedes
albopictus, as this mutation could set up the foundation for the E1-Ala226Val mutation
that provides the enhanced infectivity of CHIKV.33 Also, the E2-Gly60Asp was a
determinant factor in CHIKV infectivity for both these species.57
1.1.3

VIRUS LIFECYCLE

As with other alphaviruses, the CHIKV life cycle begins with attachment to a host cell
via receptor mediated endocytosis in clathrin coated vesicles,8, 22, 58 a process described
in Figure 1.2. Under the acidic pH of the endosome, there are conformational changes in
the structures of the envelope glycoprotein complexes. The complex E1 and E2
heterodimers dissociate to form the E1 trimers. The trimers use the hydrophobic fusion
loop to insert into the host membrane, and refold to form a hairpin-like structure. The
nucleocapsid and viral genome are then released into the host cell cytoplasm. During
translation, the nsP123 (a polyprotein precursor) from the viral genome binds to the
nsP4 to form the replication complex (RC). The RC then produces the full length minus
strand (negative strand RNA) required for replication. When the nsP123 concentration
increases, the nP123 is cleaved to non-structural proteins nsP1, nsP2, nsP3, and nsP4.
As these non-structural proteins and the host cell proteins serve as the plus strand
(positive strand) in replication, they produce the 26S subgenomic RNAs and genomic
(49S) RNAs. The 26S subgenomic positive stranded RNA encodes the polyprotein
precursor for structural proteins. The cleavage process takes place in the Golgi complex,
and then the products (non-structural proteins and structural proteins) are transported to
the plasma membrane. The viral RNA is packaged into the nucleocapsid, and the mature
virions bud out of the plasma membrane.
.
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Figure 1.2. Replication cycles of CHIKV. The picture is reproduced from Rashad A. et
al8 with permission).

1.1.4

CLINICAL SYMPTOMS

Following the transmission, CHIKV replicates and expands to liver and joints.5 There
are similar symptoms with other viruses, such as dengue fever, yellow fever, or Ross
River fever. After an incubation period of 2-4 days, acute clinical symptoms start with
the onset of high fever, rigors, headache, fatigue, nausea, vomiting, myalgia, and rash.5
In particular, intense joint pain (polyarthralgia) is the most characteristic which
incapacitate patients.5 This acute stage lasts from 1-10 days. The chronic stage depends
on the acute stage, and is characterized by polyarthralgia. It can last from weeks to
years,8 which affects individual patients, and results in social health impacts10 due to
debilitating infection in large working population. Neurological disorders59 and eye
infection60 are also reported in infected patients, while

meningoencephalitis and
5
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haemorrhagic manifestations such as haematemesis and malaena leading to death have
been reported.6

1.1.5

DIAGNOSIS

Since no vaccines or effective therapeutics are available, early detection and proper
diagnosis are becoming increasingly important in treating the CHIKV disease. Viral
culture is considered a gold standard for CHIKV diagnosis. It is based on innoculation
of mosquito cell cultures, mammalian cell cultures, or mice.61 However, for a rapid
diagnosis, techniques such as a detection of reverse transcription polymerase chain
reaction

(RT-PCR),

real-time

RT-PCR,

real-time

amplification (RT-LAMP) are recommended.1,

62

loop-mediated

isothermal

More frequently, serodiagnostic

methods;63-64 such as enzyme-linked immunosorbent assay (ELISA), indirect
immunofluorescent method, hemagglutination inhibition, or neutralization techniques
were used effectively as reliable techniques in the identification and characterization of
CHIKV. The detection of immunoglobulin M (IgM) and immunoglobulin G (IgG)
antibodies using capture enzyme-linked immunosorbent assay (MAC-ELISA) is a rapid
and reliable technique in serology.

1.1.6

CHIKV GENOME AND STRUCTURE

A full understanding of the structure and genome of CHIKV is crucial for the
development of drugs to combat the virus. CHIKV is a positive-sense and singlestranded RNA virus in the alphavirus genus, Togaviridae family.65 In 1984, Simizu et al
used African and Asian strains of CHIKV to analyse the structural proteins of CHIKV.66
In 2002, Khan et al identified the full genomic sequence of CHIKV (S27, African
prototype),67 opening up further investigations into the elucidation of the structure and
genome of this virus. CHIKV’s genome includes two opening reading frames (ORFs)
that consist of 11,805 nucleotides in total without including the cap at the 5' end, a lpoly (A) tract, and a poly (A) tail at 3' end.67 The first ORF has 2474 amino acids
encoding non-structural proteins (nsP1, nsP2, nsP3, and nsP4) at the 5' region, while the
second consists of 1244 amino acids encoding structural proteins (the capsid C,
envelope glycoproteins E1, E2, E3, and 6K). Between these two ORFs, there is a
6
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junction region. In addition, there is a 7-methylguanosine group capped at the 5' end and
the polyadenylated group at the 3' end. The arrangement of the genome can be as
follows:

5'-cap-nsP1-nsP2-nsP3-nsP4-(junction

region)-C-E3-E2-6K-E1-poly(A)3'

(Figure 1.3).

Figure 1.3. Genome organisation of CHIKV (adapted from Singh S. K. and Unni S. K.22).
The role and function of non-structural and structural proteins of CHIKV have been
examined based on information of other alphaviruses, such as Sindbis virus (SINV) and
Semliki Forest virus (SFV). According to these studies, the non-structural proteins of
CHIKV play an important role in the formation of the transcription/replication complex
of the virus and the negative strand synthesis.58, 68-70
Studies of SFV and SINV nsP1 indicate that nsP1 is a multifunctional protein.71 It is
involved in the formation of the virus cap,70,

72-73

and directing RNA replication

complex to membranes or liposomes,74 as well as associating with endosomes and
lysosomes at the cytoplasmic surface of membranes.72,

75

It has also been implicated

with both guanine-7-methyltransferase and guanylyltransferase activities.74

Investigations of nsP2 from SINV and SFV show that the nsP2 has multiple enzymatic
activities.76-77 Primarily, it belongs to the papain superfamily of cysteine protease.78 It
has functions of proteolytic enzyme at C-terminal domain whereas at the N-terminal
domain, it posses the activities of ATPase and GTPase,76-77 RNA helicase,79 and RNA
triphosphatase.80 Moreover, it is involved in the regulation of synthesis of the 26S
subgenome81-82 and activates the switch from early to late stages,82 as well as playing a
role in the translocation of 50% of the translated nsP2 into the nucleus.83 The nsP2 plays
a vital role in the replication of virus; which combined with the exhibition of some
degree of sequence specificity,76 has resulted in it being an attractive target for drug
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design. More recently, the crystal structure of nsP2 protease of CHIKV was solved
(PDB id: 3TRK).

The specific functions, roles, and activities of the nsP3 protein remain relatively elusive;
however, genetic and functional analysis of the nsP3 from SINV revealed that it is a
phosphoprotein participating in the process of synthesis of the minus strand and the
subgenome of the virus.69,

73, 84

It has been reported that deletion of phosphorylation

sites in the SFV nsP3 decreases the level of RNA synthesis.85 The nsP3 protein consists
of two domains; the N-domain which is highly conserved, and the C-domain which is
not.73 There is an “X domain”, or macrodomain (a first 160 amino acid domain with
unknown function), present at the N-terminal region of the nsP3 with a determined
crystal structure (PDB id: 3GPG).73 The structure on its conserved adenosine binding
site was also obtained (PDB id: 3GPO).73 In addition, it was found that the mutation of
amino acids at the position Asn10 and Ala24 in ADP-ribose binding of the nsP3
macrodomain in SINV affects the replication and viral RNA synthesis, though it has no
effect on the binding region.86-87

Several attempts have been made on SINV to propose the roles of the nsP4 in the RNAdependent RNA polymerase activity88 and in replication, and transcription of the virus.88-91
The results showed that the N-terminal Tyr residue of the nsP4 of SINV may be
substituted with Phe, Trp, or His without changing the wild-type phenotype in cultured
cells. However, other substitutions, except for Met, were lethal or quasilethal.91 The
nsP4 is also stable and remains active during the infection cycle.89 Previous research on
the mutants reported that the mutations in the nsP4 were Glu191 subtituted for Leu and
Glu315 to Gly, Val, or Lys, together with one mutation in the nsP1 (Thr349 to Lys);
which suppress the minus strand RNA synthesis.91 Arg183 of SINV nsP4 polymerase
was found to have an important role in alphavirus minus strand RNA synthesis.92

Most studies of the structural proteins of CHIKV are based on the biology and
pathogenesis of the virus, as infection is mediated by these glycoproteins. The E2 is
responsible for receptor binding, while membrane fusion is supported by the E1.93 In
2008, Santhosh et al56 found the mutation in E1 Ala226Val, leading to the epidemic
outbreaks of CHIKV in India. Ongoing insights into the structure of CHIKV have been
8

Chapter 1. Introduction
revealed by two crystal structures of surface glycoprotein complexes; namely precursor
p62-E1 heterodimer (PDB id: 3N40), and the mature E3-E2-E1 (PDB id: 3N42)
determined in 2010.93 The E3 protein plays an important role in the proper folding of
p62 and the formation of the p62-E1 heterodimer,94-95 but the E3 is not in the
component of mature CHIKV.66 The 6K associates with the complex p62-E1 and is
transported to the plasma membrane before assembly.65 The assembly process takes
places due to the interactions of the genomic RNA and the nuclear capsid protein. The
6K protein facilitates particle morphogenesis, but it is not stoichiometrically
incorporated into virions.65 The structural change of envelope glycoproteins in
membrane fusion was investigated by Li et al.96 The resulting roles of the E2 in receptor
interactions, and the existence of epitopes, are essential for the design of a vaccine
against this virus.

Recently, structural analysis of CHIKV at pseudo-atomic level resolution was
reported,65 by combining electron cryo-microscopy (cryo-EM) techniques for the whole
virus and X-ray crystallography for the component of structural proteins, together with
the published crystal structure of the CHKV E1-E2 glycoprotein heterodimer.93 A 5.3 Å
resolution cryo-EM map of CHIKV-like particles was interpreted, and the mechanisms
of neutralization of antibodies were proposed. The study revealed that like other
alphaviruses, CHIKV has an icosahedral spherical structure with T=4 quasi-icosahedral
symmetry (diameter of about 60-70 mm, Figure 1.4 A). This structure consists of 80
spikes: including 20 icosahedral “i3” spikes (located on the icosahedral 3-fold axes),
and 60 quasi-3-fold “q3” spikes (located in general positions) with a quasi-3-fold axis.65
The spikes i3 and q3 are significantly different, possibly indicating different stages of
generation of fusogenic E1 trimers. The complete q3 spike combines with one-third of
an i3 spike to form a single T=4 icosahedral asymmetric unit (Figure 1.4 A). These
spikes are made by the envelope glycoproteins E1, E2, and together with virus
membrane, transmembrane (TM) helix, and a capsid covering genome RNA to form a
nucleocapsid (Figure 1.4 B). The E1 glycoprotein is composed of 439 amino acids
including 404 N-terminal residues, 30 residues which comprise the TM helix, and 5
amino acids which form the cytoplasmic domain, as well as an N-linked glycosylation
site at Asn141. The E1 is divided into three domains, namely domain I, II, and III, with
domain I located in between domain II and III. The E2 consists of 364 residues, a 26
9
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residue TM helix, and 33 residues cytoplasmic domain. The E2 also has three domains,
domain A, B, and C, which are known as distinct immunoglobulin-fold domains.
Domain A takes part in receptor-binding process, lying in between domain B and
domain C. Domain B covers the fusion loop in domain II of E1 in the mature structure.
Under the pH acidic environment, the virus becomes fusogenic by combining three E1
to make a trimer. The fusion loop is then exposed to insert into the host cell membrane.
Therefore, hiding the “fusion loop” may interfere with the virus entry and infection of
human tissue.

Figure 1.4. Structure of the CHIKV, showing the structure of virus particles in a T=4
icosahedral symmetry (A) and the components of a single unit with a nucleocapsid
consisting of spikes (made by envelope glycoproteins), virus membrane, and
transmembrane (TM) helix; and a capsid covering genome RNA inside (B), (adapted
from Sun S. et al.65)

1.2 CURRENT TREATMENT FOR CHIKV INFECTION
There is no effective vaccine or antiviral agent currently available for CHIKV
infection.10 Treatment is mostly based on alleviating symptoms by using analgesics
(non-salicylate analgesics), antipyretics,1,

6

anti-inflammatory agents (corticosteroids

and non-steroidal anti-inflammatory (NSAIDs));6, 9, 21 along with taking bed rest, and
undertaking an extra fluid diet.1 Some agents for the treatment of acute CHIKV include
Methotrexate; NSAIDs: Rofecoxib, Celecoxib, Parecoxib; corticosteroids: Prednisolon;
antirheumatic: Sulfasalazine and Methotrexate; non-salicylate analgesics: Paracetamol,
Morphine; traditional herbal medicine: Fernelia spp species.
10
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1.2.1

SPECIFIC INHIBITORS OF CHIKV

While some inhibitors have been shown to be effective against CHIKV in vitro,
currently, there is no antiviral drug available for CHIKV treatment. Further biological
testing (in vivo) is required. These inhibitors are listed in Table 1.2, along with the
current update of inhibitory effects and the clinical trials.

Table 1.2. Some potential inhibitors for CHIKV.
Compound
Chloroquine
N

HN

N

Cl

(1)
IC50 = 1.1 µg/ml

Ribavirin
H 2N
O
N
HO
O
HO

N

N

OH

(2)
EC50 = 83.3 µg/ml

Arbidol

Inhibitory effects and current update
Chloroquine (1) was reported as in vitro antiviral
compound more than 35 years ago.97 However,
recently, a mouse model showed that this compound
enhances virus replication, and aggravates the
disease.9, 98 Chloroquine phosphate has also been
used for chronic chikungunya arthritis with antiinflammatory, rather than antiviral effects.99-101 Some
studies revealed that chloroquine was considered as
an entry inhibitor as it could interact with the
endosome-mediated internalization process in the
infection cycle.98, 102 Chloroquine was tested in Phase
III clinical trials in France in 2006; however, this
compound was terminated in 2007 with no antiCHIKV effect.8
Ribavirin (2) is well-known as an antiviral inhibitor
in vitro.103 The mechanism is varied between
different viruses, such as interaction with
intracellular viral RNA production, inhibition of
inosine 5'-monophosphate dehydrogenase (IMPDH),
leading to depletion of cellular GTP pools, and action
as a potent mutagen for some RNA viruses (error
catastrophe mechanism), even though the precise
mechanism is still unclear.9 Ribavirin can be used
either alone or in combination with α-interferon to
get a synergistic effect in vitro against CHIKV
(concentration of α-interferon 3.9 IU/ml, and
ribavirin 18.75 μg/mL).104-105 However, up to now,
no evidence on clinical efficacy of ribavirin on
CHIKV or ribavirin in combination with α-interferon
for anti-CHIKV is reported.9
Arbidol (3) was developed 20 years ago in Russia for
treatment of acute respiratory infections.8 This
compound elicits a broad effect on RNA, DNA,
enveloped, and non-enveloped viruses.106 The
mechanism may be interference with the mediated
11
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fusion,107 blocking the viral entry into the target cells
through inhibition of glycoprotein conformational
changes.108-110 In 2011, arbidol and its derivatives
were used for in vitro testing for CHIKV. The results
reported that arbidol could inhibit CHIKV but very
weak effects even though the IC50 value is much
lower than the toxic concentration (IC50 = 12.2 μM,
CC50 ≥ 200 μg/mL).111 Evidence from in vivo studies
is required to validate activity of arbidol on CHIKV.8

Arbidol
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HO

S
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Br

(3)
IC50 = 12.2 µM
Mycophenolic acid

Mycophenolic acid (4) was discovered approximately
112
O 100 years ago.
It is an inhibitor for the enzyme
HO
IMPDH involved in de novo biosynthesis of guanine
O nucleotide.113 It was known as having good activity
O
O
with antiproliferation, anticancer, as an antiviral
agent, and an immunosuppressant.8 Recently, this
(4)
compound showed inhibition of the CHIKV
IC50 = 0.2 µM
replication using virus-induced cell death.114
However, the compound was reported as suffering
from a metabolic drawback associated with rapid
conjugation of the C-7 phenolic hydroxyl group with
glucuronic acid,113 thus in vivo studies are required.8
Trigocherrin A
Trigocherrin A (5) is a natural compound, isolated
Cl
from the bark of Trigonostemon cherrieri Veillon
(Euphorbiaceae),115 a tree in New Caledonia, or the
Cl
species found in tropical Asia, India, and Sri Lanka
O
HO
OH
O
to New Guinea.8 Recently, in testing CHIKV
O
O
HO
Ph
inhibitory effect, this compound showed inhibition of
O
viral replication function on virus-induced cell death,
O
Ph
O
using a virus-cell-based assay.116
O
OH

O

(5)
EC50 = 1.5 µM
Harringtonine117
O
O
O
HO

OH

O

O

O
N

Harringtonine (6) is an alkaloid compound, isolated
from Cephalotaxus harringtonia tree in Japan.8 It
displayed CHIKV inhibition, by affecting the early
stages of infection after cellular endocytosis.117 Also,
it was found to affect the CHIKV RNA production
inside the infected cell and viral protein expression
through the nsP3 and the E2 proteins.117 This
compound is still undergoing in vivo testing.8

O

(6)
EC50 = 0.24 µM
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Some other compounds are less common, thus requiring further testing to be considered
promising lead compounds (Figure 1.5). However, they were not approved for human
use. For example, quinine (7) inhibited the in cellulo growth of CHIKV.9 Increasing
concentrations of quinine affected the nsP1, as mutations were observed suggesting an
impairment of the function of the viral guanylyltransferase activity. Another compound,
named 6-azauridine (8), showed its inhibition on both DNA and RNA virus replication,
and orotidine monophosphate decarboxylase, an enzyme involved in the de novo
biosynthesis of pyrimidine, cytidine, and thymidine.118 Trigowiin A (9) and prostratin
(10) were isolated from the bark of Trigonostemon howii of the Euphorbiaceae species
in central Vietnam during the biological testing for CHIKV.119 This compound showed
a weak anti-CHIKV activity, however, it possessed its selectivity for CHIKV, against
the SINV and SFV. Prostratin119 showed better inhibitory effects on CHIKV than (9) in
a CHIKV inhibition assay. 12-o-tetradecanoylphorbol 13-acetate (11) was reported to
inhibit CHIKV through the activation of the signal transduction enzyme protein kinase
C, also selective for CHIKV inhibition.119 Lupenone (12) and β-Amyrone (13) are
isolated from the leaves of Anacolosa pervilleana (Madagascan plant). (12) showed
moderate anti-CHIKV activity in a virus-cell-based assay,120 while (13) had a moderate
anti-CHIKV activity in the assay. Polycytidylic acid or poly(I:C) (14) is a synthetic
double-stranded RNA (dsRNA) analogue. It displayed an immunostimulant action as an
inducer for the interferon via interaction with the toll-like receptor 3 in CHIKV
infection assay.121
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Figure 1.5. Less common structures of some potential inhibitors for CHIKV.
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1.2.2

CURRENT APPROACH FOR CHIKV VACCINE

With the widespread distribution of CHIKV, there is a need for a safe and effective
vaccine. Currently, there is no effective vaccine for CHIKV although there have been
some efforts on this approach. An understanding of antibody-mediated and cellmediated immune responses is important for vaccine development.5 Unfortunately,
there is very little information pertaining to the interaction of CHIKV infection and
adaptive immune system in re-infection.5, 8 Some potential vaccines which need to be
developed are listed in Table 1.3.122
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Table 1.3. Potential vaccines for CHIKV.
Type of vaccine

Vaccine

Production

Developed
year

Inactivated
vaccines

Formalin-inactivated vaccine123

A whole virus grown in monkey cell cultures

1970s

A whole virus grown in monkey cell cultures

1970s

Phase II:
discontinue
Preclinical

A virus on Vero cells

2006

Preclinical

181/clone 25 vaccine strain

Serial passage CHIKV strain in culture cells

1986

TSI-GSD-218 CHIKV vaccine127

An attenuated strain CHIKV

2000

Phase II
Underway
Phase III

Tween 80-ether extraction124
125

Vero adapted formalin inactivated vaccine
Live-attenuated
vaccines
Genetically
engineered
vaccines

126

128

Chimeric virus vaccine

Recombinant adenovirus vaccine129
CHIKV-IRES vaccine130-131
DNA vaccines132-133
Subunit protein vaccines134-137
Virus-like particle vaccine138-139
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VEEV (attenuated vaccine strain TC-83), an
attenuated strain of EEEV or SINV and the
structural protein genes of CHIKV
A non-replicating complex adenovirus vector
encoding the structural polyprotein cassette of
the CHIKV
A cDNA clone generated from the wild-type
La Reunion strain
Single or three individual plasmids
Recombinant CHIKV envelope proteins
Non-infectious virus-like particles coated
with the same protein

Status

2008

Preclinical

2010

Preclinical

2010

Preclinical

2008

Preclinical

2012

Preclinical
Completed
Phase I

2010
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1.2.3

ALTERNATE APPROACHES

Some other approaches are targeting virus entry and maturation, viral nucleic acids, and
cellular receptors. For example, agents used on each interference can be listed as
follows: using furin inhibitors, or decanoyl-RVKR-cholormethyl ketone to impair the
maturation of the E2 glycoprotein;9,

140

small hairpin RNA molecules to interfere

RNAs;141 2',5'-oligoadenylate synthetase (OAS3),142-143 cellular IMPDH enzyme,114 and
visperin144 in controlling CHIKV replication or human antibodies. Recently, silencing
of HSP-90 (a chaperone protein related to heat shock) using small interfering RNA
(siRNA) has been shown to disturb CHIKV replication in cultured cells.145

1.3 CURRENT RESEARCH IN CHIKV DRUG DISCOVERY
1.3.1

CELL-BASED HIGH THROUGHPUT SCREENING APPROACHES

Recently, high throughput screening methods have been developed to identify potential
CHIKV inhibitors. For example, a CHIKV replicon and a concomitant screen with SFV
surrogate infection model were used to screen 356 natural compounds, and clinically
approved drugs.146 A cell-based high throughput screening assay using resazurin against
a kinase inhibitor library of 4,000 compounds, combined with the image-based high
content assay approach was applied.147 A phenotypic assay was also used to identify
one natural compound that partially blocks nsP2 activity and inhibits CHIKV
replication in vitro.148

1.3.2

IN SILICO APPROACHES

In recent years, in silico approaches are promising to save time and the cost of the drug
discovery process. With the availability of the crystal structures of several proteins of
the CHIKV genome and other related alphaviruses, structure-based approaches using
molecular docking and virtual library screening can be applied to identify potential
inhibitors (hits) from a large database of compounds. These hit compounds may be
experimentally tested, or used to investigate a structure-activity relationship to optimize
17

Chapter 1. Introduction
the compound’s activity. Generally, drug targets are key proteins which is identified
through cellular and protein biochemical processes associated with the disease. These
biomolecules are known as being involved in signalling or metabolic pathways that are
specific to the disease process149-150 For CHIKV, non-structural proteins and envelope
glycoproteins were considered potential targets.8 Non-structural proteins of the virus
play an integral role in viral replication and transcription, so they are attractive targets
for designing potent inhibitors of CHIKV.151 Recently, two crystal structures, namely
the nsP2 protease (PDB id: 3TRK) and the nsP3 macrodomain (PDB id: 3GPG)73 have
been available for use as a starting point in antiviral research. Homology models for
structure nsP4 was also proposed to provide structures for drug design.152 The envelope
glycoprotein complexes were determined by X-ray crystallography, the immature form
(PDB id: 3N40) and the mature form (PDB id: 3N42).153 These complexes are also of
interest as targeting the envelope glycoproteins can affect the virus entry.

1.4 STRUCTURE-BASED DRUG DISCOVERY FOR CHIKV
1.4.1

OVERVIEW OF COMPUTER-AIDED DRUG DISCOVERY

In fighting disease, drug discovery and development are very expensive and timeconsuming processes.154 The drug discovery process involves different stages such as
target identification (target ID), hit identification (hit ID), lead discovery and
optimization, biological testing (preclinical trials), and clinical trials.149, 155 Therefore,
utilizing computational techniques not only increases the efficiency and effectiveness of
research, but also saves time and reduces costs; in particular during lead discovery and
lead optimization.

The field of computer-aided drug design (CADD) was started in the 1960s and in the
late 1980s up to now, this has been growing and has become an integral part of drug
discovery with the development of computer hardware and software, and the increasing
availability of protein structures of biochemical targets of pharmaceutical interest
(Figure 1.6).156 There have been a number of studies reported on describing specific
computational methods, clarifying their role and importance, and highlighting recent
18
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advances, as well as their successful applications and challenges.156-169 These contain
many applications of this approach in antiviral drug design, in particular in analysis of
viral protein target. The prediction and simulation of conformational, steric, and
physicochemical properties helps to elucidate the characteristics of the target. The
binding pockets and interactions may be identified using computational approaches.
Rationalization of drug action and virtual screening to identify potential inhibitors,
together with the structure-activity relationship of these ligands, were applied.163

Figure 1.6. Applications of CADD to the various stages of drug development (adapted
from Tang Y. et al.170).
Computational approaches in CADD can be classified into two main groups: the ligandbased approaches and the structure-based approaches.

Ligand-based approaches: This is an indirect approach which is useful in the case of a
lack of an experimental receptor structure together with the difficulty of designing a
reliable model.171 Ligand-based methods are particularly valuable in the early stage drug
discovery.163 These approaches rely on known active compounds and utilize their
similar descriptors taken from their molecular characteristics, properties, and biological
activity data to elucidate the structural and physicochemical properties of the ligands.163
Molecular characteristics may be physicochemical descriptors in one dimension, 1D
(e.g., molecular weight, atom counts, logP, and pKa); two dimensions, 2D (e.g.,
topological descriptors); and three dimensions, 3D (physicochemical properties such as
location, constraints, and shape descriptors). Ligand-based approaches introduce a
definition of a pharmacophore as the ensemble of steric and electronic features,
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necessary to account for the common molecular interactions with the protein target, and
to trigger (or to block) its biological response.154, 163 A pharmacophore model describes
the three-dimensional chemical features, using pharmacophoric descriptors such as
hydrogen bond donors, hydrogen bond acceptors, hydrophobic, aromatic, positive
ionizable groups, and negative ionizable groups. There are many different ways to build
a pharmacophore model. It can be based on chemical structures of known active
compounds from different chemical scaffolds or diverse chemical structures for
compounds (with IC50 or Ki values ranging over more than three orders of magnitude).
Similarities of molecular properties such as pharmacophore features, shaped-based
models or a quantitative structure-activity relationship are also utilized. The underlying
assumption here is that ligands having similar physiochemical properties are likely to
show comparable activity spectra.

Structure-based approaches: Unlike the ligand-based methods, structural data of a
protein target is a prerequisite in a structure-based approach.166 The full threedimensional (3D) structure of the protein may be obtained from X-ray crystallography
or nuclear magnetic resonance (NMR) techniques. In the case where the structure of
protein is unknown, homology modeling can be used based on the similarity of the
genomic sequences with other viruses.150 Protein-ligand docking and structure-based
virtual screening are examples of these approaches. They utilize information of the
protein structure to identify and optimize drug candidates by examining molecular
interactions between ligands and target macromolecules, as detailed below.154

1.4.2

PROTEIN-LIGAND DOCKING ASSISTS IN DRUG DISCOVERY

Pioneered in the early 1980s,172 protein-ligand docking has developed as an integral part
of drug discovery.173 It has become an invaluable tool that assists efficiency in drug
discovery to understand interactions of protein-ligand complexes.174-176 In the 2000s, a
series of reviews summarized the methodology, and highlighted the successful
applications, recent advances, and challenges of this approach.162, 166-167, 173, 177-187

Given a small molecule and a protein target of a virus, docking attempts to insert the
small molecule into a binding site of the protein target. In other words, the aim of
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docking is to get the “best match” of a protein-ligand complex,178 or to accurately
predict the orientation and conformation of a small molecule (ligand), i.e. the lowest
binding energy (known as binding mode or binding pose), and then estimate binding
affinity of the ligand into a known structure (Figure 1.7).

Figure 1.7. Representation of the strategy used for protein-ligand docking.
Therefore, protein-ligand docking includes two processes: docking (geometric sampling
of potential ligand/protein binding mode); and scoring (using an equation and specific
parameters to estimate a ligand binding affinity). Consequently, a protein-ligand
docking program consists of these two essential components: sampling (ligand sampling
and protein flexibility) and scoring. There are three main kinds of sampling setups: first,
the protein and ligand are kept rigid, only translational and rotational manipulations of
the ligand are investigated; second, the protein is rigid and ligand is assumed to be
flexible (all degrees of freedom of the ligand are explored); and third, the protein is fully
or partly flexible as well as the ligand. Some popular docking programs are DOCK188,
AutoDock,189 FlexX,190 GOLD,191 and GLIDE;192 most of which utilise the flexible
ligand and a rigid receptor approach.

To make protein-ligand docking more practical, improvements from docking with rigid
structure to partly or full flexible receptor have been undertaken during the last years.173,
176-179, 183, 186

However, protein flexibility is still the major hurdle where ligand sampling
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is concerned. In addition, there has been no universally applicable scoring function
available. Therefore, finding the most appropriate algorithm for the prediction of
protein-ligand binding of each specific target is a major focus of research. Many search
algorithms and scoring functions have been developed over the years, alongside
numerous scoring functions, taking into consideration speed and accuracy.173

1.4.2.1 Search algorithms

As previously mentioned, most docking programs account for ligand flexibility. In order
to search for precise conformation and configuration, an optimal search algorithm
should explore all of degrees of freedom to sample sufficiently so as to include the true
binding modes. These algorithms may be classified into three main groups: systematic
searches (incremental construction, conformational search, exhaustive or databases),
random or stochastic methods (Monte Carlo, genetic algorithms or evolutionary
algorithm, Tabu search), and deterministic or simulation searches (molecular dynamics
and energy minimization).173,

176-177, 179, 186

Some algorithms implement a hybrid

approach combining two or all three of the methods.

Systematic search: In this search algorithm, all of the degrees of freedom of ligand are
investigated. It can systematically rotate all rotatable bonds of a ligand through 360°
using a fixed increment, to obtain all possible combinations for evaluation. This
approach is, however, succeptable to a combinatorial explosion in computational cost.
Another approach is that the ligand is divided into different fragments or a core
fragment and flexible parts (sidechains), and then these components are docked into the
active site. The results will be covalently linked together (other incremental search
algorithms) or rebuilt the ligand from fragments (Hammerhead algorithm). Libraries of
pre-generated conformations may be utilized to tackle the combinatorial explosion problem.

Random (or stochastic) search: The search makes random changes for a single ligand
or a population of ligands. A pre-defined probability function is used to evaluate the
ligand. The common groups are Monte Carlo (MC) and genetic algorithms. In the MC
method, following random changes and energy minimization for the generated
conformations, the Boltzmann probability function is used as the criteria of evaluation.
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If a change in temperature is also combined to increase the probability, this is called
Simulated annealing. In the genetic algorithms or evolutionary algorithms, the theory of
the evolution in biological system is applied to search for the correct ligand binding
mode.162 The Tabu search is another method to explore areas of conformational space,
and the value of root mean square deviation (RMSD) between the calculated molecular
coordinates, and every molecule’s previously recorded conformation should be less than
a cutoff value to be accepted. Swam optimization tries to search for a search space for
the ligand using Swam Intelligent method by taking the information of the best
positions of its neighbors.162

Deterministic (simulation) method: These algorithms use molecular dynamics (MD)
simulation or energy minimization to explore the conformations. The ensembles of
populations are generated and are docked rather than a single conformer. MD is the
most popular approach, however has weaknesses in its inability to cross high-energy
barriers within simulation timescale, leading to arrest of ligands in a local minima of the
free energy surface.177 To overcome this, simulations can be carried out for the different
parts of a protein-ligand system at different temperatures, or ligand starting positions.
Energy minimization is often used in combination with other approaches.

The search algorithms for protein flexibility in docking are still limited, though there are
some reviews and studies on it.193-197 MD and MC, are usually applied for a search of
protein conformations. Another strategy is the use of rotamer libraries to model protein
conformational space based on experimental data, and favourable sidechain
conformations. A protein ensemble grid is different approach in which the algorithm
uses an ensemble of conformations of protein for docking rather than a single one, and
then maps them on a grid representation.

1.4.2.2 Scoring function

For a docking process to be successful, the adopted scoring function is the deterministic
factor for obtaining an accurate prediction of conformation of a protein-ligand complex,
and a correct ranking of final structures. In other words, scoring is used to predict the
binding affinities, and differentiate between correct and incorrect orientations, and
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conformations (poses). The ideal docking program should satisfy both computational
efficiency and reliability. Therefore, speed and accuracy are two key components of a
scoring function. Free-energy simulation can be based on atomistic MD simulation,
applied for quantitative modeling of protein-ligand interactions, and binding affinity
predictions; however, this approach is expensive. Most docking programs still do not
include entropic effects explicitly. There are different scoring functions which are
classified in terms of shape, chemical complementation, force fields, empirical results or
system knowledge. The three main categories are force-field-based, empirical, and
knowledge-based scoring functions.162,

166, 173, 176-177, 179, 181-182, 186, 198-199

Beside these

scoring functions, some other approaches to improve scoring such as consensus scoring
(combining the information from multiple scoring functions), or clustering, and
entropy-based scoring methods.162

Force-field-based scoring: This type of scoring function tries to model many types of
interactions involved in protein-ligand binding by utilizing physics-based functional
forms, and parameters derived from experiments or quantum mechanical simulations.166
There are different types of force field scoring functions. They have similar functional
forms but their force field parameters are different, for example G-Score with Tripos
force field,200 and AutoDock with AMBER force field.176 Most of them only consider a
single protein conformation to make it possible to omit calculation of the internal
protein energy. In molecular mechanics force fields, the binding free energy is
calculated as a sum of two energies, receptor-ligand interaction energy (van der Waals
(vdW) and electrostatic interactions) and internal ligand energy (steric strain induced by
binding). In AMBER force fields, the vdW term is referred to a Lennard-Jones potential
function (such as 12-6 Lennard-Jones).166 The general AMBER force field (GAFF)
including some parameters is suitable for simulating small molecules.201 The
CHARMM force field is similar to AMBER force fields, but has some additional terms.
The CHARMM22 force field is is usually used for modelling protein. The recent
CGenFF force field can be applied as a general force field for small molecules.202 The
disadvantage of standard force-field-based scoring function is that it does not include
solvation, and entropic term explicitly.176
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Empirical scoring: This type of scoring uses a sum of various empirical energies to
estimate the binding energy. A set of weighted empirical energy terms may be
composed of vdW, electrostatic, hydrogen bonding energy, desolvation term, entropy,
and hydrophobicity term.162 This scoring is far simpler than force-field-based scoring,
however, it depends on the molecular data sets used to perform regression and fitting,
leading to reproducibility of the experimental binding affinity data.

Knowledge-based scoring: The binding affinity can be calculated based on the
information of experimental protein-ligand complexes data. This is estimated as a sum
of free energies of protein-ligand atom-pair interactions (the potential mean force). The
frequencies or probability distributions of interatomic distances between two atoms are
converted into distance-dependent interaction free energies of protein-ligand atom pairs
using the inverse Boltzmann method.162

Some popular docking programs together with their searching algorithms and their
scoring functions are summarized in Table 1.4.

In conclusion, there are many docking programs with different scoring functions.
However, no single one is the best. The ideal scoring function is still not available. The
problem is that all of the scoring functions mentioned above, are based on different
assumptions and simplifications, and do not fully take into account of entropic and
solvation effects. Compromises between the conformational searching algorithms and
scoring functions could improve docking algorithms, however, it may not improve
binding affinity prediction. Thus, it is difficult to obtain a chemical accuracy, and the
results depend on the specific system.

25

Chapter 1. Introduction
Table 1.4. Docking programs with corresponding search algorithm and scoring function.
Docking
program

Fees

DOCK188

AutoDock
Vina203

No (academics);
Incremental build
Yes (profit)
No (academics);
Lamarckian algorithm
Yes (profit)
No (academics); Lamarckian algorithm
Yes (profit)

FlexX190

Yes

GOLD191

Yes

Glide192

Yes

FRED204

Yes

ICM205

Yes

AutoDock189

Ligand searching
algorithm

Fragmentation and
Incremental construction
Genetic algorithm
Exhaustive search
(Monte Carlo)
Conformational ensembles
(Rigid body docking)
Pseudo-Brownian
sampling and local
minimization (Metropolis
Monte Carlo)

Scoring function
Force field or
contact score
Force field
Combining
knowledge-based
potentials and empirical
scoring functions
Empirical score
Empirical score
Empirical score
Gaussian score or
empirical scores
Mixed force field and
empirical score

1.4.2.3 Setting up a docking protocol

To perform docking, preparations of protein and ligand are indispensable. For the target
protein, the structure is usually obtained by X-ray crystallography or by NMR structure
determination. The structure may be apo, holo (complexed with another compound) or
if the structure is not available, it may be predicted by threading or homology modeling.
If the function of protein is unknown, it is crucial to search for possible binding sites in
the structure (discussed below). Some crucial factors should be considered to check the
structure carefully. Initially, structural integrity is needed to check. Polar hydrogen
atoms are also added. The next step is to assign proper protonation and tautomeric states
of ionizable residues including aspartate (Asp), glutamic acid (Glu), arginine (Arg),
lysine (Lys), and histidine (His). The orientation of asparagine (Asn) and glutamine
(Gln) residues also require checking. The active site or binding site needs to be defined
before docking, and the treatment of water molecules in docking is considered. Water
molecules may affect the formation of the complex as they can form hydrogen bonds
with the ligand and the protein. Geometry refinement of the protein/receptor-ligand is
required to correct small artefacts in the protein or ligand such as strained bond
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lengths/angles or intermolecular steric clashes.187 Energy minimization of the structure
should be used. Preperation of the ligand, like the protein, requires great care. Ligands
can be taken from various sources, such as a database or electronic vendor catalogues.
Filtering using the drug-like properties is recommended to eliminate molecules, with
unfavourable properties: such as poor solubility, pharmacokinetics characteristics
relating to adsorption, distribution, metabolism and excretion; oral bioavailability and
toxicity. The most popular filter used in drug design is Lipinski “rule of five”206 that is,
molecular weight (MW) lower than 500 daltons, logP less than 5, number of hydrogen
bond donors less than 5 and number of hydrogen bond acceptors less than 10.207 Usual,
compounds are represented in 2D format and then converted to a 3D representation.
Several methods are available for generation of a 3D structure. Special care must take
into account of tautomeric and protonation states, stereochemistry of chiral centres. The
next step is docking with sampling to generate different binding poses; scoring and
ranking. Most docking programs as mentioned previously, focus on docking with rigid
docking and flexible ligands. Protein flexibility may be treated for some specific
sidechains of protein residues.

1.4.2.4 Prediction of binding sites

In structure-based drug design with molecular docking and virtual screening
approaches, the question of where in the structure of the protein the ligand binds is of
interest. Therefore, it is a requirement to understand the structure and function of a
protein target, in particular, knowledge of locations that small molecules (ligands) could
bind in the structure is of key importance to help rationally design of ligands, to fit with
high binding affinities and specificity that can modulate the functions of this target.208210

A binding process is the sum of many contributions such as environment (pH, ionic

strength), and presence of water molecules, in which the shape complementarity of
protein and ligand together with their physicochemical properties are balanced.209
Proteins can change conformations upon ligand binding, which may influence the steric
accessibility of a binding cleft and can interfere with the ability of an algorithm to
identify a potential binding site.208 Small molecules are known to usually bind in the
largest pockets on the surface of protein, and their binding free energies is a result of
enthalpy-entropy compensation.209
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There have been many different approaches developed to identify binding sites of a
protein, depending on whether the co-crystallised structure of a protein-ligand complex
is known or not.209 Thus, these approaches can use a co-crystallisation of a protein with
a ligand if available, use structural or sequence similarity with a known binding site, or
use in silico prediction methods. For computational methods, some algorithms utilize
protein surface analysis to identify ligand binding pockets in the protein. The others use
probe clustering and energy contour analysis which is based on analysis of binding
energies of probes placed on a grid around the protein.210 Other types of characteristics
such as surface accessibility, the net charge on the protein residues in a protein as a
function of pH, and sequence conservation can be used. MD simulations are also used
to generate dynamic ensembles of protein conformations for binding site detection. In
general, computational approaches for prediction of binding sites on a protein can be
classified into three main groups: geometric-based (using geometrical pocket
description or free accessible volume calculation to identify the sterically favoured
cavities among all clefts on the protein’s surface); energetic-based (finding energetically
favoured positions, e.g. by calculation of interactions with different probes and the
protein’s surface); and knowledge-based (using structure and sequence comparison to
generate templates of similar sequence or functionality to identify evolutionarily
conserved regions to rank cavities generated with geometric approaches). The
geometric-based methods are fast and easy to use while the others are more timeconsuming and require user expertise.209

1.4.2.5 Structure-based virtual screening

The most notable application of protein-ligand docking is structure-based virtual
screening.211 It has become increasingly important to improve the speed and efficiency
of drug discovery and development.211-215 The main purpose is to reduce the large
number of compounds from databases and select the most promising compounds for
biological testing.176 It is known as a fast tool for drug design which is valuable to
discover lead compounds complementary to experimental methods, for example highthroughput screening. A large volume of studies have shown its importance and
successful application in this field of drug design and development.211-224 Some popular
programs available for this purpose are DOCK,188 FlexX,190 GOLD,191, 225 AutoDock189,
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226

and AutoDock Vina.203, 227 However, based on docking, virtual screening has similar

challenges in accuracy of scoring and ranking. If many ligands are docked, the time for
scoring and ranking in screening a large sample is of utmost important. More reliable
scoring functions should include calculations for nonbonded interactions such as cationπ interaction, CH-π interaction, and π-π stacking interactions.224 The choice of ligand
libraries for screening is also of concern. Several databases are available, for instance,
the

National

Cancer

Institute

(NCI)

(dtp.nci.nih.gov/branches/dscb/diversity_explanation.html),

Diversity
NCBI PubChem

Set
(pub-

chem.ncbi.nlm.nih.gov), eMolecules (www.emolecules.com) and ZINC228 composed of
a variety of compounds or libraries of natural products,229 metabolome,230-231 and
nutraceuticals.232 If in the case of a new target, where no information about binding sites
for ligands is known, blind docking for the entire protein is applied to identify sites that
ligands bind tightly. Other computational approaches can be used to predict the binding
sites as discussed previously. Validation of the approaches is the most critical due to the
inaccuracies of the scoring functions, which will affect the results of ranking. The main
factors should be taken into account are the quality of the obtained docking poses, and
the ability of the methods to discriminate known active and inactive compounds after
docking in the same target. False-positive hits or decoy molecules have similar physical
structures but are chemically distinct from ‘true’ hits, and can be used as competitive
binders to a protein.233-235

1.4.2.6 Validation of docking method

Docking is usually validated by the ability to reproduce the experimental data in
predicting the binding pose, and binding affinity to distinguish the active and inactive
compounds. The commonly accepted criterion for docking success is pose selection by
a comparison of the RMSD between the docked structure (top scoring pose) and the
experimental structure (the co-crystal structure). With the protein-ligand co-crystal
structure, a docking protocol can be evaluated and improved. However, the errors
exiting in the bound structures due to the poorly refined ligand geometries could lead to
misleading interpretation of key binding interactions. They can be errors in the ligand
structure (for instance missing atoms, incorrect bond orders or other connectivity
issues); or incorrect bond distances, angles or dihedral angles; or conformational errors
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(for example, cis- or twisted amides, distorted rings, non planar aromatic groups, or
groups of planar structures of not being planar); incorrect orientations or bad steric
clashes between protein and ligand. Therefore, it has become commonly to apply
protein preparation tools to structure.236 If the RMSD value is no more than 2 Å, it is
considered a docking success.167,

179, 184, 237-238

Moreover, other criteria to validate

docking include Generally applicable replacement for RMSD (GARD),238 enrichment
factors, receiver operating characteristic (ROC) factors,227 area under ROC curves
(ROC AUCs),239 and binding affinity calculations.240 Using a decoy set of inactive
compounds to dock and after ranking by scoring, enrichment is calculated by dividing
the ratio of active molecules in the entire dataset by the ratio of active molecules in the
top 5 or 10% of the top ranked molecules. The enrichment plot or ROC curves are
plotted. The sensitivity of a given docking/scoring combination and specificity are
shown in ROC plots.

1.4.3 MOLECULAR DYNAMICS SIMULATIONS IN DRUG DISCOVERY

Given the structure of a macromolecule and its complexes, molecular dynamics (MD)
simulation is one of the computational approaches to investigate the motions of a
system of particles.241 MD simulation of biological macromolecules (proteins) of
interest was introduced in 1977.242 Since then, this technique has become a powerful
computational method, quickly showing wide application to many fields, and constant
improvement quantitatively and qualitatively in structure-based drug discovery to
understand drug-receptor interactions.243-246 Especially with the recent advances in
algorithms and computer hardware and software, long-timescale from microsecond to
millisecond for thousands of atoms has been achieved.247 The interaction for the
particles is calculated and included sequentially to the time of simulating. The result of
the process (MD trajectory) provides information on the atomic level of positions,
velocities and energies. Statistical mechanics related to distribution and motion of atoms
are required to connect microscopic simulations with macroscopic observables such as
changes of conformations, binding free energy, and mechanism of reaction. MD
simulation has been applied to a wide range of biological problems, including protein
folding,248-249 protein-ligand interactions,250 electron transfer state in photosynthesis,251
enzyme reactions,252-253 determination of protein structures from NMR,254 refinement of
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protein X-ray crystal structures,255 and calculation of free energy changes from
mutations in proteins.245-246, 252, 254, 256
Classical all-atom MD simulations use a Newtonian equation of motion (F = ma

(Equation 1.1), with F is the force on the particle, m is its mass, and a is its acceleration)
to simulate the movement of each atom in the system. The MD method starts with the

initial set of coordinates obtained from X-ray crystal structures, NMR structures or
theoretical models (homology models), or a combination of these. Given the atomic
model, the interactions for all atoms must be defined. The Newtonian equation is
subsequently applied to calculate the force after the systems are minimized to eliminate
high energy interactions, such as steric clash, prior to simulation. The integration of the
equations of motion after equilibration generates an ensemble of equilibriated states,
including coordinates and velocities of the atoms as a function of time. The simulations
require three components: initial coordinates (obtained from experimental structures or
from models, or some combination of both), a potential (obtained from a force field and
the coordinates), and algorithms for propagation.244 The process of how an MD
simulations proceeds is set out in Figure 1.8.
Initial atomic model

Calculate molecular forces acting on each atom

Move each atom according to those forces

Advance simulations time
Figure 1.8. How MD simulations proceed (adapted from Durrant D. et al246).
1.4.3.1 Force fields

The mathematical functions describing the potential energy of a system and their related
parameters are called a “force field”, which is set to describe the interactions between
atoms and molecules. A typical molecular CHARMM force field for a molecular system
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is estimated as follows in Equation 1.2. In brief, a molecular force field usually include
six terms; namely the bond, angles, dihedral, improper dihedral angles, nonbonded, and
Urey-Bradley (UB) terms.
�⃗�� = � K b (b − b0 )2 + � K θ (θ − θ0 )2 +
U��R
bonds

+
+

�

impropers

�
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Equation 1.2. Equation used to calculate the atomic forces in MD simulations, from
MacKerell A. D. et al,202, 257 where Kb, 𝐾θ , 𝐾𝜒 , 𝐾𝜑 and KUB are the bond, angles,
dihedrals angles, improper dihedral angles and Urey-Bradley force constants,
respectively. b, θ, ∅, φ, r1,3 are the bond length, bond angle, dihedral angle, improper
torsion angle, and the Urey-Bradley 1,3-distance, respectively; with the subscript zero
means the equilibrium values. The Urey-Bradley is a harmonic term, used for bondstretching or angle bending in distance between atoms 1 and 3 (the two terminal atoms)
in an angle. It is important to more accurately model in vibration spectra.258 n and δ are
the values of dihedral multiplicity and phase. The nonbonded includes the van der
Waalsand electrostatic interactions. The van der Waals interaction is using LennardJones 6-12 potential with Rmin,ij is the radius in the Lennard-Jones term; qi and qj are the
partial atomic charge of atom i and j, respectively.𝜀𝑖𝑖 is the effective dielectricconstant,
and rij is the distance between atoms i and j.
The different force fields have a critical influence on the results of MD simulations.245
The most common currently used force fields are AMBER,259 CHARMM,257
GROMOS260 and OPLS.261 The choice of force field usually depends on the preference
of the molecular simulation suite.244 Among of the most commonly-used simulation
packages are the AMBER,262 CHARMM,263 GROMACS264 and NAMD.265 These
programs share common basic features, but differences lie in their capacities, and
underlying philosophies.244

1.4.3.2 Setting up and running MD simulations

To set up and run a MD simulation, some important ingredients should be considered
carefully: such as the initial atomic coordinates of the system, the choice of force field,
simulation program (integration method), time steps, type of ensemble, boundary
conditions, salvation, and time length of the simulation.266-267 The length of simulation
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time depends on the investigated system and the aim of the study. The integration
method will decide parameter of time steps. Any change to these factors will affect the
outcomes of the simulation, as well as the requirements of computational time.268 In
addition, the type of ensemble must be selected. Traditional MD for biomolecular
systems often use NTP (N, number of particles, T, temperature, and P, pressure) or
isothermal-isobaric ensemble, which include the constant NTP. Furthermore, in MD
simulations, treatment of electrostatic interactions (long range coulombic forces) is very
important.267 Nowadays, one can use the Ewald summation method, such as the
Particle-Mesh Ewald (PME) for electrostatics.269-270

Moreover, boundary conditions and solvent models are required. Due to the influence of
interactions at the boundaries of the system on energy calculations, the boundaries must
be taken into account. The most common way in simulation of biomolecular systems is
using periodic boundary conditions. Periodic boundaries cover the system in a cell
(typically a cubic box or a sphere or other geometric shape), and surround it with mirror
replica cells of the system. The size of the box must be large enough so that the
molecule does not “see” itself.267 The interaction energies can be calculated across the
cell boundaries, so the boundary effect is minimized. Two types of solvent models are
commonly used, namely implicit (or continuum) and explicit models. The implicit
solvation means the solvent is represented with a continuum medium. Two common
algorithms used to calculate the solvent electrostatic effects are the Poisson Boltzmann
surface area (PBSA) and the Generalized Born surface area (GBSA) model.244 These
models are less expensive, but the major problem is that they do not take into account
entropic effects, and their difficulty in dealing with heterogeneous environment, which
affect many biological processes. On the other hand, the explicit solvation is the model
in which the solvent molecules and counterions are treated as explicitly surrounding the
biomolecule.244 This method is the most accurate, however it is also time-consuming.
Among different water models developed, TIP3P water model is adopted for the
CHARMM force field.271-272

In general, a MD simulation consists of minimization, equilibration, and production
steps. The initial system is minimized to relax potential steric clashes in the structure.
The minimized structure is then equilibrated. When equilibration is reached, the values
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of average temperature, pressure, and energies are stabilized. The production phase will
be the next step and used to calculate the desired properties.
1.4.3.3 Analysis of a MD simulation

The results of MD simulations are analyzed using trajectories to gain insights into the
structure; such as protein stability and flexibility. The frequently used analyses are
global measures by calculating a RMSD273 and a root mean square fluctuation (RMSF)
or B-factors;274 secondary structure analysis, hydrogen bonds (HBs), and hydrophobic
contacts;

clustering

analysis,

quasi-harmonic,

and

principal

component

analyses/correlation function, and binding free energy calculation.244
RMSD is usually used to investigate the global stability of the system,275 while RMSF is
used to obtain the local structural flexibility and stability. They are calculated as
following equations:
N

1
2
2
2
RMSD = � ��xim − xil � + �yim − yil � + �zim − zil �
N
i=1

Equation 1.3. The RMSD between atoms of the trajectory frames and the
corresponding atoms of the initial structure, where N is the number of atoms, xm, ym, zm
are the Cartesian coordinates of the initial structure and xl, yl, zl are the Cartesian
coordinates of trajectory at frame t.275
T

1
RMSF = � �(xi − x�)2
T
i=1

Equation 1.4. The RMSF of an atom, where T is the number of trajectory frames, and 𝑥̅
is the time-averaged position.275
The resulting trajectories are analyzed by the CHARMM22263 and VMD (version
1.9.1).276 A simple geometry criterion was used to define a hydrogen bond: the distance
between proton donor (D) and acceptor (A) atoms less than 3.5 Å, and the angle
D − H ⋯ A greater than 120°.70 If the percentage of HBs occupation is higher than 50%,

they are considered as the medium, whereas the strong HBs are determined by HBs

occupations of greater than 75%.70 The hydrophobic contacts between the carbon atoms
of non-polar parts of residues of proteins were also monitored with a cutoff distance of
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4.0 Å.277-278 Clustering analysis was conducted using the Clustering Plugin in VMD for
all of the snapshots from the trajectories.

Clustering analysis involves the grouping of similar samples of data, joining the
ensembles of data into the group to identify the most populated conformations sampled.
Structural clustering is a useful method to reduce the sample size for conformational
analysis to understand the molecular motion within conformational space.279 Principalcomponent analysis uses a constructed matrix of atomic fluctuations to find the lowest
modes, which represent the most of fluctuations. Quasi-harmonic analysis gives normal
modes in the harmonic system, while correlations functions are used to measure the
correlation of two fluctuating quantities over the time.244

1.4.3.4 Combining molecular docking and MD simulations

Docking and MD simulations have their own strengths and weaknesses, listed in Table
1.5. Some reviews highlighted the improvement of computational protocols using a
combination of MD simulations in docking procedures.280-281 MD simulations before
docking may explore the conformational space of the protein receptor, while using MD
simulations after docking helps to optimize the final structures, analyze protein
flexibility, and stability of different complexes, account for solvent effects, and obtain
accurate energetic properties.167
Table 1.5. Strengths and weaknesses for docking and MD simulations280-281
Docking
Fast and inexpensive: docking
Strengths
explore conformation space of
ligands in a short time, allowing the
scrutiny of large libraries of druglike compounds at a reasonable
cost.
Weaknesses Lack of or poor flexibility of the
protein. Absence of a unique and
widely applicable scoring function,
necessary to generate a reliable
ranking of the final complexes.

MD simulations
Accurate because it treats both
ligand and protein in a flexible
way, allowing for an induced fit
of the receptor-ligand. The effect
of explicit water molecules can
be studied directly.
Costly and time-consuming.
The system can get trapped in
local minima.
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1.4.4

BINDING FREE ENERGY CALCULATIONS

Given a protein (P) and a ligand (L), the ligand can bind to a protein to form a complex
PL. The binding affinity of PL in an equilibrium concentration can be computed simply
by using the following equation:

K=

[L][P]
[PL]

(Equation 1.5)

This binding affinity can then be related to the free energy of binding (free energy
change to changes in enthalpy and entropy) using:
∆Gbind = −RTlnK d = ∆H − T∆S (Equation 1.6)

Where ΔGbind is the change in free energy of a binding process, ΔH and ΔS are the
corresponding changes in enthalpy and entropy, respectively. R is a gas constant with
R=8.314 JK - 1 mol - 1 , and T is the temperature of the system in Kelvin degree, and Kd is
dissociation constant.

The binding free energies (or binding affinities) are used as a criterion for
differentiation of inhibitors from other small molecules (binders), and also selection of
strong ligands based on their protein binding strengths. It has become a major interest in
structure-based drug design. The computational approaches can be used to estimate the
binding free energies together with the experimental assays. However, obtaining
accurate values of binding free energies remains a challenge.282,283 Upon protein
binding, the protein and ligand may be affected by conformational changes influenced
by water and ions. Recently, there has been a very large number of approaches
developed to solve this problem using different atomistic models.283-298 The approaches
can have the simplicity of a scoring function (docking) or the complexity and
sophistication of free energy methods.292 Most of them are still under active study, and
have different trade-offs between accuracy and computational efficiency.

As mentioned above, docking and scoring use a single bound conformation containing a
simplified energy model, such as an empirical force field, with a simple solvent model.
Thus, it can provide approximate binding affinities (scores) of ligand and protein.
However, the docking results are system-dependent.292 The starting configuration of the
protein–ligand complex is also considered.299 Some attempts have been made to
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improve docking such as taking account redistribution of ligand charges (potential
energy models), solvent models, protein flexibility, and considering changes of
configuration entropy.292 In contrast to docking, free energy methods can give more
accurate binding energy, but need more computational cost. These approaches generate
thermodynamic averages (converged results) using a conformational sampling. They
can be classified into two methods: end point and pathway methods. The end point
methods require simulation of the bound and free states of the ligands to generate
conformations of both states, and compute the binding free energy based on the
difference between them. The pathway methods calculate binding free energy using the
simulation of many immediate states to sum up all of small changes along a multistep
pathway.292 A choice of calculating absolute or relative free energies using implicit or
explicit solvent, and the length of the simulation will hugely impact computational time,
the accuracy, and efficiency of the calculation. Popular methods include free energy
perturbation (FEP), thermodynamic integration (TI), linear interaction energy (LIE),
molecular mechanics-PBSA (MM-PBSA), and molecular mechanics-GBSA (MMGBSA), discussed below.

1.4.4.1 Free energy perturbation (FEP)

The FEP and TI approach are the theoretically rigorous methods, and offer accurate
binding free energy; including the absolute binding free energy of a ligand, and relative
binding energies between two ligands, X and Y, bound to the same protein (P).300 This
approach depends on a thermodynamic cycle (Figure 1.9). The perturbation theory is
that different binding free energy between the first state (before binding) and final state
(after binding) can be calculated by the formula ∆G = −RTln〈e−∆U/RT 〉 (Equation 1.7)

in which ΔU is change of the energy function between two states, and the angle brackets
are a Boltzmann average (ensemble average) obtained from MC or MD simulations.301
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Figure 1.9. Thermodynamic cycle for calculating relative binding free energies between
two ligands bound to the same protein (from Michel J. et al300).
Based on this theory, the difference of binding free energies of two ligands X and Y
bound in the same protein in Figure 1.9 is calculated as follows:
∆∆Gbind = ∆Gbind (Y) − ∆Gbind (X) = ∆GB − ∆GU (Equation 1.8)

Where ΔGbind(X) and ΔGbind(Y) are binding free energies for ligand X, Y, respectively;
and ΔGU and ΔGB are unphysical transmutation free energy from ligand X to ligand Y
in the unbound and bound state, respectively.
In the case where ligand X and Y are similar, the values of ΔGU and ΔGB are easier to
obtain than ΔGbind(X) and ΔGbind(Y) because the mutation from ligand X to ligand Y is
assumed to cause only localized changes. If ligand X and Y are too different, large
changes between them may cause sampling problems. So, in the FEP method, the path
of transformation is divided gradually into many small steps (intermediate) to allow
smooth conversion of ligand X to Y.300 The binding free energy difference between two
states, X and Y, is the sum of the contributions from all steps. The formula to calculate
the value for each step is:
∆G = −RT ∑N−1
i=1 ln 〈exp �−

H(λi+1 )−H(λi )
RT

�〉λi (Equation 1.9)

Where ΔG is the free energy difference between two states, X and Y. λi varies from 0
(state X) to 1 (state Y); H(λi) and H(λi+1) represents Hamiltonian of the system at λi,
λi+1; and 〈 〉𝜆𝑖 indicates an ensemble average. Absolute binding free energies can be
obtained from FEP method by setting the interaction potential of the ligand to zero in

one of the states. That means transforming the ligand into dummy atoms that do not
interact with their surroundings.250
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The FEP is currently considered the most powerful and promising approach.293-294 It
takes into account entropic contributions to binding affinities arising from solvent
effects and protein/ligand flexibility. However, the FEP results could have high
precision, but low accuracy.302-303 Most of the computational time is spent on
“perturbations”, meaning uninteresting configurations corresponding from unphysical
paths (X to Y), which makes the method difficult for application.295

1.4.4.2 Thermodynamic integration (TI)
Another pathway approach, similar to FEP is TI.300 In the TI method, the difference in
free energy between two states, A and B, is calculated based on using multiple
intermediate states, defined by a coupling parameter λ.304-305 The average of the
derivatives of the Hamiltonian at each λ, H(λ) is calculated and then TI uses numerical
integration over λ to calculate the free energy difference between two states, where λ
has the same meaning as in FEP:
1 ∂H(λ)

∆G = ∫0 〈

∂λ

〉 dλ (Equation 1.10)

Where ∆G is the Gibbs energy difference between two states, 〈 〉 is an ensemble
average obtained at λ. The pathway of intermediates between the states of interest can
be parameterized between λ=0 and λ=1.284
1.4.4.3 Molecular mechanics-Poisson Boltzmann surface area (MM-PBSA) or
Molecular mechanics-Generalised Born surface area (MM-GBSA)

Compared to the pathway methods, the end point methods such as MM-PBSA or MMGBSA are more computationally efficient, and widely applied for the estimation of the
accurate relative binding free energies of related compounds.250,

306-309

The methods

combine the Poisson Boltzmann (PB) or Generalised Born (GB) electrostatics with
molecular mechanics (MM), and solvent accessibility (SA) models, or continuum
solvent approaches, to estimate binding energies.299,

307-309

An initial MD simulation

using continuum solvent approach provides a thermally average ensemble of structures.
Several snapshots are then processed, removing all water and counterion molecules, and
used to calculate the total binding free energy of the system with the equations:
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∆Gbind = ∆H − T∆S ≈ ∆EMM + ∆Gsol − T∆S (Equation 1.11)
∆EMM = ∆Einternal + ∆Eelec + ∆Evdw
∆Gsolv = ∆GPB/GB + ∆GSA

(Equation 1.12)

(Equation 1.13)

Where ΔEMM is the change of the MM energy in the gas phase, which include ΔEinternal
(corresponding to the bond, angle, and dihedral energies), ΔEelec (electrostatic energy)
and ΔEvdw (van der Waals energy); ΔGsol is the solvation free energy which is sum of
electrostatic solvation energy, ΔGPB/GB (polar contribution, calculated by solvent
accessible surface area (SASA)) and the non-electrostatic solvation ΔGSA (nonpolar
contribtion). The conformational entropy change, –TΔS, is the most difficult term to
evaluate, estimated using quasi-harmonic analysis or normal mode analysis of the
trajectory. The entropy change can be assumed to be cancelled if only the relative
binding energies of a series of structurally similar compounds is required; however if
the absolute energy is important, or if the compounds are notably different, then the
contribution to the final free energy cannot be ignored.285

Although the MM-PBSA and MM-GBSA have shown their successful application in
biochemical systems,310-314 especially as post-docking methods in virtual screening,308
their performances rely on the system in question. The modification in simulation
protocols can affect the approach; such as the sampling strategy of generating
snapshots, methods to calculate entropy, and other parameters (charges models, force
fields, the solute dielectric constant, and radius parameters in continuum solvent
models). In general, the MM-PBSA is more sensitive to the parameters of the systems
than MM-GBSA.309

1.4.4.4 Linear interaction energy (LIE)

A new semi-empirical method for calculating binding free energies for ligands from
MD simulations has recently been introduced.315 This method is based on a linear
approximation of polar and non-polar free energy contributions from the MD averages.
The idea originated from the problem that with a diversity of compounds with “small
perturbations,” it would be very difficult to calculate their binding free energies using
FEP. Therefore, the absolute binding free energy of a ligand is calculated as the change
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in free energy when the ligand is transferred from aqueous solution (unbound or free
state) to its solvated receptor binding site (bound state).316 In other words, two
simulations are required: one with the ligand free in solution, and one with it bound to
solvated receptor. The equation for binding free energy is used as follows:
vdw
elec
〉 + β ∆〈Vl−s
〉+ γ
∆Gbind = α ∆〈Vl−s

(Equation 1.14)

Where Δ 〈 〉 are differences between the averages of the nonbonded van der Waals

(vdW) and electrostatic (elec) interactions in the bound or unbound states, collected
from MD simulation averages between the ligand and its surrounding environment (l-s).

The parameters are the weight coefficients α and β for the non-polar and polar binding
energy contributions, respectively; and an additional constant, γ.
Since its initial use, there have been a large number of studies showing LIE as a
promising method for computation of binding free energy for protein-ligand.285, 295, 315330

LIE approach is considered to be a good alternative compared to other approaches

such as FEP and TI as it estimates the absolute binding free energies; slower than
scoring of single conformations, but faster than rigorous FEP approach.320 When
examining the general validity of the electrostatic linear response approximation, the
differences in electrostatic response properties between protein and water solvent were
investigated by introducing different electrostatic scaling coefficients; βwat and βprot, and
αwat and αprot. The constant term γ in solvation energy was also discussed and it depends
linearly on surface area.319, 331-334 So the following LIE equation was:
vdw
vdw
〉bound − αwat 〈Vl−s
〉unbound
∆Gbind = αprot 〈Vl−s
elec
elec
−βprot 〈Vl−s 〉bound − βwat 〈Vl−s 〉unbound + γ (Equation 1.15)

The general equation with the values αprot = αwat, βprot = βwat and γ = 0 gave a significant
improvement compared to the orginial one. Aqvist and Hansson reported the
relationships between electrostatic free energies and the solvation energetic for several
model compounds in different solvents.316 Some deviations from linear respone were
found, in particular, for neutral dipolar solutes and for uncharged ligands having certain
dipolar groups in the case of water solvent through effect of hydrogen bonding network.
The optimal value of β = 0.5 was suggested to be reconsidered, for instance β < 0.5 to
gain more accurate predictions. The α is an empirical constant which can be fitted to
experimental binding free energies. In addition, the coefficients α and β converge to the
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same values in both bound and unbound states. These findings supported the use of the
basic LIE equation 1.14.
A refined LIE model, the FEP-derived model showed that the value of β varies
depending on the number of hydroxyl groups. The more hydroxyl groups the compound
has, the lower the value of β (Table 1.6).316
Table 1.6. Values of the β parameter as a function of the chemical nature of the ligand,
according to Hansson et al.320
Chemical nature
Charged compounds
Neutral compounds
Neutral compounds bearing a single hydroxyl group
Neutral compounds bearing two or more hydroxyl groups

β
0.5
0.43
0.37
0.33

So, the final binding energy is calculated as:
vdW
vdW
elec
elec
〉 + β 〈Vbound
〉 + γ (Equation 1.16)
∆Gbind = α 〈Vbound
− Vunbound
− Vunbound

elec
elec
〉 represents the averages change in electrostatic energy
− Vunbound
Where 〈Vbound
vdW
between the bound and unbound (free or unbound or just solvent) states, and 〈Vbound
−

vdW
〉 the average change in vdW from an aqueous solution to a protein
Vunbound

environment. α, β and γ are empirically determined constants. The α, β is for the non-

polar, polar contributions, respectively; and are the same values in the bound and
unbound state. 316 Applying a value of α = 0.18 has shown to successfully reproduce the
experimental binding free energies in a wide variety of ligand-protein systems.328
βFEP values can be assigned to each chemical group present in the ligand, as shown in
Equation 1.17 and the values are provided in Table 1.7. The weighting factors depend
on salvation energies of each chemical group. The value of wi is 1.0 for all neutral
groups or 11.0 for the anions and cations.326 The advantage of this approach is that the β
coefficient is flexible and provides higher accuracy, since deviations from the linear
response due to chemical groups such as amides, amines, or carboxylic acids is
explicitly taken into account.
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β = β0 +

∑i wi ∆βi
∑i wi

(Equation 1.17)

Table 1.7. Values for the β parameter in Equation 1.17, according to AlmlÖf M. et al.326
Parameter
Δβi
Δβi
Δβi
Δβi
Δβi
Δβi

Value
-0.06
-0.04
-0.02
-0.03
+0.02
+0.09

Chemical nature
Alcohols
1°, 2° -Amines
1° Amides
Carboxylic acid
Anions
Cations

In addition, a correlation of β and the hydrophobicity of the binding site using a
weighted desolvation non-polar ratio (WNDR) has been investigated.321 The result
suggested that the β is predictable by calculating the WNDR; in particular for systems
in which different ligands bind to different binding sites of the same protein. The
parameter γ is influenced by the hydrophobicity of the binding site.324

1.5 PROJECT BACKGROUND AND AIMS
In recent years, there has been an emergence or re-emergence of some alphaviruses in
various countries; in particular the CHIKV. This presents a worldwide threat to human
health, and creates an economic burden for the affected countries. However, there are
currently no vaccines or effective drugs available for the treatment of CHIKV virus. In
addition, there has been little research to find anti-CHIKV compounds. Therefore, a
significant need for research into medicines to combat the virus exists. During the past
decade, computational approaches have become an increasingly powerful tool in drug
discovery and development. It has not only helped scientists succeed in developing
many therapeutic compounds for specific diseases, but has also aided the development
of time-saving and cost-effective procedures.

With this in mind, we aim to discover and develop an approach leading to the
identification of a number of lead compounds to combat CHIKV disease. This study
will primarily utilise computational techniques in all stages of the process. We will use
all available information of CHIKV, together with a combination of computational
tools, to maximize the efficiency of this study. The study has three principal objectives:
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1. To identify potential inhibitors for CHIKV using a structure-based approach with
molecular docking and virtual screening.
2. To investigate the stability and flexibility of protein-hit compounds complexes with
molecular dynamics simulations.
3. To obtain accurate binding free energies from molecular dynamics simulations and
provide guidance in rational optimization of hit compounds.
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CHAPTER 2. DISCOVERY OF INHIBITORS
TARGETING CHIKV NON-STRUCTURAL PROTEIN 3

2.1 INTRODUCTION
2.1.1

FUNCTION AND ROLE OF THE NSP3 OF CHIKV

The nsP3 protein is considered an attractive target for CHIKV drug discovery72 due to
its participation in the early stages of the transcription processes of viral replication,
though the specific functions of the nsP3 protein remain elusive.8, 69, 84, 87 The nsP3 is
the third non-structural protein in the CHIKV genome. It consists of two domains, the
N-domain and the C-domain;70, 73 the N-domain is highly conserved, but the C-domain
is not.73 The C-domain is phosphorylated on serine and threonine residues on up to 16
positions.73, 85, 335-337 The role of this phosphorylation is still unclear, but deletion of the
residues involved in the phosphorylated process has been shown to decrease the level of
RNA synthesis.8,

73, 336

The N-domain contains the X-domain or a macrodomain, the

region comprising the first 160 residues; is commonly present in eukaryotic organisms,
bacteria, archea; and also many positive-strand RNA viruses such as hepatitis E, rubella,
coronavirus, and alphaviruses.70 The alphavirus macrodomain has a highly positively
charged patch on the surface, at the crevice of ADP-ribose 1"-phosphate active site and
its periphery.73 The other side of the protein, far from the active site, possesses a
negative charge. Thus, the nsP3 macrodomain is considered to complex with ADPribose derivatives and RNA. It is believed to control the metabolism of ADP-ribose 1"phosphate and/or other ADP-ribose derivatives with regulatory functions in the cell.8, 338

In addition, studies based on the SINV reported that the nsP3 phosphoprotein is an
essential component of the viral replication and transcription process.87 Functional
analysis of the effects of mutations of nsP3 on RNA synthesis demonstrated that
alterations may cause a loss of capacity for minus strand synthesis, or a failure to
increase plus strand synthesis. A change of Ala68 to Gly leading to a modification of
the His-Ala-Val peptide was predicted to form part of the active site of the conserved
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nsP3 macrodomain.87 However, no effects on the ADP-ribose binding was found.73 In
addition, the mutation of amino acids at the position Asn10 and Ala24 in ADP-ribose
binding of nsP3 macrodomain in SINV affected the replication and viral RNA
synthesis, without affecting the binding region.86-87

Recent findings revealed that the CHIKV nsP3 was described to have a novel function
as a regulator of the cellular stress response.339 Studies of SINV-infected cells indicated
the importance of nsP3 in the interactions with alphavirus-host.340 Functional analysis
of SFV at the C-terminal region of nsP3 showed that the mutations, where 10 residues
at the C-terminal are lacking, suppresses the establishment of infection; while lacking
the 30 C-terminal residues led to reduced synthesis of subgenomic RNA.341 The nsP3
macrodomain has been shown to be responsible for SINV and SFV replication in
neurons and neurovirulence in mice.85-86

2.1.2

EARLY ATTEMPTS TO DISCOVER CHIKV NSP3 INHIBITORS

The crystal structure of the nsP3 macrodomain of CHIKV was determined in 2010.73
This structure includes four subunits; and the asymmetric unit consists of six-stranded
β-sheets and four α-helices (Figure 2.1). The core β-sheet and positions of the α-helices
have proven to be highly conserved. Also present in the nsP3 structure is the ligand
ADP-ribose.70, 73 The active site is in the crevice, between the top of the β-strands 2, 4
and 5 and is surrounded by two loops between β2-α1 and β5-α3.
Currently, there is only one publication regarding molecular modelling for the CHIKV
nsP3 macrodomain based on the crystal structures (PDB id: 3GPG) and its complex
with ADP-ribose (PDB id: 3GPO).70 The study focused on an understanding of the
specific binding of the ADP-ribose to the nsP3 macrodomain of CHIKV, while also
comparing with VEEV. The results of MD simulations of the structure with ADP-ribose
identified the binding modes and the key residues for interactions between ADP-ribose
and the nsP3.70 The negatively charged PO42- component of ADP-ribose showed the
strongest interaction with the protein, and the binding free energies estimated from MD
simulations were in good agreement with previous experimental data.
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Figure 2.1. X-ray crystal structure of the macrodomain of CHIKV in complex with the
ADP-ribose.73

2.2 OVERVIEW OF THIS STUDY
There is very little information available on the nsP3 macrodomain and its inhibitor.
Therefore, this study focused on using a combination of computational approaches,
including molecular docking, virtual screening, MD simulations, and binding free
energy calculations to discover potential lead compounds that inhibit the nsP3 in
CHIKV and propose compounds for biological testing (Figure 2.2).
X-ray crystal structures
nsP3 macrodomain
(PDB id: 3GPG),
and nsP3-ADP-ribose
(PDB id: 3GPO)

Reproducing
experimental
results

Virtual
screenings

Top hit
compounds

Potential lead
compounds

Binding
free energy
calculations

Molecular
dynamics
simulations

Figure 2.2. Schematic diagram of in silico approaches.
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2.2.1

MOLECULAR DOCKING AND VIRTUAL SCREENING

A docking protocol was established (details described in the Experimental procedures
and methods section), which included the following stages:

The nsP3 macrodomain protein was downloaded from the Protein Data Bank (PDB id:
3GPG) and this was used as the receptor for docking. The protein structure was
submitted to WhatIF website to correct manually chirality errors, and the conformation
of sidechains of His, Asn, and Gln.

The next step was to carry out energy minimization to relax the structure and remove
steric overlaps using the CHARMM22 force field in the Accelrys Discovery Studio
(DS) 2.0 software package.342 The steepest descent algorithm with 3,000 steps was
applied. With a Cα RMSD of 0.59 Å between the minimized structure and the X-ray
structure, the minimized structure was utilized for the subsequent docking process.
Polar hydrogen atoms were added with AutoDock Tools (version 1.5.4). The ligand
ADP-ribose was extracted from the complex crystal structure (PDB id: 3GPO) and
prepared by AutoDock Tools for docking in Vina. The other ligands employed for
virtual screening were taken from National Cancer Institute (NCI) Diversity Set II.

Parameters of the grid box size and centre of the box were defined, and other parameters
including a search space or exhaustiveness (E) and number of binding modes to
generate (num_modes), were selected using AutoDock Tools. For docking, the grid box
needs to be large enough to accommodate the ligands. Initially, in this case, the grid box
size and its location of the binding site were defined based on the place where the ligand
ADP-ribose was bound in the X-ray structure. During virtual screening, the location and
the size of the grid box were carefully investigated via blind docking (in which the box
is sufficiently large to cover the whole protein), and focused docking (in which a
smaller box was centred on potential binding sites of interest). Blind docking can reveal
potential binding sites in the nsP3. The parameters for docking were chosen such as E
and the maximum num_modes set to the default values with E = 8 and num_modes = 9.
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The docking protocol was validated by re-docking ADP-ribose to compare with the
crystal structure of the nsP3-ADP-ribose complex. The re-docking results were
evaluated in terms of RMSD value and the binding affinity. After evaluation, the
established docking protocol was used for different virtual screenings. In an effort to
identify potential inhibitors (hit compounds), 1541 compounds from the NCI Diversity
Set II were screened by docking against the nsP3 macrodomain of CHIKV. Based on
the starting point of docking with ADP-ribose at ADP-ribose binding site, virtual
screening (VST) was carried out with three different setups. The first was a focused
docking centred on the ADP-ribose binding site (Pocket 1: VST1 and VST2). The
second setup was a blind docking centred either at the middle of the Pocket 1 (VST3) or
the protein (VST4) with the box large enough to cover the whole protein. The third
setup was a focused docking centred at the predicted binding sites by MetaPocket,343
(Pocket 2: VST5 and Pocket 3: VST6). The focused dockings at Pocket 2 (VST5) and
Pocket 3 (VST6) were also carried out. Interactions of ligands and protein were
analyzed from docking results using Accelrys DS 3.5. The Lipinski’s rule was also used
to give a general drug-likeness information for hits.206

2.2.2

MD SIMULATIONS

The program NAMD265 was used for MD simulations to investigate the stability and
flexibility of the hit-target complexes, and study their interactions. The apo protein and
the complexes of protein-hit compounds were prepared to run simulations (details of the
procedure are given in the Experimental procedures and methods Chapter). The protein
atoms were represented with the CHARMM22 force field,257 and the corresponding
parameters for the ligands were generated with AmberTools.262 The systems were
solvated under periodic boundary condition with explicit solvent model TIP3P and 0.15
M NaCl. The Langevin algorithm was used to maintain the temperature at 298.15 K and
pressure at 1 atm. The PME algorithm was used to compute long range electrostatic
interactions.269 The cutoff distance for vdW interactions were set at 12 Å and the pairlist distance was 13.5 Å. The minimization process was applied first and followed by
equilibrium simulations with weak harmonic restraints on the heavy atoms for 3 ns. The
production runs were continued for 50 ns.
49

Chapter 2. nsP3
The trajectories for analysis were saved every 10 ps. To determine the system stability,
the RMSDs of the heavy atoms over 50 ns was calculated with respect to the starting
structure versus the simulation time. The RMSF of Cα atoms during the simulations was
measured to obtain information on local flexibility of the system. The resulting
trajectories such as HBs and hydrophobic contact interactions were analyzed by the
CHARMM22263 and VMD (version 1.9.1),276 (details in Experimental procedures and
methods Chapter, section 5.2). The Clustering Plugin Tool in VMD is used for
clustering analyses.

2.2.3

BINDING FREE ENERGY CALCULATIONS

Having obtained the simulation results of protein and its complexes, the simulations of
ligands in solvent (water) were run to apply LIE approach to estimate the absolute
binding free energies for ligands in complexes with the protein targets. Preparation of
simulations for ligands are described in Chapter Experimental procedures and methods.
NAMDEnergy plugin in VMD was utilized to compute the energy components over the
frames obtained from the MD simulations.265, 276 The α, β, and γ in the LIE equation
need to be defined based on the properties such as hydrophobicity of the ligand and
binding site to estimate absolute free energies of binding.

2.3 RESULTS AND DISCUSSION
2.3.1

DOCKING RESULTS WITH ADP-RIBOSE

The docking outcomes of ADP-ribose into the nsP3 protein were evaluated and
compared with the available co-crystal structure (PDB id: 3GPO). The different ligand
conformations were ranked based on their predicted binding affinities with the default
scoring function in Vina (Table 2.1). The RMSD value was calculated between the
docked structure and the initial structure (Table 2.1). The best docked pose had a
binding affinity of -10.2 kcal/mol.
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Table 2.1. Poses in the docking of ADP-ribose into the nsP3. RMSD refers to the
heavy-atom RMSD from the co-crystal structure for ADP-ribose with the nsP3.
Poses

Binding affinity (kcal/mol)

RMSD (Å)

1
2
3
4
5
6
7
8
9

-10.2
-8.9
-8.9
-8.9
-8.6
-8.5
-8.4
-8.3
-7.8

0.6
8.6
1.8
5.5
8.4
4.4
5.7
10.0
4.5

Details of analysis of interactions between the complex of the best docked of ADPribose and the nsP3 are shown in Table 2.2 and Figure 2.3. The residues in the active
site of nsP3, namely Ile11, Ala23, Asn24, Asp31, Val33, Leu108, Gly112, Val113,
Tyr114, Tyr142, and Arg144, formed HBs with ADP-ribose. Most of the hydrogen
bond donors arose from the protein residues, with corresponding acceptors contained in
the ADP-ribose. The only exception is that the ribose component of ADP-ribose can be
the donor in interactions with Tyr142. In addition, the diphosphate component of ADPribose showed the strongest interaction compared to the rest of this ligand with the
greatest number of HBs.
Table 2.2. Analysis of interactions between the best docked of ADP-ribose and the
nsP3 macrodomain.
Part of ADP-ribose
Adenine

Number of HBs

Ribose

2

Diphosphate

5

Ter-ribose

3

2

Interactions (Å)
Arg144(HH21)-N1=2.5
Ile11(HN)-N1=2.1
H9-Tyr142(O)=2.4
Leu108(HN)-O3’=2.4
Val33(HN)-O1A=2.4
Val113(HN)-O2A=2.4
Val113(HN)-O2B=2.4
Gly112(HN)-O2B=2.1
Tyr114(HN)-O2B=2.1
Asp31(HN)-O1D=1.9
H9-Ala23(O)=2.4
Asn24(HD21)-O3D=2.1
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Figure 2.3. Re-docking ADP-ribose (A) into the active site of the nsP3: (B) The best
docking pose of ligand ADP-ribose is represented as a stick model (coloured by atom
type) while the protein nsP3 is shown in the solvent surface (coloured by interpolated
charge with a probe radius of 1.4 Å). (C) The interactions of this pose and the nsP3
residues show hydrogen bonding interactions at the binding site of the nsP3.
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Moreover, the accuracy and reliability of docking were evaluated by superimposing
both the docked structure and the X-ray structure. The heavy atom RMSD was 0.6 Å,
smaller than the 2.0 Å (often used as a criterion for the correct bound structure
prediction)344 (Table 2.1 and Figure 2.4), indicating that molecular docking reproduced
the binding mode in the co-crystal structure. A comparison of interactions of docking
results with published data (Table 2.3) confirms that there was a good agreement with
the key interactions, and showed the current docking protocol was able to reproduce the
correct pose. The differences in important residues from forming HBs and hydrophobic
contacts were acceptable due to different methods used.

Figure 2.4. Superimposition of the ADP-ribose after docking (in red, the top pose) and
its structure in the co-crystal structure (in blue) at the active site of nsP3. The heavyatom RMSD between the two structures is 0.6 Å.
Table 2.3. Comparison of the identified hydrogen bonding interactions in the nsP3ADP-ribose docked complex with the previously published data. In Ref [73], key
residues including bonding residues (in bold), were identified by experimental work
with the crystal structure of complex nsP3-ADP-ribose (3GPO) while residues in Ref
[70] were determined by MD simulations of ADP-ribose in the nsP3 based on the above
crystal structure.
Current work

Ref73

Ref70

HBs

11

11

11

Interacting
residues

Ile11, Ala23,
Asn24, Asp31,
Val33, Leu108,
Gly112, Val113,
Tyr114, Tyr142,
Arg144

Asp10, Ile11, Asn24,
Asp31, Thr111,
Gly112, Val113,
Tyr114, Tyr142,
Arg144

Asp10, Ile11,
Asn24, Asp31,
Val33, Ser110,
Thr111 Gly112,
Val113, Tyr114,
Arg144
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2.3.2

IDENTIFICATION OF INHIBITORS FOR THE NSP3 MACRODOMAIN

Results of virtual screenings based on bind docking and focused docking are listed in
the Table 2.4. The top ten compounds for each VST and their binding affinities were
selected (structures appended in Appendix 1).
In addition to the proposed ADP-ribose binding site (the active site, Pocket 1), two
additional binding sites (Pocket 2 and 3) were identified based on blind docking. The
residues making up each pocket are listed in Table 2.5.
Pocket 1 and Pocket 3 share a number of interacting residues including Asn24, Asp31,
Val33, Gly112, Val113, and Tyr114. Pocket 2 was found on the opposite side and
behind Pocket 1. The locations of pockets in the nsP3 and the locations of top hit
ligands in the three pockets are illustrated in the Figure 2.5.

54

Chapter 2. nsP3
Table 2.4. Results of the top ten compounds of different virtual screens for the nsP3. The binding affinities are shown in kcal/mol.
VST1a
1. NCI_25457
(-10.8)
2. NCI_116702
(-10.7)
3. NCI_309892
(-10.3)
4. NCI_109451
(-10.2)
5. NCI_127133
(-10.2)
6. NCI_328101
(-10.2)
7. NCI_372275_a
(-10.2)
8. NCI_45545
(-10.2)
9. NCI_84100_b
(-10.2)
10. NCI_37168
(-10.1)

VST2b
1. NCI_34567_a
(-10.9)
2. NCI_37553
(-10.9)
3. NCI_25457
(-10.8)
4. NCI_116702
(-10.7)
5. NCI_58052
(-10.6)
6. NCI_127133
(-10.5)
7. NCI_293778
(-10.5)
8. NCI_670283
(-10.5)
9. NCI_328101
(-10.4)
10. NCI_372499_b
(-10.3)

VST3c
1. NCI_61610
(-11.1)
2. NCI_293778
(-11.0)
3. NCI_345647_a
(-10.9)
4. NCI_25457
(-10.8)
5. NCI_58052
(-10.6)
6. NCI_127133
(-10.5)
7. NCI_372499_b
(-10.3)
8. NCI_37553
(-10.3)
9. NCI_309892
(-10.2)
10. NCI_37168
(-10.2)

VST4d
1. NCI_61610
(-11.1)
2. NCI_37553
(-11.0)
3. NCI_345647_a
(-10.9)
4. NCI_25457
(-10.8)
5. NCI_293778
(-10.8)
6. NCI_127133
(-10.7)
7. NCI_116702
(-10.6)
8. NCI_58052
(-10.6)
9. NCI_670283
(-10.5)
10. NCI_324623
(-10.3)

VST5e
1. NCI_127133
(-8.3)
2. NCI_293778
(-8.2)
3. NCI_338042
(-7.6)
4. NCI_132232
(-7.5)
5. NCI_310326
(-7.4)
6. NCI_328101
(-7.4)
7. NCI_69359_a
(-7.3)
8. NCI_90737
(-7.3)
9. NCI_122819_a
(-7.2)
10. NCI_400976
(-7.2)

VST6f
1. NCI_670283
(-10.6)
2. NCI_319990
(-10.2)
3. NCI_80731
(-10.1)
4. NCI_84100_b
(-10.1)
5. NCI_372287_a
(-10.0)
6. NCI_84100_a
(-9.9)
7. NCI_97920
(-9.6)
8. NCI_58502
(-9.5)
9. NCI_227186_a
(-9.4)
10. NCI_293778
(-9.4)

(a) In VST1, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43.0 Å, -13.2 Å) with a dimension of 16 Å × 16 Å × 16 Å. (b) In VST2, the
grid box is fixed at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST3, the grid box is fixed at
the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 50 Å × 50 Å × 56 Å. (d) In VST4, the grid box is fixed at the centre of the
protein (7.7 Å, 45.3 Å, -5.3 Å) with a dimension of 50 Å × 50 Å × 56 Å. (e) In VST5, the grid box is fixed at the centre of Pocket 2 (7.7 Å, 45.4
Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (f) In VST6, the grid box is fixed at the centre of Pocket 3 (2.3 Å, 44.6 Å, -18.3 Å) with a
dimension of 20 Å × 20 Å × 20 Å.
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Table 2.5. Pocket residues in the nsP3 macrodomain.
Pocket
Pocket 1

Pocket 2

Pocket 3

Pocket residues
Asp10, Ile11, Ala22, Ala23, Asn24, Gly30, Asp31, Gly32, Val33,
Cys34, Gly70, Pro107, Leu108, Leu109, Ser110, Thr111, Gly112,
Val113, Tyr114, Tyr142, Cys143, Arg144, Asp145, Trp148
His-1, His0, Ala1, Pro2, Ser3, Tyr4, Phe129, Met132, Asp133,
Ser134, Thr135, Asp136, Ala137, Asp138, Val139, Ile156, Gln157,
Arg159, Thr160
Ala22, Ala23, Asn24, Pro25, Arg26, Leu28, Pro29, Gly30, Asp31,
Gly32, Val33, Cys34, Pro51, Val52, Gly70, Pro71, Asn72, Tyr76,
Leu108, Ser110, Thr111, Gly112, Val113, Tyr114

Figure 2.5. Representation of three binding pockets identified in the nsP3 with top hit
compounds binding in the pockets. Pocket 1 is the ADP-ribose binding site with ligand
NCI_25457 (A, in burgundy), NCI_345647_a (B, in red), and NCI_61610 (C, in pink).
Pocket 3 shares some residues with Pocket 1 with ligand NCI_670283 (E, in yellow).
Pocket 2 is in the other side of Pocket 1 with ligand NCI_127133 (D, in dark green).
In the focused dockings targeting Pocket 1 (the ADP-ribose binding site, VST1 and
VST2), the top hits were NCI_25457 (-10.8 kcal/mol) and NCI_345647_a (-10.9
kcal/mol) (Figure 2.6). Among the top ten hits, four are shared between VST1 and
VST2, which differ in the size of the grid box used. It is worth noting that the change in
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size of the grid box affected the searching process in Vina, with some new hits being
identified. However, the binding affinity values between them are not significantly
different from each other. To find more inhibitors, and other potential binding sites in
the structure of nsP3, blind docking was used to dock into the entire protein with the
grid box centred either at the middle of the ADP-ribose binding site (VST3) or the
protein (VST4). For the blind docking (VST3 and VST4), six of the top ten hits are
common to VST3 and VST4, and their binding affinities were reproduced within 1.0
kcal/mol. This indicated that the blind dockings are likely to have converged. The
results show that most of the top ten ligands fitted well in Pocket 1, and that this pocket
can accommodate ligands of different size. However, ligands with bulky structures,
such as NCI_293778, NCI_58052 and NCI_61610 (in both VST3 and VST4, Figure
2.6), protruded from the binding site. Therefore, the other pockets surrounding Pocket 1
may serve as alternative binding sites for potential inhibitors.

Screenings in VST5 and VST6 produced hits already identified from previous screens,
along with some new hits (Table 2.4). For virtual screening, changes to the size of the
grid box and its location affected the searching process in Vina. An increase in the
dimension of the box is likely to be suitable for larger molecules. For instance, in the
blind docking (VST3 and VST4), NCI_61610 (-11.1 kcal/mol) was identified as a top
hit, but it did not belong to the top 10 hits in VST1 and VST2. It was also important to
note that the majority of hit compounds have a tighter binding in Pocket 1 compared to
those in Pocket 2. Most compounds effectively occupied Pocket 2 and Pocket 3 with the
significant interactions. Ligands NCI_127133 (-8.3 kcal/mol) and NCI_670283 (-10.6
kcal/mol) (Figure 2.6) bind in Pockets 1, 2, and 3, though in different conformations.
Interestingly, the ligand NCI_293778 appeared able to bind in all three pockets, and it
may infer that Pocket 1 was more favourable for binding, given the binding affinity of
-10.5 kcal/mol compared to -9.4 kcal/mol (Pocket 3) and -8.3 kcal/mol (Pocket 2).
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Figure 2.6. Structures of the top hit compounds, obtained from screenings for the nsP3.
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Detailed analyses of the interactions between the ligands and protein target were carried
out in regard to HBs and hydrophobic contacts (Appendixes 2-7).224 The results showed
that the hydrogen bonding interactions played a more important role in the binding to
Pocket 1 and Pocket 3, whereas hydrophobic contacts were responsible for most
interactions in the binding to Pocket 2. The contribution of aromatic rings by π-stacking
or π-network was emphasized in the enzyme. Most of the ligands can fit very well in the
Pocket 1 by forming hydrogen bonds with backbone nitrogen of Val113 or Thr111,
and/or interacting through π-stacking or π-network with aromatic ring of Tyr114 or
Trp148. For example, top-hit ligands NCI_25457 and NCI_61610 could interact with
protein through HBs with residues Val113 and Gly112, respectively; and also πstacking with Trp148 (Figure 2.7). In addition, the residues located in the region 110114 play a crucial role in ligand binding to Pocket 1. Mostly, ligands served as
hydrogen bonding acceptors while residues of protein were donors. Only interactions
between ligands and Thr111, in some cases, this residue can change its role to be an
acceptor. In agreement with previous reports,70 residues Ser110, Thr111, Gly112, and
Tyr114 define Pocket 1 and were key residues in forming interactions with ligands. In
addition, we found these residues concurrently define Pocket 3. Among them, Tyr114
formed HBs with ligands, or interacted through the π-network on the aromatic ring with
most of ligands in both Pockets 1 and 3. Residues Asp31 and Asn75 contributed in
forming hydrogen bonds for ligands in Pocket 3. For ligands bound in the Pocket 2, we
found residues Tyr4 or Met132, Asp133, and Thr135 are key residues in forming
hydrogen bonding interactions between ligands and protein. Additionally, ligand
interactions were observed by π-stacking from the aromactic ring of Tyr4.
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D

Figure 2.7. Binding pose and interactions of hit compounds in the nsP3 macrodomain:
(A) NCI_25457 in Pocket 1: HBs with Val113 and π-π interaction with Trp148; (B)
NCI_61610 in Pocket 1: HBs with Gly112 and π-π interaction with Trp148; (C)
NCI_127133 in Pocket 2: HBs with Asp133; (D) NCI_670283 in Pocket 3:
Hydrophobic contacts only. The ligands (in cyan) and the residues surrounding the
ligands (in grey) were displayed in sticks and coloured by atoms (carbon in cyan in
ligand or in grey in residues, nitrogen in blue, oxygen in red).

2.3.3

MD SIMULATIONS

MD simulations were undertaken to investigate the stability of the protein and its
complexes as well as gain insights into the accurate binding modes of the protein and its
inhibitors.

The

NCI_670283,

top-hit

and

compounds

NCI_127133;

and

NCI_61610,
the

NCI_25457,

tenth-hit

NCI_345647_a,

compounds

NCI_37168,

NCI_372499_b, NCI_37168, NCI_324623, NCI_400976, and NCI_293778 from each
screening were also subsequently submitted to MD simulations (Table 2.6). MD
simulations were carried out with the NAMD package with the CHARMM force field
for 50 ns following 3 ns equilibrium simulations.
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Table 2.6. Chemical structures of five top hit compounds for the nsP3 macrodomain
and their properties.
Compound’s Structural formula
name

Binding
affinity
(kcal/mol)

Lipinski’s
values

NCI_61610

-11.1

LogPa:
5.31
H-Db: 4
H-Ac: 4
MWd:
548.60

-10.8

LogP:
5.37
H-D: 0
H-A: 3
MW:
348.39

-9.4

LogP:
10.87
H-D: 0
H-A: 4
MW:
594.73

-10.9

LogP:
2.17
H-D: 6
H-A: 10
MW:
546.52

-10.6

LogP:
4.81
H-D: 0
H-A: 2
MW:
356.45

N
NH
NH

O

O

HN
NH
N

NCI_25457
N

N

O

NCI_293778
N

N

N

N
S

O

NCI_345647_a

OH

OH

O

OH
HO

O

OH

NCI_670283

OH

O

O

O
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O

NCI_127133

-8.3

LogP:
4.52
H-D: 3
H-A:4
MW:
434.4

-10.1

LogP:
2.98
H-D: 1
H-A: 5
MW:
322.32
LogP:
1.91
H-D: 0
H-A: 3
MW:
308.34
LogP:
1.37
H-D: 0
H-A: 4
MW:
328.37

HN
HO

O
O

NCI_37168

N
H

O2N
N
C
O
HO

NCI_372499_b

NCI_324623

N

H
N

OH

N

O

OH

-10.3

-10.3

O

O
N

-7.2

NCI_400976

N
C
H 2N

NH2

LogP:
2.50
H-D: 3
H-A:4
MW:
237.31

(a) A calculated octanol-water partition coefficient; (b) H-D: Hydrogen bond donor; (c)
H-A: Hydrogen bond acceptor; (d) MW: Molecular weight.
2.3.3.1 Overall stability of the nsP3 and its complexes

In order to assess overall stability, the values of positional RMSD for backbone from
the starting structure are used as a major criterion. Backbone RMSD curves for the nsP3
and its complexes with different ligands with respect to the starting structure after the
systems reached equilibrium within 3 ns, are shown in Figure 2.8. The plots showed that
most of the systems were relatively stable during the 50 ns simulations within 1-2.5 Å.
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A

B

Figure 2.8. The backbone RMSD profiles for the apo protein nsP3 and its different
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit compounds;
(B) Complexes of the nsP3 and tenth-hit compounds.
2.3.3.2 Investigating the flexibility of the nsP3 and its complexes
To understand the flexibility of the complex, the RMSF of the Cα atoms of each residue
was calculated from the trajectory data for 50 ns for the protein nsP3 and its complexes.
The RMSF profiles presented in Figure 2.9 show they are comparatively similar
between the apo protein and the complexes.
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A

B

Figure 2.9. RMSF values of Cα atoms of the apo protein nsP3 and its different
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit compounds;
(B) Complexes of the nsP3 and tenth-hit compounds.
With regards to hit compounds in Figure 2.9 (A) and (B); the residues making up the
binding pockets were quite stable during the simulations (the fluctuation within 1.0 Å).
Subtle differences were observed for a few regions, including the loop at residue 31-34.
It is worth noting that for three ligands NCI_61610, NCI_25457, and NCI_345647_a
bound to the protein at Pocket 1, the RMSFs for the binding loop region 31-34 were
decreased compared to those in the apo protein. However, this RMSF for this loop was
not significantly perturbed for the ligands NCI_670283 and NCI_127133 when bound
to Pocket 3 and Pocket 2, respectively.
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2.3.3.3 Atomic interaction between the protein nsP3 and ligands

Detailed analysis of the interactions between the ligands and nsP3 were carried out on
the HBs interactions and hydrophobic contacts. The outcomes are listed in Table 2.7
and Table 2.8.
Table 2.7. Hydrogen bonding analyses on the trajectories sampled in MD simulations
of hit compounds for the nsP3.
NCI_61610

Number
5

NCI_25457

3

NCI_345647_a

7

NCI_670283

4

NCI_127133
NCI_37168vst1

1
7

NCI_372499vst2

4

NCI_37168vst3

13

Details of HBs
Asn24 (HD22)-O1
Tyr114 (HN)-O
Gly112 (HN)-O
Thr111 (OG1)-H1
Cys34 (HG1)-O1
Val113 (HN)-N
Val33 (HN)-N
Val33 (HN)-O
Ile11 (HN)-O4
Ile11 (HN)-O6
Gly112 (HN)-O1
Val33 (HN)-O
Gly32 (O)-O5
Thr111 (HN)-O1
Arg144 (HE)-O3
Thr111 (HN)-O
Gly112 (HN)-O
Ser110 (HN)-O
Thr111 (HG1)-O
Arg159 (HH12)-O2
Asn24 (HD22)-N1
Asn24 (HD22)-O2
Asn24 (HD22)-O3
Asp32 (HN)-N1
Asp31 (HN)-O2
Asp31 (HN)-O3
Cys34 (HG1)-O2
Asp145 (OD1)-H
Asp145 (OD1)-H1
Asp45 (OD2)-H
Asp145 (OD2)-H1
Asn24 (HD22)-N1
Asn24 (HD22)-O2
Asn24 (HD22)-O3
Gly30 (HN)-O3
Cys34 (HN)-N1
Cys34 (HN)-O2
Cys34 (HN)-O3
Leu108 (O)-H1

% occupancy
98
92
88
13
10
29
21
20
39
12
18
17
14
13
10
77
65
25
10
22
18
20
16
26
18
16
10
13
19
19
26
25
24
24
10
12
12
11
92
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NCI_37168vst3

NCI_324623vst4

5

NCI_400976vst5
NCI_293778vst6

1
4

Thr111 (HN)-O1
Gly112 (HN)-O
Gly112 (HN)-O1
Val113 (HN)-O
Tyr114 (HN)-O
Asn24 (HD22)-O
Val33 (HN)-O1
Cys34 (HG1)-N1
Thr111 (HN)-O
Gly112 (HN)-O
Tyr4 (HN)-N1
Asn24 (HD22)-N
Arg26 (HE)-N2
Arg36 (HH12)-N2
Asp31 (HN)-N1

92
90
69
49
90
56
49
11
24
34
11
81
32
12
13

Table 2.8. Hydrophobic contact analyses on the trajectories sampled in the MD
simulations of hit compounds for the nsP3.
Ligand

Non-polar part of residues

NCI_61610

Ala22, Pro25, Leu28, Val33, Pro107, Val113, Tyr114, Trp148

NCI_25457

Ala22, Val33, Pro107, Val113, Tyr114, Trp148

NCI_345647_a

Ile11, Val33, Ala36, Val113, Tyr114, Trp148

NCI_670283

Ala22, Leu28, Val33, Pro107, Val113, Tyr114

NCI_127133

Ala1, Pro2, Tyr4

NCI_37168vst1

Ala22, Ala23, Val33, Pro107, Thr111, Val113, Tyr114, Arg144

NCI_372499vst2

Val33, Arg144, Trp148

NCI_37168vst3

Ala22, Ala23, Val33, Pro107, Val113, Tyr114, Trp148

NCI_324623vst4

Ala22, Val33, Phe45, Pro107, Val113, Tyr114

NCI_400976vst5

Ala1, Pro2, Tyr4, Phe129, Arg159

NCI_293778vst6

Ala22, Ala23, Pro25, Arg26, Leu28, Val113, Tyr114

For hit compounds, hydrogen bonding and hydrophobic contact analyses indicated that
all investigated ligands are stabilized the protein by a number of HBs (Tables 2.7 and
2.8). Complementary to the docking where the protein was kept rigid, MD simulations
revealed that when the ligands bind to the nsP3, the ligand and/or the residues in the
binding pockets fluctuate and adapt their structure in order to better accommodate the
ligands by optimizing HBs and/or hydrophobic contacts. Most ligands at Pocket 1 and
Pocket 3 bound strongly to the nsP3; always displaying strong HBs, particularly with
Asn24, Val33, Cys34, Thr111, Gly112, Val113, and Arg114, while Tyr4 is important in
Pocket 2.
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Moreover, based on the occupancy of HBs for each ligand, the results showed that
Pocket 1 could have the highest potential for ligand binding, as Pocket 1 had more HBs
with higher occupancy than those in Pocket 3 > Pocket 2. As mentioned above, some
residues, such as Val33, Val113, Tyr114, Arg144, and Trp148 (for compounds binding
to Pocket 1), displayed noticeable movement upon binding. For the ligands
NCI_127133 (Pocket 2), and NCI_670283 (Pocket 3), the results showed the fluctuation
of residues Ala1, Pro2, and Tyr4 (at Pocket 2), and residues Val113, and Tyr114
(Pocket 3), were required for a correct fit into the nsP3. In particular, some ligands
(NCI_61610 and NCI_37168) established the strong HBs interactions with the nsP3 at
Pocket 1, emphasized on the residues at region of 110-114. For instance, occupancy of
HBs of NCI_61610 and residues at Pocket 1, namely Asn24, Tyr114, Gly112 was 98%,
92%, and 88%, respectively. Ligand NCI_37168 hydrogen-bonded with residues
Thr111 (92%), Gly112 (90%), Tyr114 (90%); and two medium hydrogen bonds
between NCI_670283 and Thr111 (77%); and Gly112 (65%) at Pocket 3 were observed.
For ligand NCI_61610 at Pocket 1, half of the ligand was quite stable, while the other
half was flexible enough to fit well through interacting with Trp148 by π-π interaction
and forming HBs with residues in the region 110-114 (illustrated in Figure 2.10). For
ligand NCI_670283 at Pocket 3, the part of ligand which interacted with the region of
residues from 110-114 was optimized to fit well in the pocket, even though the
frequency of HBs interactions were medium with Thr111 (77%), Gly112 (65%), and
weak with Ser110 (25%), respectively (Figure 2.10).
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A

Thr111
13%
H
N

Gly112
88%

N
H

H

O

N

N

Tyr114
92%
N

N
H

O

Asn24
98%

Cys34
10%

(19)

B

Thr111
77%
Gly112
65%

Ser110
25%
O

O

(21)

Figure 2.10. Hydrogen bonding interactions between the nsP3 and ligands: (A) Ligand
NCI_61610 at Pocket 1 and (B) Ligand NCI_670283 at Pocket 3, with representation of
ligands and key residues for interactions surrounding the ligands (in stick).
Furthermore, the key residues interacting in the region 110-114 of the protein at Pockets
1 and 3, served as hydrogen bond donors, except in the complex nsP3-NCI_61610,
where residue Thr111 served as an acceptor. This observation is in close agreement with
docking results as well as with earlier simulations and experimental data.70 In addition,
it emerged that the structure of NCI_61610 and NCI_345647_a are more polar, thus
more hydrogens bonds were found in their complexes than others.
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The solvent accessible surface areas (SASA) were also calculated to monitor the
possible solvation environment change upon ligand binding (Appendix 8). It was
expected that the SASA for hydrophobic interacting residues in the complex proteinligand would be decreased compared to those in apo protein. At Pocket 1, when the
ligands bind to protein, it can be seen that the SASA of residue Tyr114 showed a
decrease from 70.2 Å2 in the apo nsP3 to 63.4 Å2 for the nsP3-NCI_61610 complex, and
63.8 Å2 for nsP3-NCI_345647_a complex. Also, the SASA of Val33 displayed a
reduction from 68.8 Å2 in the apo state to 57.4 Å2 and 52.9 Å2 for the bound state in
nsP3-NCI_25457, and NCI_345647_a, respectively. However, changes observed in
SASA for Val33, Val113, and Trp148 are not consistent for different ligands. It can be
rationalised that these residues were not only able to form hydrophobic contacts, but
also form polar hydrogen bonding interactions. Thus, the change in SASA will be
compromised by the polar interactions and both of protein and ligands will modulate the
SASA values.

2.3.3.4 Clustering analysis

Throughout the simulations, the complex structure of the protein and ligands could vary
under the effects of environment, so structural clustering was used to identify the most
popular conformation during the simulation, and more important to compare the
structures from MD simulation and docking. Clustering analysis was carried out on all
of the snapshots from the trajectories, and the clusters were visualized and
superimposed with the initial structure. The value of RMSD was used to evaluate the
difference between clustering structures and initial structure. The different
conformations of protein and its complexes at 0 ns, 10 ns, 20 ns, 30 ns, 40 ns, and 50 ns
were superimposed. Slightly fluctuations were found in all complexes, though had very
little significance. For example, for the ligand NCI_61610, in Figure 2.11,
superimposition of the most popular conformations of protein obtained from
simulations and RMSD value for the ligand was 1.2 Å (at 10 ns), 1.1 Å (at 20 ns), 1.8 Å
(at 30 ns), 2.2 Å (at 40 ns), and 2.0 Å (at 50 ns), with respect to the initial structure.
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Figure 2.11. Superimposition of the different conformations of ligand and complexed
ligand NCI_61610-nsP3 during simulation with the initial structure (red: at 0 ns, grey:
at 10 ns, green: at 20 ns, pink: at 30 ns, orange: at 40 ns, and blue: at 50 ns).
2.3.3.5 Combination of MD simulations and docking for the nsP3

In order to probe the effects of the static protein structure used in the docking, multiple
docking simulations and virtual screenings were carried out based on the sampled
conformations of protein nsP3-NCI_61610 at the different timepoints (5 ns, 10 ns, 15
ns, and 20 ns). This complex was selected as NCI_61610 showed the highest potential
for interacting with the protein after analyzing the outcomes of docking and simulations.
These results are listed in Table 2.9 and Table 2.10. The binding affinities of these
docking runs in Table 2.10 were not significantly different from those obtained from
previous docking based on the X-ray structure. Additionally, the binding modes are
similar (details of interactions analysis in Appendixes 9-12). For virtual screening, most
of the top hits were the same compounds as previous screening indicated although there
were some new hits. That indicates that in the case of nsP3, the docking results were not
very sensitive for the static structure used.
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Table 2.9. Re-docking results for complex nsP3-NCI_61610 with different
conformations of the nsP3 protein taken from the different timepoints in simulations at
Pocket 1.
nsP3 conformation

At 0 ns

Binding
affinity
(kcal/mol)
-11.1

At 5 ns
At 10 ns

-10.3
-11.3

At 15 ns

-10.6

At 20 ns

-11.4

Interaction between the inhibitor and residues
of protein (with distance in Å)
Tyr114(HH)-N=2.0
Val33(HN)-O=2.3
Asn24(HD21)-O=2.4
Tyr114 (OH)-H1=1.9
Asn24 (HD22)-O=2.1
Tyr114 (OH)-H1=2.3
Asn24 (HD22)-O1=2.5
Ser110 (HN)-O=1.9
Tyr114 (OH)-H1=2.3

Table 2.10. Virtual screening results for blind docking into Pocket 1 with different
conformations of the nsP3 taken from the different timepoints in simulations. The
binding affinities are shown in kcal/mol.
VST-5nsa
1. NCI_293778
(-11.6)
2. NCI_84100_b
(-10.7)
3. NCI_84100_a
(-10.6)
4. NCI_80997_b
(-10.5)
5. NCI_37553
(-10.4)
6. NCI_61610
(-10.3)
7. NCI_670283
(-10.2)
8. NCI_59620_a
(-10.2)
9. NCI_308835
(-10.2)
10. NCI_60785_a
(-10.2)

VST-10nsb
1. NCI_37553
(-11.1)
2. NCI_293778
(-11.1)
3. NCI_60785_a
(-11.0)
4. NCI_ 59620_a
(-10.8)
5. NCI_27592_a
(-10.7)
6. NCI_670283
(-10.7)
7. NCI_82802_a
(-10.7)
8. NCI_328101
(-10.5)
9. NCI_59620_a
(-10.5)
10. NCI_308835
(-10.5)

VST-15nsc
1. NCI_293778
(-10.5)
2. NCI_308835
(-10.3)
3. NCI_37553
(-10.3)
4. NCI_97920
(-10.0)
5. NCI_84100_b
(-9.9)
6. NCI_59620_a
(-9.8)
7. NCI_84100_a
(-9.8)
8. NCI_37627
(-9.8)
9. NCI_60785_b
(-9.7)
10. NCI_25457
(-9.7)

VST-20nsd
1. NCI_37553
(-12.1)
2. NCI_61610
(-11.9)
3. NCI_670283
(-11.7)
4. NCI_293778
(-11.3)
5. NCI_60785_a
(-11.1)
6. NCI_63680
(-11.1)
7. NCI_82802_a
(-11.0)
8. NCI_219894
(-10.8)
9. NCI_80997_b
(-10.7)
10. NCI_328101
(-10.7)

(a) VST-5ns, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43.0 Å, -13.2 Å)
with a dimension of 20 Å × 20 Å × 20 Å. (b) In VST-10ns, the grid box is fixed at the
centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c)
In VST-15ns, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with
a dimension of 20 Å × 20 Å × 20 Å. (d) In VST-20ns, the grid box is fixed at the centre
of the protein at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å
× 20 Å × 20 Å.
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2.3.4

BINDING FREE ENERGY CALCULATIONS FOR THE LIGANDS
BINDING TO THE NSP3 PROTEIN

The converged trajectories of complexes obtained from simulations were used to
calculate the binding free energy for the hit compounds. The average values of vdW and
elec interactions for each ligand in the two states, bound state (Vbound) and unbound state
(Vunbound) were calculated (Table 2.11).
In applying the LIE equation, the vdW values of the ligands complexed with the
enzyme were more negative than when only in solution, showing that the ligand has
more favourable vdW interactions when complexed. The electrostatic interactions of
ligands in all the complexes were significantly less favourable than those of the ligand
in water. When using the values of empirical parameters α, β and γ, for example β =
0.43 for neutral compounds, α = 0.18 and γ = 0.0,328 the value of binding free energies
of all of complexes did not agree with the docking results (ΔG1 in Table 2.11). However,
as it has been shown that α and γ need to be recalibrated depending on the different
systems; the α value has been suggested to be dependent on the system and the force
field used in the LIE calculations while the γ relies on the nature of the binding site. In
this case, due to the lack of experimental data of complexes, the chemical nature of the
ligands and the binding sites were taken into the consideration. Most binding sites are
composed of both polar and non-polar residues, so the magnitude of hydrophobicity in
the selection of γ is not easy to define in practice, the exact value of γ does not affect the
relative ranking. A larger value of α = 1.043 was adopted as it had been shown to
provide a better estimate in the study of cytochrome P450-camphor analogue
complexes.324 The results of ΔG2, with α set to 1.043, are shown in Table 2.11, and
revealed better agreement with the binding affinity obtained from docking. This gave a
good explanation when comparing the binding free energies for different ligands at the
same pocket. It could be explained that van der Waals and electrostatic results were
compromised by hydrogen bonding interactions and hydrophobic contacts between the
ligands and the nsP3 that contributes to the binding free energy.
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Table 2.11. Average binding free energies (kcal/mol) of top-hit compounds and tenth-hit compounds for the nsP3 calculated by LIE method
using data trajectories from the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 (in kcal/mol using α = 1.043, β =
0.43, and γ = 0).328 ΔG is the predicted binding affinity by Vina (in kcal/mol).
Compound

𝐯𝐯𝐯
𝐕𝐛𝐛𝐛𝐛𝐛

𝐯𝐯𝐯
𝐕𝐮𝐮𝐮𝐮𝐮𝐮𝐮

𝐞𝐞𝐞𝐞
𝐕𝐛𝐛𝐛𝐛𝐛

𝐞𝐞𝐞𝐞
𝐕𝐮𝐮𝐮𝐮𝐮𝐮𝐮

ΔvdW

ΔElec

ΔG1

ΔG2

ΔG

NCI_61610

-75.5

-54.3

-76.9

-93.1

-21.2

16.2

3.6

-15.2

-11.1

NCI_25457

-47.7

-36.2

-28.3

-32.9

-11.6

4.7

-0.1

-10.0

-10.8

NCI_345647_a

-64.3

-49.5

-36.9

-44.7

-14.8

7.8

0.7

-12.1

-10.9

NCI_670283

-51.7

-37.7

-28.9

-32.4

-14.0

3.4

-1.1

-13.2

-10.6

NCI_127133

-45.5

-36.6

-66.3

-65.8

-8.9

-0.6

-1.8

-9.6

-8.3

NCI_37168vst1

-43.6

-29.7

-41.2

-47.0

-13.9

5.7

-0.04

-12.0

-10.1

NCI_372499vst2

-36.3

-27.8

-49.9

-53.4

-8.5

3.5

-0.03

-7.3

-10.3

NCI_37168vst3

-45.0

-30.1

-50.0

-44.4

-14.9

-5.6

-5.1

-17.9

-10.2

NCI_324623vst4

-41.5

-29.8

-41.7

-49.2

-11.6

7.50

1.12

-8.9

-10.3

NCI_400976vst5

-31.9

-23.2

-33.7

-70.8

-8.7

37.1

14.4

6.9

-7.2

NCI_293778vst6

-72.2

-55.9

-38.1

-48.1

-16.3

10.1

1.4

-12.7

-9.4
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The binding free energies in Table 2.11 indicated that most of hits compounds showed
good interactions with Pocket 1 and Pocket 3, as the values of ΔG2 were higher than
those obtained from docking, except the ligand NCI_400976vst5 at Pocket 2. A
comparison of binding free energies results of top-hit compounds complexes and tenthhit compounds complexes revealed that the binding free energies of most of top-hit
compounds were better than those of tenth-hit compounds even though they were
similar in docking results, which supported a close agreement between docking results
and MD simulations results (Table 2.11). Two ligands NCI_37168vst3 and
NCI_293778vst6 were tenth-hits which had the binding free energies lower then those
in top-hits. However, these two ligands showed better binding affinities than some tophits. These result emphasized important roles of MD simulations for investigating the
binding affinity for ligand. Further work and results from experimental data are required
to clarify the issue.

2.3.5

ANALYSIS AND SELECTING LEADS FOR BIOLOGICAL TESTING

In docking and virtual screening, based on the binding affinities and interaction
analysis, the highest priority potential compounds would be top-hit compounds, namely
NCI_61610 (-11.1 kcal/mol), NCI_345647_a (-10.9 kcal/mol), NCI_25457 (-10.8
kcal/mol), NCI_670283 (-10.6 kcal/mol), NCI_37168 (around -10.0 kcal/mol),
NCI_372499_b (-10.3 kcal/mol), and NCI_324623 (-10.3 kcal/mol).

Throughout analyzing MD simulations and binding free energy calculations using
simulation results, insights into the interactions of ligands and the protein nsP3 were
analyzed at an atomic level. Therefore, the compounds considered would be NCI_61610
(-15.2 kcal/mol), NCI_670283 (-13.2 kcal/mol), NCI_293778 (-12.7 kcal/mol),
NCI_345647_a (-12.1 kcal/mol), NCI_37168 (-12.0 kcal/mol), and NCI_25457 (-10.0
kcal/mol).

Taking the results from docking, simulations and binding free energy calculations
together, a list of compounds was proposed for biological testing would be NCI_61610,
NCI_345647_a, NCI_25457, NCI_670283, and NCI_37168 (Table 2.12).
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Table 2.12. Potential lead compounds for the nsP3 proposed for biological testing.
No

Compounds

1

NCI_61610

Chemical structure

N
NH
NH

O

O

HN
NH
N

2

O

NCI_345647

OH

OH

O

OH
O

HO

OH

3

OH

O

NCI_25457
N

N
O

4

NCI_670283

O

O

5

NCI_37168

O2N
N
C
O
HO
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2.4 CONCLUSIONS
In conclusion, with a combination of molecular docking, virtual screening, and MD
simulations, we identified potential inhibitors for CHIKV against the nsP3
macrodomain. So far, very little information is known in the literature about the nsP3
macrodomain and its inhibitors. Therefore, this study is of great importance in the
identification of potential novel inhibitors for the chikungunya virus. It is also the first
in combining computational tools to identify potential inhibitors targeting CHIKV
through taking advantages of the recently determined high-resolution crystal structure of
nsP3 in complex with ADP-ribose. Considering the presence of a positive charge at the
ADP-ribose binding site, this binding pocket may have the tendency to accommodate
negatively charged ligands, which may not have acceptable pharmacokinetic properties.
Therefore, we decided to identify all possible binding pockets based on available
methods. Starting with re-docking ADP-ribose, the bound structure and the key
interacting residues in the ADP-ribose binding pocket were successfully reproduced. It
was evident that the binding affinity of ADP-ribose was less than -10 kcal/mol showing
this negatively-charged ligand binds very tightly into the nsP3. This study also
supported that the current docking protocol utilising AutoDock Vina is robust in
reproducing experimentally determined binding modes.

Subsequently, virtual screening with the NCI Diversity Set II was undertaken to identify
inhibitors targeting CHIKV. In addition to the well-characterised adenine binding
pocket (Pocket 1), two additional binding pockets (Pocket 2 and Pocket 3) were
identified through blind docking and MetaPocket. Pocket 3 was overlapped partly by
Pocket 1, while Pocket 2 was found on the opposite side of the protein. A comparison of
the binding affinities at the three different binding pockets revealed that all the hits at
Pocket 1 bind to the protein well, with binding affinities of less than -10 kcal/mol. This
suggests that the Pocket 1 would be the most favourable for ligand binding. In contrast,
Pocket 2 might not be a good place for binding compared to Pocket 1 and Pocket 3 as
those had higher binding affinities. It is also important to note that some ligands were
repeated many times in the list of virtual screening results. With the different
conformations, these ligands can bind to different pockets e.g. the ligand NCI_127133
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binds to Pocket 1 and 2; ligand NCI_670283 binds to Pocket 1 and 3; and ligand
NCI_293778 binds to Pocket 1, 2, and 3. In such circumstances, these ligands present
better prospects as inhibitors.

By analysing the hydrogen bonding and hydrophobic interactions between the ligands
and the nsP3, key residues were identified. The region of residues 110-114 was
predicted as the most important area in interacting with ligands. This is consistent with
previous work by Rungrotmongkol et al.70

Furthermore, equilibrium MD simulations were carried out to validate the molecular
docking results. Analysis of the simulations confirmed that the docked complex of most
of the ligand-nsP3 were stable over the simulation of 50 ns. However, subtle structural
rearrangements in the nsP3 were observed to better accommodate the ligands. MD
simulations also confirmed that Pocket 1 is the more favourable pocket.

Binding free energy calculations were conducted using MD simulations results. Most of
the top-hit compounds were found to have higher potential inhibitory than the tenth-hit
compounds in terms of the binding free energy calculations values.

In future work, the detailed binding modes for the identified inhibitors will be better
characterized, with more extensive computational free energy calculations, and the
inhibitory effects will be verified by experimental studies. Additionally, our current
work also provides important input for constructing a pharmacophore for future ligandbased drug design and generating the chemical libraries for inhibitors targeting CHIKV.
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CHAPTER 3. DISCOVERY OF INHIBITORS
TARGETING CHIKV NON-STRUCTURAL PROTEIN 2
3.1 INTRODUCTION
3.1.1

FUNCTIONAL IMPORTANCE OF THE NSP2 IN DRUG DESIGN

The second non-structural protein in the CHIKV genome, nsP2, is a multifunctional
enzyme,8, 345 and an attractive target for anti-CHIKV drug discovery and development.
In its free form, the protein induces cytotoxicity, and may be responsible for
transcriptional shut-off.68 The CHIKV nsP2 also inhibits the cellular response to type I346347

and type II347 interferons (IFN) to block the host antiviral response. The complete

nucleotide sequence of the CHIKV genome reveals that the nsP2 protein is the largest
non-structural protein, being 798 amino acids long, and possessing a large net positive
charge.67 Nucleoside triphosphatase, helicase, and RNA-dependent 5'-triphosphatase
activities reside in the N-terminal domain while activities of cysteine protease, also
known as thiol protease, are present in the the C-terminal domain.345, 348-349 The nsP2
protease plays an essential role in viral replication cycle through a cleavage of the nonstructural polyproteins into non-structural proteins.345 The mechanism of protease
catalysis of VEEV (a virus in the same family of CHIKV) is related to the deprotonation
of a thiol group of cysteine residue at the active site by assistance of an adjacent
histidine residue (Figure 3.1).8 This could be explained by the reaction of imidazole ring
of histidine and the thiol group of cysteine to form a thiolate/imidazolium ion pair
which is highly nucleophilic.350 The ion pair attacks the scissile amide bond and the
intermediated products are stabilized by the oxyanion. Through catalysis, the
intermediate converts to the thioester and releases the C-terminal substrate fragment.
Hydrolysis regenerates the active site and the N-terminal substrate fragment. In
addition, based on a study on the nsP2 protease of the SINV (another alphavirus), the
substitution of amino acids at the catalytic dyad, either cysteine or histidine at the active
site, can completely abolish this enzyme function.346
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Figure 3.1. Proposed mechanism of protease catalytic of the nsP2 (adapted from
Andrew T. R. et al).350
3.1.2

EARLY ATTEMPTS TO DISCOVER CHIKV NSP2 INHIBITORS

Although the function and role of the nsP2 protease is well-known, few studies have
focused on targeting inhibitors for this CHIKV enzyme. Several studies constructed
homology models of the nsP2 protease based on the counterparts of the VEEV to assist
in drug design for CHIKV,351-353 before a crystal structure of the nsP2 protease became
available in late 2011. With the homology models, inhibitors of the nsP2 enzyme were
screened, allowing compound designs based on the pharmacophore models.351-353 The
active site was predicted to be in the major surface groove of the C-terminal-domain
region, and likely binds to the substrate polyprotein sequences in the cleavage process.8
The key residues responsible for interactions between the nsP2 protease and ligands
were established and pharmacophore features of inhibitors were suggested.351 Based on
docking results, the four best compounds, Compound 22-25 (Figure 3.2) were proposed
as potential inhibitors of CHIKV nsP2. In another study, the structure-activity
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relationships of the hit compounds were evaluated.353 Compound 28 and compound 29
were reported as promising lead compounds with predictions of CHIKV replication
inhibition at low µM concentrations, (compound 28 with EC50=5.0 µM; compound 29
with EC50=3.2 µM). The structures of mentioned compounds were in Figure 3.2
Overall, these studies have provided useful information for understanding ligand
binding and key interacting residues for the nsP2 protease. However the possible
limitation is that they were conducted using the homology models of the nsP2 protease.
The recently determined crystal structure of the nsP2 protease opened a new pathway
for drug design targeting this enzyme.

81

Chapter 3. nsP2
Compound352

Compound
(ID: 27943-Binding Database)351
O

O
HN

O
N

O
F

P

O

NH

OH
OH

N

N

OH

HO

N

N

O
O

(22)

O
O

(26)
Compound352

Compound
(ID: 21362-TosLab)351

S
N

N

N

N

O

OH

O

F

HO

N

O
OH

(27)

(23)
Compound
(ID: ASN 01541696-Asinex)351
N

O

OH
N

S

N
H

HN N

Compound353
O

O

N

N
H

S

N

O

(28)

(24)

Compound353

Compound
(ID: ASN 01107557-Asinex)351
O
N+

O

OH
N
HN N

(25)

OH

S

OH

N
H
O
HN

N
O
O

(29)
Figure 3.2. Structures of some potential inhibitors for the nsP2.
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3.2 OVERVIEW OF THIS STUDY
Based on the recently reported crystal structure of CHIKV nsP2 protease (PDB id:
3TRK), this current study aimed to discover potential new inhibitors of the CHIKV
nsP2 protease through structure-based approaches, by combining molecular docking and
MD simulations. The same process with discovering inhibitors targeting the nsP3
(described in Chapter 2) was applied for the nsP2 protease (more details in
Experimental procedures and methods section).

There was modification to the protocol in that the best four compounds 22-25 taken
from Ref351 were docked in the binding site of the nsP2 protease to confirm its location.
This binding site was assigned binding site 1 (Pocket 1). In addition, identification of
the active site of the enzyme was discussed (see Results section), and the proposed
active site was named Pocket 4 in this study.

In silico virtual screening based on docking was then performed to explore inhibitors
and potential binding sites of the nsP2 protease. Blind dockings and focused dockings
centred at each of the potential pockets identified were carried out. Additionally, the
potential binding pockets were predicted with the MetaPocket algorithm.343 The
compounds from library NCI Diversity Set II were docked to the entire protein (the
nsP2 protease) with a grid box placed at either the centre at Pocket 1 (VST1) or at the
centre of the protein (VST2). The binding modes of the compounds were ranked by
their predicted binding affinities. In total, there were five potential binding pockets
(labeled as Pockets 1 to 5, shown in Figure 3.3) identified for the nsP2 protease
(discussed in the Results section). The VST3/VST4, VST5, VST6, VST7, and VST8
screenings were focused at Pocket 1, Pocket 2, Pocket 3, Pocket 4, and Pocket 5,
respectively. The blind docking data initially revealed four potential binding sites in the
nsP2 protease (Pockets 1, 3, 4, 5). Encouragingly, the four binding pockets identified in
the blind docking were reproduced by the MetaPocket method, which also detected
Pocket 2 (near Pocket 1) despite the methods being based on very different algorithms.
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The top hit compounds were identified based on their binding affinities using the default
scoring function in Vina. The modes of interaction between the ligands and the protein
were analyzed in Accelrys DS 2.0. The drug-like properties of these compounds were
subsequently evaluated using the Lipinski Guidelines.206

To understand not only the rigid structures but also the dynamic behaviour, MD
simulations were subsequently carried out to provide details of the motion, and
flexibility of the nsP2 protease and its complexes upon binding of small molecules.
Analysis of simulations was carried out from the trajectories, saved every 10 ps. The
value of RMSD of the heavy atoms over 50 ns and the RMSF of Cα atoms during the
MD simulations was measured with respect to the starting structure versus the
simulation time, to obtain information on global stability, and local flexibility of the
system. The interactions in terms of hydrogen bonding and hydrophobic contact were
analyzed by the CHARMM22 and VMD (version 1.9.1).276 Clustering analysis was also
conducted using the Clustering Plugin in VMD. Detail was described in Chapter 2,
section 2.2.2.

The binding free energies for docked structures binding to the enzyme were estimated
based on MD simulations using the LIE method (see Experimental procedures and
methods chapter). A combination of all these methods helped to propose the list of
potential hits for biological testing.

3.3 RESULTS AND DISCUSSION
3.3.1

MOLECULAR DOCKING AND VIRTUAL SCREENING

3.3.1.1 Docking to confirm the binding site
The results of docking the four best compounds 22-25 from Ref351 into the Pocket 1, are
listed in Table 3.1. Pocket 1 includes the key residues for interactions Lys1045,
Gly1176, His1222, and Lys1239, which was taken from the previous data by Singh et al.351
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Table 3.1. Docking results of the best compounds for the nsP2 taken from previous
study [from Singh K. D. et al351] with the binding affinities (kcal/mol).
Binding affinity

Compound 22

Compound 23

Compound 24

Compound 25

(kcal/mol)

-6.6

-6.3

-6.3

-7.1

The binding affinities (Table 3.1) along with analyses of the interactions of compounds
and protein were in agreement with those published. The key residues for interactions at
the active site (Figure 3.3) were re-confirmed, although the binding affinities of these
compounds were just medium level with the values of around -6.5 kcal/mol.
A

B
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C

D

Figure 3.3. Binding pose and interactions of compounds 22-25 in the nsP2 protease:
(A) Compound 22 in Pocket 1: HBs with Glu1043, Lys1045 and Lys1239; (B)
Compound 23 in Pocket 1: HBs with Lys1045 and His1222; (C) Compound 24 in
Pocket 1: HBs with Tyr1079 and Asp1246; (D) Compound 25 in Pocket 1: HBs with
Glu1204 and His1222. Compound 22, 23 and 25 were in good position in the pocket,
except compound 24 was in the rear and nearly out of the pocket. The ligands (in cyan)
and the residues surrounding the ligands (in grey) were displayed in sticks and coloured
by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in
red, sulphur in organge).

3.3.1.2 Blind and focused dockings to identify potential binding sites and hit
compounds for the nsP2 protease

The outcomes of two blind dockings as mentioned above, one with the centre at Pocket
1 and one at the centre of protein, are displayed in Table 3.2. The results of top ten
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compounds and their binding affinities in focused dockings at each pocket are presented
in Table 3.3.
Table 3.2. Results of the top ten hit compounds from the blind dockings for the nsP2.
The binding affinities ΔG are in kcal/mol.
VST1a

VST2b

Hits

ΔG

Location

Hits

ΔG

Location

1. NCI_61610

-10.6

Pocket 1

1. NCI_293778

-10.3

Pocket 4

2. NCI_293778

-10.3

Pocket 4

2. NCI_61610

-10.1

Pocket 1

3. NCI_116702

-9.2

Pocket 3

3. NCI_670283

-9.7

Pocket 4

4. NCI_37553

-9.2

Pocket 4

4. NCI_116702

-9.2

Pocket 3

5. NCI_84100_a

-9.2

Pocket 3

5. NCI_217697

-9.2

Pocket 1

6. NCI_84100_b

-9.1

Pocket 3

6. NCI_84100_a

-9.2

Pocket 1

7. NCI_25457

-9.0

Pocket 3

7. NCI_84100_b

-9.2

Pocket 1

8. NCI_670283

-9.0

Pocket 1

8. NCI_298892_b

-9.1

Pocket 1

9. NCI_97920

-9.0

Pocket 3

9. NCI_37553

-9.1

Pocket 5

10. NCI_58052

-8.8

Pocket 3

10. NCI_25457

-9.0

Pocket 3

a) In VST1, the grid box is centred at Pocket 1 of the nsP2 protease (12.4 Å, 34.3 Å,
28.6 Å) with dimensions of 66 Å × 86 Å × 60 Å. b) In VST2, the grid box is centred at
the centre of the nsP2 protease (14.3 Å, 25.5 Å, 22.3 Å) with dimensions of 60 Å × 70
Å × 60 Å. The origin and axes of the coordinate systems were set the same as in the
PDB structure (PDB id: 3TRK).
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Table 3.3. Results of the top ten compounds of focused dockings for the nsP2. The binding affinities are in kcal/mol.
VST3a
1. NCI_217697
(-9.3)
2. NCI_670283
(-9.3)
3. NCI_298892_b
(-9.2)
4. NCI_328101
(-9.2)
5. NCI_25457
(-9.1)
6. NCI_116702
(-9.0)
7. NCI_80997_a
(-9.0)
8. NCI_109451
(-8.9)
9. NCI_93427
(-8.9)
10. NCI_127133
(-8.8)

VST4b
1. NCI_293778
(-9.8)
2. NCI_37553
(-9.7)
3. NCI_328101
(-9.3)
4. NCI_670283
(-9.3)
5. NCI_25457
(-9.2)
6. NCI_298892_b
(-9.2)
7. NCI_61610
(-9.2)
8. NCI_84100_a
(-9.2)
9. NCI_84100_b
(-9.2)
10. NCI_217697
(-9.1)

VST5c
1. NCI_293778
(-9.8)
2. NCI_37553
(-9.4)
3. NCI_269148_a
(-8.5)
4. NCI_146771
(-8.3)
5. NCI_227186_b
(-8.3)
6. NCI_308835
(-8.3)
7. NCI_7524_b
(-8.3)
8. NCI_227186_a
(-8.2)
9. NCI_328101
(-8.2)
10. NCI_362639
(-8.2)

VST6d
1. NCI_37553
(-9.6)
2. NCI_319990
(-9.4)
3. NCI_116702
(-9.2)
4. NCI_61610
(-9.2)
5. NCI_25457
(-9.0)
6. NCI_293778
(-9.0)
7. NCI_97920
(-9.0)
8. NCI_67436
(-8.9)
9. NCI_80997_b
(-8.9)
10. NCI_84100_b
(-8.9)

VST7e
1. NCI_293778
(-10.4)
2. NCI_670283
(-9.7)
3. NCI_121868_a
(-9.3)
4. NCI_37553
(-9.2)
5. NCI_61610
(-9.2)
6. NCI_319990
(-8.9)
7. NCI_328101
(-8.9)
8. NCI_67436
(-8.9)
9. NCI_227186_a
(-8.8)
10. NCI_122819_b
(-8.7)

VST8f
1. NCI_293778
(-10.2)
2. NCI_80734
(-9.2)
3. NCI_61610
(-9.1)
4. NCI_37553
(-9.0)
5. NCI_80735
(-8.7)
6. NCI_80997_a
(-8.4)
7. NCI_345845
(-8.1)
8. NCI_5157
(-8.1)
9. NCI_58052
(-8.1)
10. NCI_67436
(-8.1)

(a) In VST3, the grid box is centred at Pocket 1 (12.4 Å, 34.3 Å, 28.6 Å) with a dimension of 16 Å × 16 Å × 16 Å. (b) In VST4, the grid box is
centred at Pocket 1 (12.4 Å, 34.3 Å, 28.6 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST5, the grid box is centred at Pocket 2 (28.1 Å,
36.9 Å, 30.6 Å) with a dimension of 20 Å × 20 Å × 20 Å. (d) In VST6, the grid box is centred at Pocket 3 (30.4 Å, 42.1 Å, 14.8 Å) with a
dimension of 20 Å × 20 Å × 20 Å. (e) In VST7, the grid box is centred at Pocket 4 (3.2 Å, 31.9 Å, 18.1 Å) with a dimension of 20 Å × 20 Å × 20
Å. (f) In VST8, the grid box is centred at Pocket 5 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å.
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The blind docking data initially revealed four potential binding sites in the nsP2
protease (Pockets 1, 3, 4, 5) where the hit compounds could potentially bind.
Encouragingly, as mentioned above, a further pocket (Pocket 2) near Pocket 1 was also
found by the the MetaPocket method together with four binding pockets identified in
the blind docking. The top docked structures of each virtual screening are represented in
Figure 3.3, showing the locations of five pockets.

Figure 3.4. Representation of docked structures of top hit compounds in different
virtual screenings at five different binding sites of the nsP2 protease with Pocket 4 being
the active site of the nsP2 protease. Ligand NCI_61610 (A) and NCI_293778 (B1) in
Pocket 1; ligand NCI_293778 (B2) in Pocket 2; ligand NCI_37553 (C) in Pocket 3;
ligand NCI_293778 (B3) in Pocket 4; and NCI_293778 (B4) in Pocket 5. Ligand
NCI_293778 (B) with different conformations, B1-B4 could bind to different pockets
Pocket 1, 2, 4, and 5, respectively.
Pocket 1 and Pocket 4 (Figure 3.3) were groove-like while Pocket 2 (adjacent to Pocket
1, sharing some residues with Pocket 1 such as Tyr1177 and His1222), Pocket 3
(behind) and Pocket 5 (behind) were shallow. Pocket 3 was below Pocket 1, Pocket 4
was on the opposite site behind Pocket 1, and Pocket 5 was in the rear side behind
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Pocket 1. Pocket 4, containing the catalytic dyad Cys1013 and His1083, is the active
site. The residues making up each pocket are presented in Table 3.4.
Table 3.4. The important residues in each pocket of the nsP2 protease with the key
residues in bold involved in forming HBs and hydrophobic contacts between the protein
and ligands.
Binding
pocket
Pocket 1

Pocket 2

Pocket 3

Pocket 4

Pocket 5

Residues making up the pocket
Gln1039, Ala1040, Glu1043, Lys1045, Ala1046, Tyr1047, Gly1176, Tyr1177,
Pro1191, Leu1192, Gly1193, Val1194, Asn1202, Leu1203, Glu1204, Ile1221,
His1222, Thr1223, Asp1235, His1236, Met1238, Lys1239, Met1242
and Cys1233
His1151, Pro1153, Val1154, Lys1155, Gly1156, Glu1157, Arg1158, Met1159,
Glu1160, Tyr1177, Asn1178, Leu1179, Ala1180, His1222, Thr1223,
Pro1224, Phe1225, Gln1232, Arg1260, Tyr1262, Ser1293, Thr1292
and Thr1295
Glu1157, Arg1158, Met1159, Trp1161, Leu1162, Lys1165, Ile1166, Asn1167,
Gly1254, Ser1256, Arg1281, Ser1282, Arg1284, Leu1286, Lys1287, Pro1288,
Pro1289, Cys1290, Leu1300, Ser1302 and Asn1303
Cys1013, Ala1046, Tyr1047, Ser1048, Pro1049, Glu1050, Val1051, Tyr1078,
Tyr1079, Asn1082, His1083, Trp1084, Gly1090, Lys1091, Phe1093,
Tyr1201, Asn1202, Glu1204, Leu1205, Gly1206, Pro1208, Ala1209,
Met1238, Gln1241, Met1242, Gly1245, Asp1246 and Arg1249
Asn1040, Glu1050, Leu1053, Asp1064, Leu1065, Asp1066, Ser1067,
Gly1068, Leu1069, Phe1070, Ser1071, Lys1091, Phe1093, Asn1096, Glu1098,
Ala1099, Ile1102, Leu1103, Lys1106, Tyr1107, Asn1140, Arg1141, Arg1142,
Leu1143, Pro1144, Arg1267, Glu1270, Arg1271, Cys1274, Val1275,
Arg1278, Thr1313, His1314 and Asn1317

In the docking VST1, six out of ten ligands preferred binding at Pocket 3 along with
two ligands at Pocket 1 and two ligands at Pocket 4. In VST2, most of the ligands (five)
occupied Pocket 1, two ligands occupied Pocket 3, two ligands occupied Pocket 4, and
one ligand occupied Pocket 5. In VST4 with an increased box size, larger compounds
were identified as top hits despite not being present in VST3; for example NCI_293778
(-9.8 kcal/mol), NCI_84100_a (-9.2 kcal/mol), and NCI_84100_b (-9.2 kcal/mol) (their
chemical structures in Figure 3.4). It is likely that the larger grid box accommodates the
binding of these molecules better. Some hit compounds were present in different virtual
screenings, that means they could bind into different pockets with varying
conformations such as NCI_293778 (Pocket 1, 2, 3, 4, and 5); NCI_37553 (Pocket 1, 2,
3, 4, and 5); and NCI_61610 (Pocket 1, 4, and 5); NCI_670283 (Pocket 1 and 4);
NCI_84100_b (Pocket 1 and 3); and NCI_37553 (Pocket 3 and 5), the chemical
structures presented in Figure 3.4. The binding affinities of all hit compounds were
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approximately -9 kcal/mol, which indicate favourable interactions between the
compounds and the nsP2 protease.

Binding modes obtained from docking at potential binding sites were analysed to show
details of interactions and to identify key residues through quantification of HBs or
hydrophobic contacts. The results of the important residues involved in forming HBs
and hydrophobic contact for each pocket are detailed in Appendixes 13-20. The residues
surrounding ligands within 5 Å which make up each pocket are listed with the key
residues involved in forming HBs and hydrophobic contacts between the protein and
ligands in bold (Table 3.4). Most ligands were hydrogen bond donors, and the residues
of protein were acceptors in Pocket 1 and Pocket 3 while they can exchange their roles
in the other pockets. As mentioned earlier, the active site was Pocket 4 with Cys1013
and His1083 in good positions to be a catalytic dyad. The residue Trp1084 is close to
His1083 in Pocket 4 which is essential for interactions, as previously reported in the
study of the nsP2 protease of SINV.346 Among the five pockets (with respect to ligands
containing aromatic rings), π-stacking interactions and π-network interactions were
often present with His1222 at Pocket 1; Tyr1177 at Pocket 2; and Tyr1079 and Trp1084
at Pocket 4.

It was interesting to analyse interactions of protein and ligands to look at the different
conformations and how they bind to the different pockets. Intriguingly, for the top-hit
NCI_293778, a high binding affinity was observed, though analysis revealed no HBs
were formed at Pocket 5 (Figure 3.5). It could not explain why at Pocket 5, this ligand
gained the higher binding affinity at this pocket than those at other pockets. This might
be due to the strong compromise of degree of complementarity of protein and ligands as
the binding affinity does not hold all flexible complexes.
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Figure 3.5. Structures of some top hit compounds for the nsP2.
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Figure 3.6. Binding poses and interactions of hit compound NCI_293778 at different
binding pockets and key residues for interactions at each pocket: (A) At Pocket 1: HBs
with Lys1239; (B) At Pocket 2: π-π interactions with Tyr1177; (C) At Pocket 4: π-π
interactions with Trp1084; (D) At Pocket 5: Hydrophobic contact only. The ligands (in
cyan) and the residues surrounding the ligands (in grey) were displayed in sticks and
coloured by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue,
oxygen in red.
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3.3.1.3 Identification of the active site of the nsP2 protease

It is known that the nsP2 protease carries out its function through a conserved catalytic
dyad with a cysteine and a histidine; however, these residues have not been conclusively
identified in the CHIKV nsP2 protease. For instance, Bassetto et al. reported that
Cys1013 and His1083 (the numbering is according to the CHIKV nsP2 sequence) in the
homology model of the nsP2 protease were the catalytic residues,353 compared to
Cys477 and His546 in the VEEV nsP2 protease through a sequence alignment between
the CHIKV nsP2 protease and the VEEV nsP2 protease. In contrast, with a similarly
based the sequence alignment, Singh et al. predicted that the active site residues
interacting with the peptide substrate include Lys1045, Gly1176, His1222, and
Lys1239, without explicitly identifying the catalytic residues.351 Structural alignment of
the nsP2 proteases from three alphaviruses, CHIKV (PDB id: 3TRK), VEEV (PDB id:
2HWK), and SINV (PDB id: 4GUA) were carried out with MUSTANG354 (Appendix
21). The sequence identity between the CHIKV nsP2 protease sequence and the
counterparts in VEEV and SINV sequences are 40% and 44%, respectively. This
structural alignment revealed that Cys1013 and His1083 are the two catalytic residues in
the nsP2 protease of CHIKV (Figure 3.6). Their catalytic roles are supported by their
close proximity in the crystal structure. Cys1233 and His1222 in the C-terminal domain,
identified in the homology model by Singh et al., are separated by 15 Å in the solved
crystal structure (between the S atom in Cys and the N atom in His); thus, they are not
likely to be the catalytic residues unless there is a structural transition upon substrate
binding. Conversely, Cys1013 and His1083 in the N-terminal domain are sufficiently
close enough to carry out proton transfer (with the distance of 4.8 Å between the S atom
in Cys1013 and the N atom in His1083); thus, they are properly positioned to be a
catalytic dyad. In addition, the presence of Trp1084 close to His1083 was proposed to
be necessary for a functional protease.355
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Figure 3.7. Superimposition of three crystal structures, namely the CHIKV nsP2
protease (PDB id: 3TRK, in blue), the VEEV nsP2 protease (PDB id: 2HWK, in red),
and the structure of SINV (PDB id: 4GUA, in grey). The conserved catalytic residues,
cysteine and histidine (in licorice), Cys1013 and His1083 in the CHIKV nsP2 protease
(in blue), Cys477 and His546 in the VEEV nsP2 protease (in red); and Cys1021 and
His1098 in the SINV structure (in gray) are also shown.
3.3.2

MD SIMULATIONS

The top-hit compounds (NCI_217697, NCI_61610, NCI_37553, and NCI_293778) and
tenth-hit compounds (NCI_217697w, NCI_25457w, NCI_362639, NCI_84100b, and
NCI_67436) obtained from virtual screenings were subjected to MD simulations using
the NAMD package with the CHARMM force field (Table 3.5). In particular, ligand
NCI_293778, which had different conformations at the different binding sites
(NCI_293778vst4 at Pocket 1, NCI_293778vst5 at Pocket 2, NCI_293778vst2 and
NCI_293778vst7 at Pocket 4, and NCI_293778vst8 at Pocket 5), was investigated. MD
simulations were performed to study the stability and flexibility of the nsP2 protease
and its complexes as well as to obtain the accurate binding modes. MD simulations
were run for 50 ns following 3 ns equilibrium simulations.
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Table 3.5. Chemical structures of hit compounds for nsP2 and their properties.
Compound’s
name

Structural formula

NCI_61610

ΔGa

Physical
properies

-10.6

LogPb: 5.31
H-Dc: 4
H-Ad: 4
MWe:
548.60

-9.3

LogP: 4.97
H-D: 2
H-A: 0
MW:
358.50

-9.8f,
-10.4,g
and
-10.2h

LogP:
10.87
H-D: 0
H-A: 4
MW:
594.73

-9.6

LogP: 5.03
H-D: 2
H-A: 2
MW:
476.57

-8.8

LogP: 4.52
H-D: 3
H-A:4
MW:
434.40

N
HN
NH

O
HN

O

NH
N

H
N

H
N

NCI_217697

NCI_293778
N

N

N

N
S

NCI_37553

O
N
H

N

H
N

N
O

O

NCI_127133
HN
HO

O
O

N
H
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NCI-25457

-9.0

LogP: 5.37
H-D: 0
H-A: 3
MW:
348.39

-8.2

LogP: -0.68
H-D: 4
H-A: 8
MW:
344.24

-8.9

LogP: 6.30
H-D: 2
H-A: 2
MW:
392.15
LogP: 2.96
H-D: 4
H-A: 4
MW:
452.52

N

N

O

O

NCI_36239
HN
O
HO

N
N
N
O HN

O
NH

O

NCI_84100_b
(C26H20N2O2)

NCI_67436

H
N

H
N

O

O

N

8.1
NH

N
H

O
HN

O

HN
N

(a) ΔG refers to the binding affinities by Vina in kcal/mol. (b) The logarithm of the
partition coefficient between n-octanol and water calculated using ChemBioDraw Ultra
14.0. (c) Number of hydrogen bond donor atoms. (d) Number of hydrogen bond
acceptor atoms. (e) Molecular weight. (f) Located in Pocket 1 and Pocket 2. (g) Located
in Pocket 4. (h) Located in Pocket 5.
3.3.2.1 Overall stability of the nsP2 protease and its complexes

The overall stability of the nsP2 protease and its complexes was evaluated by the values
of backbone atomic positional RMSD. The results of backbone RMSD profile for the
nsP2 enzyme and its complexes with different ligands with respect to the starting
structure are showed in Figure 3.7.
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A

B

Figure 3.8. The backbone RMSD profiles for the apo protein nsP2 and its different
complexes during MD simulations from 4 ns to 53 ns: (A) Complexes of the nsP2 and
top-hit compounds; (B) Complexes of the nsP2 and tenth-hit compounds.
The plots showed that most of the systems were relatively stable during the 50 ns
simulations within 1-2.5 Å. In simulation of the complex of ligand NCI_293778vst8 at
Pocket 5, a large RMSD was observed around 47 ns (Figure 3.7 A). Examination of the
structures revealed that it was due to the relative movement between two domains and
the fluctuation of loops. This ligand was also found to gradually move from a position
whereby part of the ligand was positioned out of the pocket, to the whole ligand being
out of the pocket but still stuck at the rear after 40 ns, and finally dissociated from the
pocket after 47 ns.

98

Chapter 3. nsP2
3.3.2.2 Investigation of flexibility of the nsP2 protease and its complexes
For the flexibility of the nsP2 protease and its complexes, the RMSF curves of the Cα
atoms in the nsP2 protease and its complexes were calculated, displayed in Figure 3.8.
A

B

Figure 3.9. RMSFs values of Cα atoms of the apo protein nsP2 and its different
complexes during MD simulations: (A) Complexes of the nsP2 and top-hit compounds;
(B) Complexes of the nsP2 and tenth-hit compounds.
For the flexibility, comparative analysis of the RMSF values of the apo protein and the
complexes was focused on the binding sites of ligands. Most of the residues making up
the binding sites were quite stable during the simulation with fluctuations within 2 Å.
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Furthermore, no significantly reduced fluctuations were found in the binding pockets of
the protein between the nsP2 protease (apo protein) and its complexes with the nsP2
protease-ligand.

3.3.2.3 Atomic interaction between the nsP2 protease and hit compounds

Details of atomic interactions were obtained by HBs and hydrophobic contacts. The
residues involved in forming hydrophobic contacts based on the trajectories of the MD
simulations are listed in Table 3.6 and Table 3.7.

Table 3.6. Hydrogen bonding analyses on the trajectories sampled in the MD
simulations for hit compounds in complexed with the nsP2 protease. The HBs with
occupancy more than 10% are in highlighted in bold.
Ligands
NCI_61610

NCI_217697

NCI_37553

NCI_293778vst4

Details of HBs
Lys1239(HZ1)-N1
Lys1239(HZ2)-N1
Lys1239(HZ3)-N1
His1222(HN)-O1
Glu1204(HN)-O
Lys1239(HZ3)-O
Lys1239(HZ2)-O
Lys1239(HZ1)-O
His1222(HN)-O
Lys1045(HZ3)-N1
Lys1045(HZ1)-N1
Lys1045(HZ2)-N1
Lys1045(HZ2)-O
Gly1176(HN)-O1
Gln1039(OE1)-H
Glu1043(OE2)-H
Leu1193(O)-H1
Asn1202(OD1)-H1
Glu1204(OE1)-H
Glu1204(O21)-H
Arg1284(HH12)-O1
Arg1284(HH12)-N1
Ser1302(HG1)-O1
Lys1165(HZ2)-O
Lys1165(HZ1)-O
Lys1165(O)-H1
His1222(HD1)-N3
Asn1202(HD21)-N3
Lys1239(HZ1)-N
Lys1239(HZ2)-N

% occupancy
7.5
6.0
5.6
4.5
3.1
2.9
2.7
2.6
1.8
0.3
0.3
0.3
0.1
0.1
0.2
0.1
1.7
0.3
0.5
0.4
80.5
26.3
10.4
7.2
2.9
1.7
10.7
0.5
0.1
0.1
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NCI_293778vst5

NCI_293778vst2

NCI_293778vst7

NCI_293778vst8

NCI_217697w

NCI_25457w
NCI_362639

NCI_84100b

NCI_67436

Lys1045(HZ2)-N3
Lys1045(HZ3)-N3
Leu1192(HN)-N2
Gly1156(HN)-N
Lys1155(HZ2)-N
Lys1155(HZ1)-N
Lys1155(HZ3)-N
Met1159(HN)-N
Tyr1079(HH)-N3
Asn1082(HD22)-N2
Trp1084(HE1)-N3
Asn1082(HD21)-N3
Asn1082(HD21)-N2
Tyr1079(HN)-N1
Leu1207(HN)-N2
Ser1048(HG1)-N2
Tyr1079(HH)-N
Asn1082(HD21)-N1
Ser1067(HG1)-N2
Arg1105(HE)-N3
Lys1106(HZ2)-N2
Lys1106(HZ3)-N2
Arg1141(HH11)-N3
Glu1043(OE1)-H
Glu1043(OE2)-H
Leu1192(O)-H1
Asn1202(OD1)-H1
Glu1204(OE1)-H
Lys1165(HZ1)-N
Lys1165(HZ1)-N
His1152(HD1)-N1
His1152(NE2)-H2
Pro1153(O)-H1
Val1154(HN)-O4
Phe1224(HH)-O2
Leu1162(O)-H1
Trp1161(O)-H1
Lys1165(O)-H1
Arg1284(HH12)-O1
Asn1140(HD22)-N1
Arg1142(HN)-O
Glu1270(OE1)-H2
Glu1270(OE2)-H2
Cys1274(HG1)-N5
His1314(HD1)-O1
Asn1317(HD21)-O1

0.1
0.1
0.1
1.4
0.8
0.5
0.5
0.1
8.6
5.8
3.4
3.6
0.4
0.2
0.1
0.6
0.1
0.1
0.2
0.2
0.1
0.1
0.1
1.9
2.7
2.9
6.6
1.6
1.8
1.4
0.5
0.5
1.3
1.2
1.3
28.0
3.3
4.9
7.3
65.3
63.4
49.2
49.5
28.2
22.2
26.1
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Table 3.7. Hydrophobic contact analyses on the trajectories sampled in the MD
simulations for hit compounds in complexed with the nsP2 protease.
Ligand

Interacting non-polar parts of the residues

NCI_61610

Ala1040, Tyr1177, Pro1191, Leu1203, Ile1221, Leu1243

NCI_217697

Pro1191, Leu1243

NCI_37553

Trp1161, Leu1162, Leu1286, Pro1288, Pro1289, Leu1300

NCI_293778vst4

Pro1191, Leu1192, Leu1203, Ile1221, Leu1243

NCI_293778vst5

Tyr1177, Pro1224

NCI_293778vst2

Ala1046, Tyr1079, Trp1084, Leu1205

NCI_293778vst7

Ala1046, Val1077, Tyr1079, Trp1084, Leu1205

NCI_293778vst8

Ile1102, Leu1103

NCI_217697w

Ala1040, Lys1045, Tyr1047, Pro1191, Leu1192, Gly1193, Val1194,
Glu1204, Ile1221, Hsd1222,, Met1238, Lys1239, Leu1243

NCI_25457w

Glu1157, Trp1161, Leu1162, Lys1165, Leu1285, Pro1289

NCI_362639

Thr1292, Ser1293

NCI_84100b

Glu1157, Trp1161, Leu1162, Lys1165, Ile1166, Leu1286, Pro1288,
Pro1289, Leu1300

NCI_67436

Asp1066, Ser1067, Asn1140, Arg1141, Arg1142, Pro1144, Hsd1145,
Glu1270, Arg1271, Cys1274, Val1275

For most of the investigated hit compounds, the ligand or/and the residues in the
binding sites fluctuate and adapt their structure in order to better accommodate the
ligands by optimizing HBs, and/or hydrophobic contacts, compared to those in docking
where protein was kept rigid. Most of their interactions with the nsP2 protease were
maintained by hydrophobic contacts rather than HBs, as most of the HBs occupancy
was found to be low (less than 10%, Table 3.6).

Considering the structure of the ligands, the presence of both donor and acceptor atoms
in the ligand, NCI_61610 and NCI_37553 could form more HBs than ligands
NCI_217697 and NCI_293778. As expected, HBs were mostly formed with NCI_61610
and NCI_37553. Ligand NCI_61610 showed HBs interactions with residues Lys1239,
Glu1204, Leu1203, Tyr1177, Gly1176, and Lys1045, although these interactions were
weak (occupancies less than 10%). The complex nsP2 protease-ligand NCI_37553 at
Pocket 3 was maintained through strong HBs between its oxygen and Arg1284 (80.5%),
Ser1302 (10.4%); or between its nitrogen and Arg1284 (26.3%), illustrated in Figure
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3.9. Ligand NCI_67436 fitted in Pocket 5 by moderate HBs interactions during the
simulations with residues of the enzyme such as Asn1140 (65.3%), Arg1142 (63.4%),
Glu1270 (49.2%), and some weak HBs with Cys1274 (28.2%), His1314 (22.2%), and
Asn1317 (26.1%), (Figure 3.9). In particular, this ligand plays the roles of donor and
acceptor in forming the HBs. The interactions of ligand NCI_84100b and the nsP2
enzyme were maintained through weak HBs with Leu1162 (28%).
A

Ser1302
10.4%

Arg1284
80.5%

O
N
H

N

H
N

N
O

B
Asn1140
65.3%

N
HN

Glu1270
49.2%

NH

O

Arg1142
63.4%

Asn1317
26.1%
HN

O

His1314
22.2%

Cys1274
28.2%
N

NH

Figure 3.10. Hydrogen bonding interactions between the nsP2 enzyme and ligands: (A)
Ligand NCI_37553 at Pocket 3, (B) Ligand NCI_67436 at Pocket 5; with representation
of ligands and key residues for interactions surrounding the ligands (in licorice),
showing the interactions maintained between the ligands and residues of protein through
strong HBs interactions.
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Interestingly, a comparison of NCI_293778 bound at different binding sites revealed
that the nitrogen of this ligand could form one hydrogen bond (occupancy of 10.7%)
with the residue His1222 at Pocket 1, accompanied by surrounding hydrophobic
interactions (Figure 3.10). In contrast, NCI_293778 often lacked strong HBs at other
pockets (with low occupancies, see Table 3.6). This indicates that NCI_293778 was
more likely to be accommodated by Pocket 1 than other pockets, even though that the
binding affinity obtained for this ligand was -9.8 kcal.mol; less than for Pocket 4 (-10.4
kcal/mol), and Pocket 5 (-10.2 kcal/mol). However, the aromatic ring of this ligand
could form π-stacking interactions or a π-network with Tyr1177 (Pocket 2); Tyr1079,
and Trp1084 (Pocket 4) to maintain the interactions between the protein nsP2 protease
and the ligand.

N

N

N

N
S

Figure 3.11. The docked structure of ligand NCI_293778vst4 (in green) in Pocket 1 of
the nsP2 protease, showing the residues forming Pocket 1 and the ligand-protein
interactions (in grey).
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Compound NCI_67436 played both donor and acceptor roles in the HBs interactions.
For the other ligands, there was no significant contribution from HBs in the interactions,
even though those ligands have donor and acceptor groups available for hydrogen
bonding formations.
The SASA used to monitor the possible solvation environment change upon ligand
binding was expected to get a reduction of hydrophobic interacting residues in the
complex protein-ligand compared to those in apo protein (Appendix 22). As mentioned
in Chapter 2, section 2.3.3.3, the SASA is heavily influenced by interactions between
protein and ligands. However, most of the involved residues were inconsistent for
different ligands in the nsP2 protein. This could be explained by the formation of not
only hydrophobic contacts but also polar hydrogen bonding interactions. Thus, the
change in SASA will be compromised by the polar interactions, and both of protein and
ligands will modulate the SASAs.

3.3.2.4 Clustering analysis, comparison of simulations and docking results for the
complexed nsP2 protease-ligands

Throughout the simulations, structural clustering was used to identify the most popular
conformation, and the interaction between these clusters and the nsP2 at the different
binding sites was examined to compare with docking. Clustering analysis was
undertaken on all of the snapshots from the trajectories, and the clusters were visualized
and superimposed with the initial structure. The superimposition and the value of
RMSD were used to evaluate between the different clustering structures and initial
structure at 0 ns, 10 ns, 20 ns, 30 ns, 40 ns, and 50 ns were calculated. For example, the
potential hit compound NCI_37553, superimposition of the most popular conformations
of complex; and the RMSD value for the ligand was 1.7 Å (at 10 ns), 2.0 Å (at 20 ns),
2.0 Å (at 30 ns), 1.9 Å (at 40 ns), and 2.2 Å (at 50 ns) with respect to the initial structure
(Figure 3.11). The docking results were in close agreement with MD simulations, even
though there was flexibility of residues in the protein and ligands in forming HBs or
creating hydrophobic contacts. There was no major change in the important residues at
the binding sites of the nsP2. Moreover, understanding the effects of ligand binding to
other binding pockets on the active site was also of interest. Experimental validation is
105

Chapter 3. nsP2
required to confirm whether there is an allosteric site or a synergistic effect upon
binding at different sites within the active site of the nsP2.

Figure 3.12. Superimposition of the different conformations of ligand NCI_37553 and
complexed with the nsP2 at Pocket 3 of the nsP2 during simulations with respect to the
initial structure (red: at 0 ns, grey: at 10 ns, green: at 20 ns, pink: at 30 ns, orange: at 40
ns, and blue: at 50 ns).
3.3.2.5 Combination of simulations and docking for the nsP2

Based on MD simulations results, the sampled conformations of protein nsP2NCI_67436 at the different timepoints (10 ns, 20 ns, 30 ns, 40 ns, and 50 ns) were used
for docking and virtual screening, so as to probe the effects of the static protein structure
used in the docking. This complex was selected as NCI_67436 showed higher potential
after analyzing the outcomes of docking and simulations, listed in Table 3.8 and Table
3.9. The binding affinities of the docking runs in Table 3.8 were not significantly
different from those obtained by docking based on the X-ray structure. A comparison of
complexes of different protein conformations and the initial docked structure showed
there were changes in the binding mode, but always maintaining HBs of the ligand with
the protein to maintain the interactions of ligand and the residues in the binding pocket
during simulations (details of interactions analyses in Appendixes 23-27). For virtual
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screening, the docking results were sensitive in the exact static structure used as most of
the hits introduced were new in comparison of top hits lists in the screening results
based on the X-ray structure.

Table 3.8. Re-docking results for complex nsP2-NCI_67436 with different
conformations of the nsP2 taken from the different timepoints of simulations at Pocket
5. The binding affinity is in kcal/mol.
nsP2 conformation

Binding affinity (kcal/mol)

HBs interaction (Å)

At 0ns

-8.1

At 10 ns

-7.7

No HBs
(hydrophobic contacts only)
No HBs
(hydrophobic contacts only)

At 20 ns

-8.3

Arg1142(HH11)-O=2.3

At 30 ns

-7.0

H-Arg1267(O)=2.2
Arg1267(HE)-N=2.4
Leu1276(HN)-O=2.1
H-Thr1268(O)=2.4

At 40 ns

-6.8

Arg1278(HH11)-N=2.2

At 50 ns

-7.1

Arg1267(HH21)-N=2.4
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Table 3.9. Virtual screening results for blind docking into Pocket 1 with different conformations of the nsP2 taken from the different timepoints
of simulations. The binding affinities ΔG are in kcal/mol.
VST-10nsa
1. NCI_293778
(-8.6)
2. NCI_37553
(-8.5)
3. NCI_59620
(-8.4)
4. NCI_7524_b
(-8.3)
5. NCI_308835
(-8.2)
6. NCI_227186_a
(-8.0)
7. NCI_328101
(-8.0)
8. NCI_339161
(-7.8)
9. NCI_270738_b
(-7.8)
10. NCI_58052
(-7.8)

VST-20nsb
1. NCI_345647_a
(-9.0)
2. NCI_338042
(-8.8)
3. NCI_293778
(-8.7)
4. NCI_67436
(-8.3)
5. NCI_80997_a
(-8.3)
6. NCI_338963
(-8.2)
7. NCI_319990
(-8.2)
8. NCI_25457
(-8.0)
9. NCI_670283
(-7.9)
10. NCI_326182
(-7.9)

VST-30nsc
1. NCI_293778
(-8.3)
2. NCI_345647_a
(-8.0)
3. NCI_97920
(-8.0)
4. NCI_ 327702
(-7.9)
5. NCI_156516
(-7.9)
6. NCI_80313
(-7.8)
7. NCI_116709_b
(-7.8)
8. NCI_37553
(-7.8)
9. NCI_326757
(-7.6)
10. NCI_154585
(-7.6)

VST-40nsd
1. NCI_293778
(-8.5)
2. NCI_61610
(-7.9)
3. NCI_122819_b
(-7.7)
4. NCI_671136
(-7.6)
5. NCI_19990_a
(-7.6)
6. NCI_37641_b
(-7.5)
7. NCI_269148_b
(-7.4)
8. NCI_319990
(-7.4)
9. NCI_156219_b
(-7.4)
10. NCI_59620_b
(-7.3)

VST-50nse
1. NCI_61610
(-8.2)
2. NCI_84100_a
(-7.2)
3. NCI_146771
(-7.2)
4. NCI_84100_b
(-7.1)
5. NCI_25457
(-7.0)
6. NCI_116702
(-7.0)
7. NCI_37553
(-7.0)
8. NCI_80731
(-7.0)
9. NCI_55691
(-7.0)
10. NCI_332670
(-7.0)

(a) In VST-10nsa, the grid box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (b) In VST20nsb, the grid box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST-30nsc, the grid
box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (d) In VST-40nsd, the grid box is fixed at
the centre of the protein at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (e) In VST-50nse, the grid
box is fixed at the centre of the protein at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å.
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3.3.3

BINDING FREE ENERGY CALCULATIONS FOR THE LIGANDS
BINDING TO THE NSP2 ENZYME

The prediction of binding free energy is usually a challenge for docking and scoring in
computational drug design. In this study, the converged trajectories of complexes
obtained from simulations were used to calculate the binding free energy for the hit
compounds. The average values of vdW and elec interactions for each ligand in the two
states, bound state (Vbound) and unbound state (Vunbound) were calculated (Table 3.10).
The results in Table 3.10 indicated that the van der Waals value of the ligands in the
complex with the enzyme were much more negative than when only in solution,
showing that the ligand has more favourable van der Waals interactions in the complex.
However, it is striking that the electrostatic interactions of ligands in all the complexes
were significantly less favourable than those of the ligand in water.

Parameters selection proceeded with the same approach as for the nsP3 (see Chapter 2,
section 2.3.4 for explanation of selecting parameters). The results of ΔG2 with α set to
1.043 are shown in Table 3.10 and revealed better agreement with the binding affinity
obtained from docking. This provided good agreement when comparing the binding free
energies for different ligands at the same pocket; such as in the case of NCI_61610,
NCI_217697, and NCI_293778vst4. For instance, ligand NCI_293778vst4, with the
presence of stronger HBs (indicated by the higher value of HBs occupancy) had higher
binding affinities compared to other ligands.

A comparison of binding free energies of top-hit compound complexes and tenth-hit
compound complexes was also carried out. The results revealed that most of the top-hit
compounds had better binding free energies than the tenth-hit compounds, which
supported a close agreement between docking results and MD simulations results (Table
3.10). Ligand NCI_67436 showed the highest binding affinities compared to the value
obtained from docking and also compared to the other compounds; while the ligand
NCI_362639 had the lowest binding affinity. This is in accordance with the simulations
results analysed above, as the ligand NCI_67436 fit well in the pocket by forming
strong HBs with the residues of the pocket.
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Table 3.10. Average binding free energies (kcal/mol) of top-hit compounds and tenth-hit compounds for the nsP2 calculated by LIE method
using data trajectories from the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 (in kcal/mol using α = 1.043, β = 0.43,
and γ = 0).328 ΔG is the predicted binding affinity by Vina (in kcal/mol).
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However, between the binding affinities obtained from docking and the binding free
energies estimated from simulations, three ligands, NCI_61610, NCI_217697, and
NCI_37553 showed the lower binding free energies in simulations: -6.0 kcal/mol,
-8.9 kcal/mol, -7.4 kcal/mol, respectively compared these in docking: -10.6 kcal/mol,
-9.3 kcal/mol, -9.6 kcal/mol, respectively. Interestingly, in the case of NCI_293778,
with different conformations binding at the different binding sites, the binding
affinities in docking and from simulations indicated a consistent trend that binding at
Pocket 4 (-14.6 kcal/mol) better than Pocket 2 (-12.3 kcal/mol) > Pocket 1 (-10.3
kcal/mol) > Pocket 5 (-9.9 kcal/mol); whereas in analysis simulations above, with a
presence of HBs, Pocket 1 may be as the better place for this ligand compared to
others. In addition, HBs and hydrophobic contacts in some ligands (such as
NCI_293778vst4 and NCI_37553) were maintained. These ligands were expected to
have lower binding free energies, however this was not observed with LIE
predictions. It may be deduced that there was a compromise between van der Waals
and electrostatic results from HBs interactions and hydrophobic contacts between the
ligands and the enzyme nsP2. More work and results from experimental data are
required to clarify the issue.

3.3.4

ANALYSIS AND SELECTING LEADS FOR BIOLOGICAL TESTING

The outcomes of dockings and virtual screening showed the potential compounds to
be considered are NCI_61610 (-10.6 kcal/mol), NCI_293778 (from -9.8 to around 10.2 kcal/mol), NCI_37553 (-9.6 kcal/mol), NCI_217697 (-9.3 kcal/mol), and
NCI_25457 (-9.0 kcal/mol).

After analyzing MD simulations and binding free energy calculations, the
compounds to be selected as leads are NCI_293778 (from -9.9 to around -13
kcal/mol), NCI_67436 (-15.5 kcal/mol), NCI_217697 (-9.0 kcal/mol) as they have
higher binding affinities than the others and the interactions were maintained during
MD simulations.

From a combination of these two outcomes (from simulations and docking), a list of
compounds which have good binding affinities and the remained interactions
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between them and the nsP2 protein during MD simulations, was proposed for
biological testing; namely NCI_293778, NCI_217697, and NCI_67436 (Table 3.11).

Table 3.11. Potential lead compounds for the nsP2 proposed for biological testing.
No
1

Compounds
NCI_293778

Chemical structure
N

N

N

N
S

2

NCI_217697

3

NCI_67436

H
N

H
N

NH
N

NH

O

O

HN

H
N
N

3.4 CONCLUSIONS
In this work, the X-ray crystal structure of nsP2 protease was utilized to conduct a
combination of molecular docking, virtual screening, and MD simulations to search
for potential inhibitors. Starting with blind dockings and published information, we
identified top hit compounds, together with the five potential binding pockets of the

nsP2 protease. Subsequently, the focused dockings into these different binding sites
were investigated to discover more hit compounds, and observe further binding
modes at these pockets. The top hit compounds were then subjected to MD
simulations for 50 ns after equilibration. The simulation results demonstrated the
different binding affinities of different ligands through the number of HBs and
hydrophobic contacts. Previous studies largely focused on Pocket 1 as the active site.
However, in this study, Pocket 4, in the N-terminal domain of the nsP2 protease, was
recognised as the active site by the presence of catalytic residues, Cys1013 and
His1083. Importantly, the current work offers more opportunities to identify
potential inhibitors. The effect upon the active site of ligands binding into different
pockets requires further experimental testing. Finally, the trajectories data of MD
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simulations was utilized for the linear interaction energy to obtain accurate binding
free energies. More experimental data is required to achieve a compromise between
vdW and electrostatic interactions. A good agreement between docking results and
MD simulations were confirmed by better binding free energies of top-hit
compounds than tenth-hit compounds. Finally, it is worth emphasizing that this is the
first instance where molecular modelling with more accurate data from X-ray
structure has been studied. Our findings open up a promising approach in combining
docking and MD simulations to assist in rational drug design, especially providing
useful information for the design of inhibitors for CHIKV to help combat the disease.
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CHAPTER 4. DISCOVERY OF INHIBITORS
TARGETING CHIKV ENVELOPE GLYCOPROTEINS

4.1 INTRODUCTION
4.1.1

ENVELOPE GLYCOPROTEINS AS POTENTIAL TARGETS FOR
CHIKV DRUG DISCOVERY

The CHIKV envelope glycoproteins (E1, E2, and E3) are promising targets for drug
discovery as they play crucial roles in the virus attachment and entry.8,

68

Like other

alphavirus in Togaviridae family, CHIKV has an icosahedral structure comprising a
nucleocapsid enclosed within a phospholipid envelope. Structural analysis of CHIKV
particles revealed that there are 20 icosahedral “i3” spikes (located on the icosahedral 3fold axes), and 60 quasi-3-fold “q3” spikes (located in general positions) that consist of
a quasi-3-fold axis to form T=4 symmetry structure for the virus.65 Additionally, the
virus particles contain 80 spikes that make glycoprotein shells with 240 copies of each
of two glycoproteins, E1 and E2 heterodimers.68 The CHIKV genome, is divided into
two open reading frames (ORF), encoding four non-structural proteins and five
structural proteins (the capsid C; envelope glycoproteins E1 and E2; and two small
peptides, E3 and 6K).67 The non-structural proteins are essential for virus replication,
protein modification, and immune antagonism, while the structural proteins are products
obtained from a cleavage of a polyprotein by an auto-protease and signalase.65

The viral entry process is a receptor-mediated endocytosis in clathrin coated vesicles,
which is controlled by two viral envelope glycoproteins, E1 and E2. In the acidic pH of
the endosome environment, a conformational rearrangement of the surface glycoprotein
shell causes a dissociation of the heterodimers p62-E1 (as known as pE2-E1) and
formation of E1 homotrimers.356 This process induces a fusion of the virus and
endosomal membranes, resulting in release of the viral nucleocapsid into the cytoplasm.
The E1 has a hydrophobic fusion loop which invades the cell membrane during the
membrane fusion. The E2 contributes to receptor binding and protects the loop at a
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neutral pH. During replication, the capsid is released, and the precursors of structural
proteins are processed in the Golgi complex, then transported to the plasma membrane.

Structural and functional characterization of the envelope glycoproteins as well as the
mechanism of neutralization with an interpretation of the cryo-electron microscopy
structure of the CHIKV-like particles has been reported.68, 356-357 The mutations of four
highly conserved residues of E1, namely Gly91, Val178, Ala226, and His230 were
found to reveal their important roles in the cell fusion process.8,

358

Two highly

conserved residues, Gly91 and His230, are important for membrane fusion
functionality. A substitution of Gly91 with Glu91 caused a loss of E1 fusogenicity
whereas any replacement of His230 into Ala230 resulted in the disappearance of this
activity.358 On the other hand, Val178 and Ala226 are less conserved residues whose
mutations do not lose E1 fusion capacity but these changes depend on pH and
cholesterol.358 In particular, a change of Ala to Val in the position of 226 of E1 protein
resulted in the reduction of cholesterol dependence to infect mosquito hosts.6 Moreover,
the study on CHIKV E2 mutants identified the acid-sensitive region in the E2 (amino
acid at 229, 231, 232, 233, and 234 positions).359 The results suggested that the E2
amino acids 229 to 234 region was responsible for neutralizing antibodies, and that
these amino acids could prevent the conformational change through interacting with
antibodies, leading to initiate the viral fusion and entry.359 Also, the region of 229 to
234 was found to be a crucial role for viral replication partly due to its participation of
inducing pH-dependent conformational changes.359 In addition, the E2 glycoprotein
interacts with the the host receptor protein at the 216 residue which is involved in
initiating infection.360

4.1.2

EARLY RESEARCH TARGETING ENVELOPE GLYCOPROTEINS

Numerous studies in recent years have focused on the structural characterization of the
envelope proteins of alphaviruses.7 However, little is known about changes of their
conformation or structural intermediates during fusogenic activity or cell attachment.65
With regards to CHIKV drug discovery, there have been few studies to identify
potential inhibitors. Mostly, targets for CHIKV drug discovery are non-structural
proteins.70, 351, 353, 361 Envelope glycoproteins are another class of attractive targets for
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interfering with virus entry or virus attachment through inhibition of the viral envelope
glycoproteins, to block the in vitro CHIKV infection.

Preliminary, computational investigation of the envelope glycoprotein complexes (the
immature and mature forms)153 has previously been explored within our group,362
however a more rigorous exploration based on blind docking was deemed essential for
full characterization of potential target sites. Virtual screenings based on blind docking
and focused docking are a powerful approach in discovering the potential binding sites
and hit compounds for CHIKV. Interaction analysis of hit compounds and these
glycoprotein complexes provide useful information for CHIKV drug design.

4.1.3

COMPARISON OF TWO ENVELOPE GLYCOPROTEIN COMPLEXES

In order to identify inhibitors targeting the CHIKV envelope glycoproteins,
characterization of the two complexes, the immature (PDB id: 3N40) and mature form
(PDB id: 3N42) was necessary. As shown in Figure 4.1, the structures of precursor p62E1 heterodimer (the immature form) and the complex E3-E2-E1 heterodimer (the
mature form) are similar with an association of E1 domains (E1 domain I, domain II,
and domain III), E2 domains (E2 domain A, domain B, and domain C), and E3.
Additionally, in both structures, E2 makes contact with E3, while E1 does not create
any interactions with E3. The only major difference between the two complexes is the
presence of a furin loop, located in the E1 of the immature 3N40, but not present in the
mature 3N42.153 This loop becomes disordered in the cleavage process. In addition,
furin maturation of p62 into E3 and E2 will prime the spikes for fusogenic activiation
during cell entry. Moreover, the dissociation of E2-E1 heterodimer occurs under an
acidic environment, which rearranges E1 into fusogenic homotrimers that induce fusion
of viral and endosomal membranes. Therefore, residues in the region of the furin loop
and the fusion loop were of key interest.
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A

B

Figure 4.1. Structure of the envelope glycoprotein complexes: (A) The immature
structure (PDB id: 3N40); (B) The mature structure (PDB id: 3N42). These structures
are similar and the only difference is in the furin loop.

4.2 OVERVIEW OF THIS STUDY
In an attempt to discover hit compounds for the CHIKV targeting the envelope
glycoproteins, this study used an in silico approach. The same process of docking and
virtual screenings as used for the nsP3 and the nsP2 were undertaken. A docking
protocol was established (described details in the Experimental procedures and methods
chapter). Two X-ray crystal structures of envelope glycoprotein, an immature form
(PDB id: 3N40) and a mature form (PDB id: 3N42), were downloaded from the Protein
Data Bank. Initially, blind docking was carried out to identify the potential binding
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sites, which were identified based on the locations of binding ligand. The dimensions of
the box for covering 3N40 and 3N42 were 108 Å × 126 Å × 62 Å and 84 Å × 126 Å ×
74 Å, respectively. The value of E in docking was changed from the default value E=8
to E=16, 32, 128, 256, and 1024 in order to investigate the sampling convergence in
docking with AutoDock Vina. Potential binding sites were revealed by the place where
ligand binds into the target (discussed in the following section). The next step was a
focused docking, in which a smaller box (20 Å × 20 Å × 20 Å), was centred at the
potential binding site of interest to confirm their likehood. Another aim of this process
is to identify more hit compounds focusing on these binding sites, in order to achieve a
better sampling. The sets were carried out for each glycoprotein complexes, 3N40 and
3N42. Moreover, identification of potential binding sites was also investigated and
compared with the previous published results by using a receptor cavities tool in
Accelerys DS 3.5 and the MetaPocket program.343

4.3 RESULTS AND DISCUSSION
4.3.1

MOLECULAR DOCKING AND VIRTUAL SCREENINGS

The outcomes of screenings using blind docking and focused docking for two
glycoprotein complexes are shown in Tables 4.1, 4.2, 4.3, and 4.4.

In Table 4.1, blind dockings showed that there were two potential binding pockets
identified in the structure 3N42, and one in 3N40. However, analysis of docking results
with the change to the E value in blind docking (Table 4.2 and Table 4.3) introduced
some new binding pockets (discussed below). In total, two potential binding pockets
(3N40_Pocket 1 and 3N40_Pocket 2) were identified in the immature 3N40; and four
binding pockets (3N42_Pocket 1, 3N42_Pocket 2, 3N42_Pocket 3, and 3N42_Pocket 4)
were in the mature structure 3N42, respectively. 3N40_Pocket 1 and 3N40_Pocket 2 are
located in the similar location with 3N42_Pocket 1 and 3N42_Pocket 2.
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Table 4.1. Results of the top ten compounds of blind dockings with locations of pockets
in the immature (PDB id: 3N40) and mature forms (PDB id: 3N42). The binding
affinities ΔG are in kcal/mol.
VST1a
Hits
1. NCI_293778
2. NCI_61610
3. NCI_37553
4. NCI_156219_b
5. NCI_84100_b
6. NCI_84100_a
7. NCI_116702
8. NCI_19990_a
9. NCI_227186_a
10. NCI_227186_b

ΔG
-13.2
-12.2
-11.7
-11.5
-10.9
-10.9
-10.8
-10.8
-10.7
-10.6

Pocket
1
1
1
1
1
1
1
1
1
1

VST2b
Hits
1. NCI_293778
2. NCI_37553
3. NCI_61610
4. NCI_156219_b
5. NCI_84100_a
6. NCI_227186_b
7. NCI_84100_b
8. NCI_7524_a
9. NCI_116702
10. NCI_308835

ΔG
-13.7
-11.4
-11.2
-11.1
-11.0
-10.9
-10.9
-10.9
-10.8
-10.8

Pocket
1
1
1
1
1
1
2
1
1
1

(a) In VST1, the grid box is fixed at the centre of the structure (-23.7 Å, 1.8 Å, 23.4 Å)
with dimensions of 108 Å × 126 Å × 62 Å (PDB id: 3N40). (b) In VST2, the grid box is
centred at the centre of the structure (-26.4 Å, 7.1 Å, -24.5 Å) with dimensions of 84 Å
× 126 Å × 74 Å (PDB id: 3N42). The origin and axes of the coordinate systems were set
as in the PDB structure.
Pocket 1 and Pocket 2 were found to be similar in both the immature and mature form
structures, even though some residues from the E2 domain forming the pocket were
different. This may be due to a difference in these two structures in the virus
attachment. For the both structures, immature and mature structures, Pocket 1 was in
between E2 domain A, E2 domain C, and E1 domain II which was a favourable place
for most of the ligands. Pocket 2 located at the E2 β-ribbon. Pocket 1 was corresponding
to the combined Site 1 and Site 2 identified previously.362 In the mature structure,
Pocket 3 was in the region of between E2 domain C, E1 domain I, and E1 domain III
while Pocket 4 was behind the fusion loop and between E2 domain A, E2 domain B,
and E1 domain II. Pocket 2 was a novel binding pocket identified in the 3N40. Pocket 2
and Pocket 3 were two new binding pockets in the 3N42, while Pocket 1 and Pocket 4
have been reported.362 Most of the pockets included some E1 and some E2 residues.
The locations of the pockets along with the top hit compounds, are illustrated in Figure
4.2, and the residues making up each pocket are listed in Table 4.5. Using an increase of
the value of a search space parameter (E) from the default value E=8 to E=16, 32, 128,
256, and 1024 to investigate the sampling convergence in Vina, the results were
presented in Table 4.2 and 4.3 for two glycoprotein complexes.
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Table 4.2. Results of the top ten compounds of blind dockings for the immature structure. The binding affinities are in kcal/mol.
VST3a
1. NCI_293778
(-13.1)
2. NCI_61610
(-11.9)
3. NCI_37553
(-11.7)
4. NCI_156219_b
(-11.5)
5. NCI_84100_b
(-10.9)
6. NCI_84100_a
(-10.9)
7. NCI_19990_a
(-10.8)
8. NCI_116702
(-10.8)
9. NCI_227186_a
(-10.7)
10. NCI_7524_a
(-10.7)

VST4b
1. NCI_293778
(-13.1)
2. NCI_61610
(-12.3)
3. NCI_156219_b
(-11.5)
4. NCI_308835
(-11.0)
5. NCI_84100_a
(-10.9)
6. NCI_84100_b
(-10.9)
7.NCI_37553
(-10.8)
8.NCI_116702
(-10.8)
9.NCI_67436
(-10.6)
10. NCI_227186_b
(-10.6)

VST5c
1. NCI_293778
(-13.1)
2. NCI_61610
(-12.3)
3. NCI_37553
(-11.7)
4. NCI_156219_b
(-11.5)
5. NCI_260594
(-11.4)
6. NCI_308835
(-11.1)
7.NCI_84100_a
(-11.0)
8.NCI_84100_b
(-10.9)
9.NCI_227186_a
(-10.9)
10. NCI_19990_a
(-10.8)

VST6d
1. NCI_293778
(-13.1)
2. NCI_61610
(-12.3)
3. NCI_37553
(-11.7)
4. NCI_156129_b
(-11.5)
5. NCI_260594
(-11.4)
6. NCI_84100_b
(-11.4)
7.NCI_7524_a
(-11.0)
8.NCI_227186_b
(-10.9)
9.NCI_116702
(-10.9)
10. NCI_308835
(-10.8)

VST7e
1. NCI_293778
(-13.1)
2. NCI_61610
(-12.3)
3. NCI_37553
(-11.7)
4. NCI_308835
(-11.5)
5. NCI_156219_b
(-11.5)
6. NCI_260594
(-11.4)
7. NCI_84100_a
(-11.0)
8. NCI_60785_b
(-11.0)
9. NCI_227186_a
(-10.9)
10. NCI_84100_b
(-10.9)

VST8f
1. NCI_293778
(-13.0)
2. NCI_37553
(-11.7)
3. NCI_156219_b
(-11.5)
4. NCI_260594
(-11.4)
5. NCI_308835
(-11.4)
6. NCI_227186_a
(-10.9)
7. NCI_19990_a
(-10.8)
8. NCI_202386
(-10.8)
9. NCI_116702
(-10.8)
10. NCI_37641_b
(-10.7)

The grid box is fixed at the centre of the structure (-23.7 Å, 1.8 Å, 23.4 Å) with dimensions of 108 Å × 126 Å × 62 Å (PDB id: 3N40): (a) VST3:
E=8; (b) VST4: E = 16; (c) VST5: E = 32; (d) VST6: E = 128; (e) VST7: E = 256; (f) VST8: E = 1024
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Table 4.3. Results of the top ten compounds of blind dockings for the mature structure. The binding affinities are in kcal/mol.
VST3a
1. NCI_293778
(-13.7)
2. NCI_37553
(-11.5)
3. NCI_61610
(-11.3)
4. NCI_156219
(-11.1)
5. NCI_84100_a
(-11.0)
6. NCI_7524_a
(-10.9)
7. NCI_84100_b
(-10.9)
8. NCI_25457
(-10.8)
9. NCI_116702
(-10.8)
10. NCI_122819
(-10.7)

VST4b
1. NCI_293778
(-13.7)
2. NCI_37553
(-11.5)
3. NCI_61610
(-11.4)
4. NCI_156219_b
(-11.1)
5. NCI_227186_b
(-10.9)
6. NCI_84100_a
(-10.9)
7. NCI_7524_a
(-10.9)
8. NCI_84100_b
(-10.9)
9. NCI_308835
(-10.8)
10. NCI_116702
(-10.8)

VST5c
1. NCI_293778
(-13.7)
2. NCI_61610
(-11.5)
3. NCI_37553
(-11.4)
4. NCI_156219_b
(-11.1)
5. NCI_84100_a
(-11.0)
6. NCI_227186_b
(-10.9)
7. NCI_7524_a
(-10.9)
8. NCI_84100_b
(-10.9)
9. NCI_308835
(-10.8)
10. NCI_25457
(-10.8)

VST6d
1. NCI_293778
(-13.7)
2. NCI_61610
(-11.7)
3. NCI_37553
(-11.5)
4. NCI_156219_b
(-11.1)
5. NCI_84100_a
(-11.0)
6. NCI_7524_a
(-10.9)
7. NCI_227186_b
(-10.9)
8. NCI_84100_b
(-10.9)
9. NCI_156219_b
(-10.8)
10. NCI_25457
(-10.8)

VST7e
1. NCI_293778
(-13.7)
2. NCI_61610
(-11.6)
3. NCI_37553
(-11.5)
4. NCI_156219_b
(-11.1)
5. NCI_84100_a
(-11.0)
6. NCI_84100_b
(-10.9)
7. NCI_7524_a
(-10.9)
8. NCI_227186_b
(-10.9)
9. NCI_116702
(-10.8)
10. NCI_308835
(-10.8)

VST8f
1. NCI_293778
(-13.7)
2. NCI_37553
(-11.5)
3. NCI_156219_b
(-11.1)
4. NCI_25457
(-10.8)
5. NCI_121868_a
(-10.8)
6. NCI_308835
(-10.8)
7. NCI_116702
(-10.8)
8. NCI_122819_b
(-10.7)
9. NCI_156219_a
(-10.7)
10. NCI_227186_b
(-10.7)

The grid box is fixed at the centre of the structure (-26.4 Å, 7.1 Å, -24.5 Å) with dimensions of 84 Å × 126 Å × 74 Å (PDB id: 3N42): (a) VST3:
E = 8; (b) VST4: E = 16; (c) VST5: E = 32; (d) VST6: E = 128; (e) VST7: E = 256; (f) VST8: E = 1024
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Table 4.4. Results of the top ten compounds of focused dockings for the immature and mature structures. The binding affinities are in kcal/mol.
VST1a
1. NCI_293778
(-13.1)
2. NCI_37553
(-11.4)
3. NCI_156219_b
(-11.3)
4. NCI_19990_a
(-10.9)
5. NCI_84100_b
(-10.8)
6. NCI_84100_a
(-10.8)
7. NCI_116702
(-10.7)
8. NCI_60785_b
(-10.5)
9. NCI_308835
(-10.5)
10. NCI_227186_b
(-10.4)

VST2a
1. NCI_293778
(-11.4)
2. NCI_37641_b
(-10.7)
3. NCI_37553
(-10.0)
4. NCI_328101
(-10.0)
5. NCI_116702
(-9.9)
6. NCI_37641_a
(-9.9)
7. NCI_121868_a
(-9.8)
8. NCI_308835
(-9.7)
9. NCI_24951_a
(-9.5)
10. NCI_127133
(-9.5)

VST1b
1. NCI_293778
(-13.7)
2. NCI_37553
(-11.4)
3. NCI_61610
(-11.3)
4. NCI_25457
(-10.8)
5. NCI_116702
(-10.8)
6. NCI_308835
(-10.7)
7. NCI_97920
(-10.6)
8. NCI_7524_b
(-10.4)
9. NCI_671136
(-10.3)
10. NCI_84100_a
(-10.2)

VST2b
1. NCI_61610
(-11.6)
2. NCI_37553
(-11.1)
3. NCI_308835
(-11.1)
4. NCI_84100_b
(-10.9)
5. NCI_84100_a
(-10.8)
6. NCI_82802_b
(-0.7)
7. NCI_670283
(-10.5)
8. NCI_7524_b
(-10.4)
9. NCI_293778
(-10.4)
10. NCI_328101
(-10.3)

VST3b
1. NCI_61610
(-11.5)
2. NCI_293778
(-11.0)
3. NCI_37553
(-9.9)
4. NCI_670283
(-9.4)
5. NCI_332670
(-9.4)
6. NCI_328101
(-9.3)
7. NCI_60785_a
(-9.2)
8. NCI_50648
(-9.2)
9. NCI_60785_b
(-9.2)
10. NCI_308835
(-9.1)

VST4b
1. NCI_121868_a
(-7.6)
2. NCI_24951_b
(-10.6)
3. NCI_24951_a
(-10.2)
4. NCI_332186
(-9.7)
5. NCI_332670
(-9.6)
6. NCI_3391_a
(-9.6)
7. NCI_80313
(-9.5)
8. NCI_310326
(-9.3)
8. NCI_645330
(-9.3)
9. NCI_97920
(-9.2)

(a) In VST1a, VST2a the grid box is fixed at the centre of Pocket 1 and Pocket 2 of the immature structure (-22.3 Å, 18.3 Å, 26.3 Å; -15.9 Å, 1.5
Å, 19.7 Å; respectively) with dimensions of 20 Å × 20 Å × 20 Å (PDB id: 3N40). (b) In VST1b, VST2b, VST3b, and VST4b, the grid box is fixed
at the centre of Pockets 1, 2, 3, and 4 of the mature structure (-21.3 Å, -11.7 Å, -24.9 Å; -22.4 Å, -4.2 Å, -11.9 Å; -5.7 Å, 31.2 Å, -8.9 Å, -44.7 Å,
-39.8 Å, -38.2 Å respectively) with dimensions of 20 Å × 20 Å × 20 Å (PDB id: 3N42). The origin and axes of the coordinate systems were set
the same as in the PDB structure.
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A

B

Figure 4.2. Representation of docked structures of top hit compounds in different
virtual screenings showing the location of the pockets: (A) Pocket 1 with ligand
NCI_293778 (L1) and Pocket 2 with ligand NCI_67436 (L2) in the immature
structure (PDB id: 3N40); (B) Pockets in the mature structure (PDB id: 3N42):
ligand NCI_293778 (conformation L1) in Pocket 1, ligand NCI_67436 (L2) in
Pocket 2, ligand NCI_61610 in Pocket 3 (L3), and ligand NCI_293778
(conformation L4) in Pocket 4.
123

Chapter 4. Envelope glycoproteins
Table 4.5. Residues making up the pockets for two structures, the immature (PDB id: 3N40) and mature structure (PDB id: 3N42).
Pocket 1

Location
Between E2 domain
A, E1 domain II, and
E2 domain C

Pocket 2

E2 β-ribbon

Pocket 3

Between E2 domain
C, E1 domain I, and
E1 domain III

E1 residues: Gly12, Val13, Pro14, Ser310,
Asp311, Phe312, Phe321, Ala336, Ala359,
Asn389, Tyr390, Pro391, Ala392, Ser393,
Ala336, Thr338, Ser357, Thr358
E2 residues: Pro335, Tyr336, Lys337

Pocket 4

Behind the E1 fusion
loop and between E2
domain
B,
E2
domain A, and E1
domain II

E1 residues: Lys61, Cys62, Tyr93, Phe95
E2 residues: Asp174, Arg198, Tyr199, Lys200,
Glu208, Gly209, His226, Ala228, Glu247
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The immature structure
E1 residues: Glu50, Tyr51, Lys52, Thr53, Val54,
Ile55, Tyr180, Lys181, Asp183, Tyr185, Gln222,
Tyr242, His230, Val231, Pro232, Tyr233, Gln235,
Ser238, Lys241, Tyr242, Leu244, Lys245, Arg247,
Gly248, Ala249, Ser250, His253
E2 residues: His82, Glu99, Arg100, Ile101, Arg102,
Asn103, Thr106, His191, Pro192, Phe193, His194,
Asp196, Pro198, Val199, Ile200, Gly201, Leu215,
Pro216, Glu232, Tyr301, Asn302, Pro304, Leu305

The mature structure
E1 residues: Glu50, Tyr51, Lys52, Thr53,
Val54, Ile55, Tyr180, Lys181, Asp183, Tyr185,
Gln222, Tyr242, His230, Val231, Pro232,
Tyr233, Gln235, Ser238, Lys241, Tyr242,
Leu244, Lys245, Arg247, Gly248, Ala249,
Ser250, His253
E2 residues: Glu35, Arg36, Ile37, Gln39,
Glu40, Ala41, Thr42, His127, Pro128, Phe129,
His130, His131, Glu168, Tyr237, Asn238,
Pro240, Leu241
E2 residues: Pro198, Val199, Phe205, His206, E2 residues: Asp43, Arg104, Pro133, Pro134,
Arg208, Arg331
Val135, Ile136, Lys140, Phe141, Arg144,
Thr155, Val264, Cys266, Arg267
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4.3.2

IDENTIFICATION OF POTENTIAL BINDING POCKETS USING
DIFFERENT METHODS

The receptor cavities tool in Accelrys DS software and MetaPocket, were utilized to
identify possible binding sites in the structures. Using Accelrys DS, four pockets
mentioned above were found in both structures. Some additional pockets are also
found in two structures (Appendixes 28-29). No potential binding site was detected
using MetaPocket. Table 4.6 shows a comparison of identified binding pockets using
different methods.

Table 4.6. Comparison of locations of identified binding pockets in both structures
using different methods, blind dockings and the receptor cavities tool in Accelrys
Discovery Studio program, and compared with previous study.
Accelerys Discovery Studio
Between E1 domain II and E2 domain
A, and E2 domain C
Between E1 domain II and near the E2
β-ribbon
At the E2 β-ribbon
Behind the fusion loop, between E1
domain II, E2 domain B, E2 domain A
Between E1 domain I, E1 domain III,
and E2 domain C

Blind dockings
3N40
3N42
Pocket 1
Pocket 1

Previous study358

Pocket 1

Pocket 1

Site 2

Pocket 2

Pocket 2

No

No

Pocket 4

Site 4

No

Pocket 3

No

Site 1

Among the pockets, Pocket 1 was the largest (with its volume 352 Å3 in the 3N40
and 621 Å3 in the 3N42), accommodating most ligands, while the other pockets were
narrower and shallower (Pocket 2 in 3N40, 3N42 were 123 Å3 and 156 Å3,
respectively; Pocket 3 in 3N40, 3N42 were 42 Å3 and 129 Å3, respectively; and
Pocket 4 in 3N40, 3N42 were in turn 26 Å3 and 523 Å3, respectively), illustrated by
the volumes in Appendixes 28-29 for the 3N40 and 3N42, respectively. Additionally,
a comparison of the volumes of these four pockets between the immature and mature
forms revealed that Pocket 4 near the fusion loop was much bigger in the mature
form (523 Å3) than the immature form (26 Å3). Therefore, small molecules can bind
more easily to this pocket in the mature structure with significant effects; including
blocking the relative movement of E2 domains A and B, and also freezing the fusion
loop by stabilizing interactions; this could lead to prevention of the exposure of the
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fusion loop. These findings were in accordance with the previous results.362
However, because the Accelrys program also considered small cavities as potential
binding pockets, the cavities (Appendixes 28-29) were located by Accelrys which
were not found by docking.

4.3.3

ANALYSIS OF INTERACTIONS BETWEEN HIT COMPOUNDS
AND THEIR BINDING POCKETS

The binding affinities of all of hit compounds were approximately -10 kcal/mol,
which indicated favourable interactions with the two structures in all of the identified
binding pockets. It should be noted that focused dockings introduce new hits
compounds. Docking analysis revealed some key residues for interactions between
both the 3N40 and 3N42 structures and the ligands, listed in Table 4.7. The
interaction of these key residues are illustrated in Figures 4.3 and 4.4 (details in
Appendixes 30-49). For Pocket 1 and Pocket 4, the key residues in Table 4.7 were in
close agreement with the published findings.362 Interestingly, there was a change of
key residues in E2 of Pocket 1 from the immature to mature structure; for example
residues involved in forming hydrogen bonds in E2 were Arg100, Tyr301 in the
immature form corresponding to Arg36, Tyr237 in the mature form. The ligands
bound to Pocket 1 were expected to have higher affinities than others due to their
interactions with E1 or E2 through formation of hydrogen bonds, which may
stabilize the E1-E2 heterodimer and prevent dissociation.362 The residues in Pocket 4
could interact with the E1 fusion loop including Gly91 and His230, which emphasize
their importance in impairment of the fusion process. In particular, His230 was
reported to be important in stabilization of the fusion loop. In most of the hydrogen
bonding interactions in both structures, the ligands acted as donors; for example,
ligands

NCI_61610,

NCI_84100_a,

NCI_116702,

NCI_156219_b,

and

NCI_227186_a in the immature form; or NCI_7524_a, NCI_61610, NCI_84100_b,
NCI_116702, NCI_156219_b, and NCI_227186_b in the mature form. In contrast,
some ligands, such as NCI_227186_b in the 3N40 or NCI_61610 in the 3N42, were
hydrogen bonding acceptors.
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Table 4.7. Key residues for interactions in both envelope glycoprotein structures at
each of binding site.
Binding
pocket
Pocket 1

Pocket 2

Immature structure (3N40)

Mature structure (3N42)

E1 residues: Tyr51, Thr53, Tyr233,
Ser238
E2 residues: Arg100, Ile101, Asn103,
Pro192, Tyr301

E1 residues: Glu50, Tyr51,
Lys52, Thr53, Ile55, Tyr242,
Ser238
E2 residues: Arg36, Pro128,
Tyr237

E2 residues: Arg168, Pro170, Pro198,
Val199, Ile200, Phe205, His206

E2 residues: Asp43, Ile136,
Arg144, Arg267

Pocket 3

E1 residues: Phe312, Tyr390
E2 residues: Tyr336

Pocket 4

E1 residues: Lys61, Cys62 and
Tyr93
E2 residues: Ile37

A

N
HN
NH
O

O
HN
NH
N

B

H
N

H
N

O

O
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Figure 4.3. Hydrogen bonding analysis of compounds with the immature structure in
docking: (a) NCI_61610, (b) NCI_84100_a, (c) NCI_116702, (d) NCI_156219_b,
(e) NCI_227186_a. The key residues involved in the interactions between
glycoproteins and ligands are shown. The ligands (in cyan) and the residues
surrounding the ligands (in grey) were displayed in sticks and coloured by atoms
(carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in red,
sulphur in organge).
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E

H
N

H
N

O

O

Figure 4.4. Hydrogen bonding analysis of compound with the mature structure: (a)
NCI_7524_a, (b) NCI_61610, (c) NCI_156219_b, (d) NCI_227186_b, (e) NCI_84100_b.
The key residues involved in the interactions are also shown. The ligands (in cyan) and

the residues surrounding the ligands (in grey) were displayed in sticks and coloured
by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in
red, sulphur in organge).

4.3.4

SAMPLING CONVERGENCE IN AUTODOCK VINA

As previously mentioned, the value of exhaustiveness (E) or a search space
parameter in AutoDock Vina was increased from the default value E=8 to E=16, 32,
128, 256, and 1024 to investigate the searching convergence in docking. The results
of top hit compounds are listed above in Table 4.2 and Table 4.3. These tables
demonstrate that the exhaustiveness parameter greatly affected the searching process
for ligands conformations in docking. Analysis of docking results revealed that the
blind dockings with an increase in the exhaustiveness allowed new binding pockets.
For instance, in the immature structure, Pocket 2 appeared in docking for E = 161024, though was not present for E=8. In the mature structure, Pocket 2 and Pocket 3
were introduced in docking with E = 16, 32, 128 instead of using E=8. It is
encouraging to see the frequent presence of top hit compounds in most blind docking
procedures. Interestingly, the hit compounds maintained their conformations at the
same binding site despite changes to the E value, which brings further confidence in
sampling convergence.
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4.3.5

ANALYSIS

AND

SELECTION

OF

HIT

COMPOUNDS

FOR

BIOLOGICAL TESTING

The results obtained from all dockings showed that some compounds could bind in
many docking procedures. They seem to possess higher potential than other
compounds. The binding affinities of most of them were from -10 to -13 kcal/mol
indicating good binding affinities between the ligands and the envelope glycoprotein
complexes. As mentioned previously, the compounds which bound to Pocket 1 and
Pocket 4 were expected to be inhibitors targeting the glycoprotein complexes, as they
could interact with the residues involved in the process of virus attachment and virus
entry. Therefore, based on the binding affinities of hit compounds obtained from
blind and focused dockings, and analysis of the interactions between the compounds
and the envelope glycoproteins complexes, the proposed potential lead compounds
for biological testing are NCI_293778 (from -11.4 to -13.7 kcal/mol), NCI_61610
(from -11.6 to -12.3 kcal/mol), NCI_37553 (-11.5 kcal/mol), and NCI_156219 (-11.1
kcal/mol). (Table 4.8).

In docking, the protein structure was kept rigid, so the selection of hit compounds
from molecular docking is a good starting point for anti-CHIKV drug discovery.
More accurate binding free energies are expected to gain from molecular dynamics
simulations, however, given the larger sizes of these glycoproteins complexes, this
procedure could not be conducted in this study due to lack of time on researches.
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Table 4.8. Potential lead compounds for the envelope glycoproteins proposed for
biological testing.
No
1

Compounds
NCI_293778

Chemical structure
N
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4.4 CONCLUSIONS
Taking advantage of the envelope glycoprotein complexes, virtual screening based
on blind docking and focused dockings explored the potential binding pockets and
inhibitors for both the immature and mature structures of envelope proteins.
Promising hit compounds were identified for two complexes of the envelope
glycoproteins. Pocket 2 was a novel binding site in the immature structure. Pocket 2
and Pocket 3 were novel binding sites for the mature complex of the glycoproteins.
The key residues involved in stabilizing the complex or participating in the fusion
process were confirmed. This study also supported the current docking protocol
utilising AutoDock Vina as robust and with a good accuracy, and could be used to
indentify inhibitors. However, due to larger size of two complexes of glycoproteins,
the immature and mature structures, molecular dynamics simulations could not be
carried out during the project. Therefore, the results of hit compounds and their
binding modes obtained from docking are a good starting point for further studies.
Further experiments are required to test the inhibitory effects for the anti-CHIKV
envelope glycoproteins compounds.
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CHAPTER 5. DISCUSSION OF FINDINGS
As there is little information available investigating CHIKV drug discovery, this
study undertook to establish a computational framework to identify novel inhibitors
for CHIKV. This combined the strength of molecular docking, virtual screening,
molecular dynamics simulations and free energy calculations. The X-ray crystal
structures used were of high resolution and the results provide valuable information
about inhibitors of CHIKV, not previously available from previous studies involving
homology modeling. The information could also be used for further steps to optimize
the hit compounds into lead compounds. This chapter extends the discussion from
each chapter in an attempt to gain a comprehensive of the various strengths and
limitations.

5.1 SELECTION OF LEAD COMPOUNDS FOR BIOLOGICAL
TESTING FOR CHIKV
The potential lead compounds for CHIKV were identified based on the results of
molecular docking, molecular dynamics simulations and binding free energy
calculations for each protein targets of CHIKV, including nsP3 macrodomain, nsP2
protease and envelope glycoproteins.

Virtual screening based on docking has shown successfully the ability to predict
binding affinities of ligands when they interact with the protein of interest. The top
ten hits (or the best binders), with high binding affinities, were selected as potential
inhibitors. They all showed a good fit in the binding sites through interacting with
protein residues such as H-bonds or hydrophobic contacts. For each docking run, the
real difference between binding affinities for the top ranked compounds was in the
diversity of chemical structures as well as the shape and size of binding site. There
appears to be little correlation between structures and the binding affinities.
However, the smaller molecules may not utilise the full binding potential of the
pocket. Most pockets are hydrophobic and of the resulting hits therefore contained
aromatic rings such as benzimidazole, quinoline, quinoxaline, oxazole, and
thiophene. These rings could interact with the aromatic rings of protein residues Tyr,
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Trp, Phe and His in the pockets by π-π stacking or π-network to stabilize and
maintain the interaction of protein and ligands. The phenyl rings made hydrophobic
contacts with protein residues. The ligand backbone containing nitrogen and oxygen
atoms in combination with functional groups such as OH-, NH-, C=O in the side
chains contributed in forming H-bonds with protein residues as the hydrogen
bonding acceptors mostly and occasionally donors. These key interactions between
protein and ligands are defined based on the chemical features of ligands. This study
demonstrated that depending on each protein target, hydrophobic interactions or
hydrogen bonding interactions would play an important role in stabilizing the
binding. For example, in the case of nsP3 protein, H-bonds showed more
contribution in Pocket 1 and Pocket 3 while hydrophobic interactions are more
favourable in Pocket 2. For the nsP2 protease, in the active site, interactions were
stabilized by forming H-bonds with the catalytic dyad. Suggestions for regions of
modifying the structure to aid the design of new compounds with higher affinities
were considered, e.g, the adding of heteroatom into the aromatic rings or functional
groups to balance the hydrophobicity of ligands. Further, a pharmacophore model for
CHIKV inhibitors, could be constructed in the next step. For instance, the case of
targeting CHIKV nsP2 protease, it is likely that a model would include an aromatic
ring, a hydrophobic and two hydrogen bond donor sites.

In addition, it is also apparent that the size of compounds with diverse spatial
orientations of aromatic rings or the conformational complexity of compounds, as
well as the shape and the size of binding sites would affect their binding affinities. It
was found that some hits having bulky structures molecules, for example
NCI_61610, NCI_293778, could fit well in the large binding sites, for example, in
the case of Pocket 1 of nsP3, so they would show good binding scores. Conversely,
in the case of ligands of bigger size or the binding size not particular large, the
molecules protruded and did not bind correctly, such as in the Pocket 2 of nsP3.

The application of Lipinski’s Rule of Five to the top ten hits does not provide good
immediate outcomes. This procedure would help to evaluate the drug-likeness of
these specific derivatives for oral drugs. The results revealed that some compounds
did not satisfy the conditions, however they were still selected for biological testing.
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The major reason for that as there is not a current drug for CHIKV treatment, the
need for a treatment means that the lack of oral administration requires alternative
administration, e.g. intravenous route delivery. More importantly, the revealed hit
compounds were never actually considered to be possible drugs themselves,
however, as hits, medicinal chemistry studies investigate modifications to allow for
the synthesis of more drug-like compounds. For instance, NCI_293778 has a logP of
10.87 and although it showed good interactions and a high binding affinity,
modification would be required for them to be considered in the future as orally
available drugs.

Furthermore, when combing the results of all three targets, some virtual hits overlap
multiple times with different pockets of a single protein, and also appear in different
protein targets. It could also be the nature of the molecules themselves that makes
them in the top of different screens. A prime example of this is the NCI_61610
molecule, which was the top hit for both protein nsP3 and nsP2 and one of the
highest scoring inhibitors for envelope glycoproteins. Thus, this could be a promising
lead compound for multi-pathway inhibitions, however, it may require studies of
structure-activity relationship to avoid non-specific activity. For example,
NCI_61610 has also shown anti-inflammatory effect in mice model.363

Molecular dynamics simulations and linear interaction energy calculations were
subsequently carried out which helped to look at insights into the interactions
between proteins and ligands and to obtain more accurate binding affinities.
Importantly, the outcomes also confirmed the stability of the complexes and
validated the docking outcomes. The results revealed that the systems were stabilized
during 50 ns simulations. Although there are some fluctuations, as discussed in each
case in the previous chapters, the interactions of lead compounds and proteins were
also maintained by H-bonds or hydrophobic contacts. The residues of protein and
ligands adapted to enhance these interactions. For example, some H-bonds in
docking were weak and not sufficiently stable, but were enhanced after the molecular
dynamics simulations to new, stronger H-bonds, improving the binding in the case of
nsP2 protease. Interestingly, with the ligands that could bind to the different binding
pockets, the simulation results provided details of intermolecular interactions through
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occupancy of H-bonds and hydrophobic contacts to compare the binding affinities
for ligand. Therefore, the more accurate binding energies were gained from the
simulations results. However, there was a place for discussion of a challenge in the
binding free energy calculations in the cases.

Finally, analysis of the results showed that one of the next vital steps would be the
building of scaffolds for CHIKV inhibitors based on the obtained lead compounds.
More importantly, identified leads should be further validated in the laboratory for
their ability to actually bind to the protein target and modulate its activity, and
whether there are some allosteric sites in the protein targets or not.

5.2 IDENTIFICATION OF POTENTIAL BINDING SITES IN A
PROTEIN TARGET
There are different methods to explore binding pockets in the protein (outlined in the
Introduction chapter). Because the ligand is not co-crystalised explicitly with the
protein nsP2 or envelope glycoproteins, the location of binding site is not defined.
Blind docking into an entire protein is a common approach to see which residues the
ligand associates with. By analysing in a 5Å radius from where the ligand binds,
these residues may be detected, and thus inferred in making up the binding pocket.
The most important aspect is its ability to differentiate the real binding site from nonspecific and energetically unfavorable ones based on the inbuilt scoring function.
The ligand binding assay is required to verify the data in this case as there is no
literature published about on this area.

Using the other programs such as MetaPocket or detection of cavities tool in
Accelrys Discovery Studio can search for potential binding sites. There was an
agreement between them in terms of location of binding sites. In particular, the
MetaPocket program combining eight programs showed better correlations with
blind docking. However, limitations discussed previously in the studies involving the
envelope glycoproteins were that some detected sites were not large enough for
ligand binding.

137

Chapter 5. Discussion of findings

5.3 EVALUATION OF COMPUTATIONAL APPROACHES
AND THEIR COMBINATION
Molecular docking is a computationally efficient method which helps to screen a
large library of compounds with efficient time and low cost. Notwithstanding, it also
shows some methodological deficits, for example, using one conformation of protein
with the protein kept rigid, ignoring protein desolvation and most entropic terms,
neglecting internal energies of docking molecules and using simplified models of
solvation energies for the ligand. Therefore, a critical assessment of docking and
virtual screening was undertaken. First was the evaluation of the ability to replicate a
protein-bound conformation. In this study, a docking protocol was evaluated by
reproducing results from experimental data. Docking provided multiple docking
poses for each ligand and a RMSD for all poses with respect to the top hit. The
results of the RMSD for ligand heavy atoms was within 2 Å and also showed high
binding affinities with the similar residues for interactions in the nsP3-ADP-ribose
complex. The scoring function, with a semi-empirical algorithm, was successful in
identifying the pose similar to the co-crystal structure. Different binding
conformations for each individual ligand are ranked based on affinities and the
highest for each ligand compared to determine the best lead. In addition, the accuracy
of docking was examined carefully by investigation of the searching convergence of
docking. The increasing of a searching parameter indicated some new hits (Section
4.3.4). However, decoy molecules, which are competitive binding with ligands were
not used in the screenings. Therefore, experimental studies such as ligand binding
assays and cell-based assays are needed to obtain the IC50 value, to evaluate the
accuracy of scoring i.e. to eliminate false positives, and to determine the validity of
the screens which answer the question of whether docking provides a true ligand
among top scoring compounds.

Molecular dynamics simulations were applied to consider protein flexibility and the
solvent effect which are missing in docking. The simulation required significantly
more computing-time and power than the docking approach, and convergence of
simulation ensured. Furthermore, the similar chemical structures were clustered to
search for the most popular conformation during simulations. The resulting
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simulations were used to calculate binding free energy more accurately than the
results from docking. However, the challenge in the LIE method lies in the
parameterization of the required co-efficients, which rely on the availability of
experimental data. The final limitation was the time and computational cost for
simulations, such as with large protein, for example envelope glycoproteins, which
could be rectified given more time.

In summary, a combination of docking and MD simulations showed a potential
approach that balances the computational cost and accuracy. More importantly, the
procedure can be applied in discovering therapeutic compounds for other diseases. It
can also help to generate the library for CHIKV inhibitors.
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CHAPTER 6. EXPERIMENTAL PROCEDURES
AND METHODS

6.1 GENERAL PROCEDURE FOR MOLECULAR DOCKING AND
VIRTUAL SCREENING
The process of docking and virtual screening was carried out using AutoDock Vina
(version 1.1.2).203 AutoDock Vina is an open-source program which can be downloaded
from the website http://vina.scripps.edu. This program is designed in a similar manner
to AutoDock, based on pairing an empirical-weighted scoring function with a global
optimization algorithm.227 Vina significantly improves the accuracy of binding mode
predictions and ranking for larger molecules in terms of molecular weight and rotatable
bonds.203, 227 Vina also shortens running time in screening compared to AutoDock by
using multiple CPU or CPU cores on the system. Vina can be run on 32-bit binaries or
modern 64-bit machines with Windows, Linux, and Mac operating systems. In general,
the protein was kept rigid while the ligands were fully flexible, however, some
sidechains of residues in the protein can be selected as flexible residues in docking. The
Lamarckian genetic algorithm was used to search space for docking and the binding
affinity of a complex was calculated on the basis of a set of weighted energies in
empirical-scoring function (a united-atom scoring function involving the heavy atoms).
Calculating grid maps and assigning atom charges are not required in Vina.

A protocol was established to carry out docking and in silico screenings (described
below). The key docking parameters were defined by the location of the docking site
(centre x, y, z) and the size of a grid box of search space. The size of the box was no
less than 15 Å in each dimension and larger than the size of the ligand, and no less than
22.5 Å total.344 For virtual screening, the location and the size of the grid box were
carefully investigated via blind docking (in which the box is sufficiently large to cover
the whole protein) and focused docking (in which a smaller box was centred on the
potential binding site of interest).
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After docking, the results were analyzed and compared with available experimental
data. The top ten compounds (“hits”) were identified according to their binding
affinities using the default scoring function in Vina. The modes of interaction between
the ligands and the protein were analyzed in Accelrys DS 3.5.

6.1.1

DOCKING PROTOCOL

The docking protocol using AutoDock Vina (Figure 5.1), includes three main steps:
Step 1: Prepare a protein and a ligand (file *.pdbqt).
Step 2: Define parameters for the grid box size and centre of the box, and other
parameters such as exhaustiveness and number of binding modes to generate
(num_modes).
Step 3: Run molecular docking.
Preparation of protein

Preparation of ligand

Download a crystal structure
2D structure
Edit and correct the structure
Generate to 3D structure
Energy minimization

File *.pdbqt

File *.pdbqt

Defining parameters
- Grid box size
- Centre of the box
- Other parameters

Running docking
Figure 6.1. A diagram of the docking procedure in AutoDock Vina.
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6.1.1.1 Preparation of a protein target

The 3D crystal structure of the protein (file *.pdb) was obtained from the Protein Data
Bank website (http://www.rcsb.org), and served as the protein target in molecular
docking. Details of preparation procedure were presented as follows:
•

Edit

and

correct

this

structure

by using

Procheck

(WhatIF)

website

(http://swift.cmbi.ru.nl/servers/html/) to upload the file to detect potential errors.
•

Correct the errors from chirality (atoms CG2, CG1), side chain flip of amino acids
residue His (atoms CD2, ND1, NE2 and CE1), Asn (atoms ND2 and OD1), Gln
(atoms OE1 and NE2). Missing residues for a protein were added.

•

Minimize the structure energy in Accelrys DS visualizer 2.0 software342: Apply
CHARMM22 force field and set up parameters for minimization such as steepestdescent algorithm (3000 steps), and default for other parameters.

•

Prepare file *.pdbqt for protein and ligand: Using AutoDock Tools to generate file
*.pdbqt automatically by uploading the file pdb of protein and ligand, and then add
polar hydrogens.

6.1.1.2 Preparation of a ligand

The ligand structure was generated by OpenBabel 2.3.1 based on the ChemDraw
formula. In a case there is a co-crystal structure, the ligand structure could be extracted
from the PDB file. The chemical libraries of the NCI Diversity Set II, which contains
diverse drug-like compounds, were selected for screening. The potential hits obtained
from docking can be ordered from the Open Chemical Repository Collection for future
activity testing.

6.1.1.3 Docking parameters

The grid box size was chosen to be large enough to cover the ligand but as small as
possible to ensure sufficient conformational sampling within available searching space.
The value of search space should be no bigger than 30 Å × 30 Å × 30 Å, otherwise the
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search algorithm may suffer from insufficient sampling. An increase to the value of the
exhaustiveness is thus applied in the case of blind docking.

The preparation of the grid parameter file was done by using AutoDock Tools 1.5.4:
Adjust the grid box manually to get the suitable parameters which cover the entire
protein or the binding site, and taking note the x, y, z coordinates of the centre and sizes
in the x, y, z dimension (Å) of the grid box.

Other parameters are the number of CPUs to use (--cpu), explicit random seed (--seed),
exhaustiveness of the global search (--exhaustiveness, E), maximum number of binding
modes to generate (--num_modes), maximum energy difference between the best
binding mode and the worst one (--energy_range, unit: kcal/mol), and weight of
docking algorithm (--weight). The docking parameters can be set with default values
(listed in Table 5.1) or changed depending on the aims of the study. E value can be
increased to expand the search space for searching conformations of complex.

Table 6.1. Default values of docking parameters.
Docking parameter
Number of CPUs
Exhaustiveness
Num_modess
Energy_range
Weight

Default value
1
8
9
4
1

6.1.1.4 Preparation of a configuration file (conf.txt)
File configuration includes protein and ligand file inputs (*.pdbqt), the values of centre
and size of of a grid box (centre_x, centre_y, centre_z; and size_x, size_y, size_z), and
docking parameters.

Details for molecular docking with different CHIKV protein targets in this study were
described as follows.
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6.1.2

PREDICTION OF BINDING SITES ON PROTEIN

In docking with AutoDock Vina, the grid box used for docking will be defined easily if
the location of ligand binding is known. However, in some cases where the binding sites
are unknown or one would like to explore alternative binding sites, computational
methods such as blind docking, MetaPocket, Accelrys DS can be applied to predict
potential binding sites.
6.1.2.1 MetaPocket 2.0343

The procedure includes three stages, namely calling based methods, meta-pocket site
generation, and mapping binding residues. Given protein structure, there will be 8
predictors, namely LIGSITEcs, PASS, Q-SiteFinder, SURFNET, Fpocket, GHECOM,
ConCavity, and POCASA to identify pocket sites on the protein surface. All the
predictors are run in parallel and a ranking-scores comparable, z-score is calculated
separately for each pocket site in different predictors. The pockets will be clustered in
terms of their spatial similarity and total z-score values. The final pocket sites are the
potential ligand binding sites on protein surface. The potential binding pockets were
obtained by the webserver http://projects.biotec.tu-dresden.de/metapocket/index.php,
taking 5-10 minutes to get the potential pockets depending on the protein size.

6.1.2.2 Receptor cavities tool in Accelery Discovery Studio 3.5
Accelerys DS 3.5 package342 was also applied to explore potential binding sites using a
receptor cavities tool. Based on a grid search and “eraser” algorithm, the program
defines location of binding sites from receptor cavities in the structure of protein. The
binding sites were displayed as a set of points (points count), and their volumes were
calculated as the product of number of site points and the cube of the grid spacing.
These pockets were compared to those identified in blind dockings in terms of location
for both of the envelop glycoprotein structures.
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6.1.3

APPLYING A DOCKING PROCEDURE

6.1.3.1 The nsP3 macrodomain

The nsP3 macrodomain protein was downloaded from the Protein Data Bank (PDB id:
3GPG) and this was used as the receptor for docking. The docking protocol was
established by re-docking the ADP-ribose into the nsP3 as observed in the co-crystal
structure (PDB id: 3GPO). The ligand ADP-ribose was extracted from the complex
crystal structure. The protein structure was edited and uploaded into the Procheck
(WhatIF) website, and manually corrected some errors present in sidechains of His,
Asn, and Glu flips. The next step is running energy minimization to relax the structure
and remove steric overlaps. With a Cα RMSD of 0.59 Å between the minimized
structure and the X-ray structure, the minimized structure was utilized for the docking
process. Polar hydrogen atoms were added and save into file *.pdbqt format in
AutoDock Tools.

Using AutoDock Tools, the binding site was defined as the place where ADP-ribose
binds. The values of different grid box dimensions and its centre were used for docking
and screenings, listed in Table 5.2, (See more discussion in Chapter 2).
Table 6.2. Parameters of a grid box in different docking and virtual screenings for the
nsP3 protein.
Docking and virtual screening

x, y, z coordinates

Dimension of a grid box

Pocket 1

9.7 Å, 43.0 Å, -13.2 Å

16 Å × 16 Å × 16 Å

Pocket 2

9.7 Å, 43 Å, -13.2 Å

20 Å × 20 Å × 20 Å

9.7 Å, 43 Å, -13.2 Å

50 Å × 50 Å × 56 Å

7.7 Å, 45.3 Å, -5.3 Å

50 Å × 50 Å × 56 Å

Pocket 2

7.7 Å, 45.4 Å, 11.5 Å

20 Å × 20 Å × 20 Å

Pocket 3

2.3 Å, 44.6 Å, -18.3 Å

20 Å × 20 Å × 20 Å

Blind docking
(at the centre of Pocket 1)
Blind docking
(at the centre of the protein)
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6.1.3.2 The nsP2 enzyme

The 3D crystal structure of the nsP2 protease of CHIKV was obtained from the Protein
Data Bank (PDB id: 3TRK) and served as a protein target in docking. Using Procheck
(WhatIF), no errors were found. Water molecules and the other co-factors were deleted.
The structures of the four best compounds taken from the previous study351 were drawn
in ChemDraw (ChemBioDraw Ultra 13.0) and then converted to 3D structure using
OpenBabel. These compounds were docked into the nsP2 protease based on the key
residues of Pocket 1 identified in the previous study.351 The preparation of docking was
the same as previously, and Pocket 1 was confirmed. The blind dockings, with a grid
box size of 60 Å × 70 Å × 60 Å at the centre of protein, and with a grid box size of 66
Å × 86 Å × 70 Å at the centre of the binding site, were carried out. Focused docking
with a smaller box (20 Å × 20 Å × 20 Å), centred on the potential binding sites of
interest was then undertaken. Additionally, the MetaPocket was used to identify
potentially pocket sites of the nsP2 other than the active site.343

The values of different grid box dimensions and its centres were used for docking and
different screenings, listed in Table 5.3, (See more discussion in Chapter 3).

Table 6.3. Parameters of a grid box in different docking and virtual screenings for the
nsP2 protease.
Docking and virtual screening

x, y, z coordinates

Dimension of a grid box

12.4 Å, 34.3 Å, 28.6 Å

66 Å × 86 Å × 60 Å

14.3 Å, 25.5 Å, 22.3

60 Å × 70 Å × 60 Å

Pocket 1

12.4 Å, 34.3 Å, 28.6 Å

16 Å × 16 Å × 16 Å

Pocket 1

12.4 Å, 34.3 Å, 28.6 Å

20 Å × 20 Å × 20 Å

Pocket 2

28.1 Å, 36.9 Å, 30.6 Å

20 Å × 20 Å × 20 Å

Pocket 3

30.4 Å, 42.1 Å, 14.8 Å

20 Å × 20 Å × 20 Å

Pocket 4

3.2 Å, 31.9 Å, 18.1 Å

20 Å × 20 Å × 20 Å

Pocket 5

15.2 Å, 13.9 Å, 11.5 Å

20 Å × 20 Å × 20 Å

Blind docking
(at the centre of Pocket 1)
Blind docking
(at the centre of Pocket 2)
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6.1.3.3 The envelope glycoproteins

Two X-ray crystal structures of envelope glycoprotein, an immature form (PDB id:
3N40) and a mature form (PDB id: 3N42), were downloaded from the Protein Data
Bank. The dimensions of the box covering 3N40 and 3N42 were set to 108 Å × 126 Å ×
62 Å and 84 Å × 126 Å × 74 Å, respectively. Potential binding sites were revealed by
the location of ligands binding into the target. The next step was a focused docking, in
which a smaller box (20 Å × 20 Å × 20 Å), was centred at the potential binding site of
interest. The receptor cavities tool in Accelrys DS and MetaPocket program were also
used to predict other potential binding sites of the envelope proteins.343

The values of different grid box dimensions, and their centres, were used for docking
and different screenings, listed in Table 5.4, (See more discussion in Chapter 4).
Table 6.4. Parameters of a grid box in different docking and virtual screenings for
envelope glycoprotein complexes.
Docking and virtual screening

x, y, z coordinates

Dimension of a grid box

23.7 Å, 1.8 Å, 23.4 Å

108 Å × 126 Å × 62 Å

26.4 Å, 7.1 Å, -24.5 Å

84 Å × 126 Å × 74 Å

Pocket 1 of the 3N40

-22.3 Å, 18.3 Å, 26.3 Å

20 Å × 20 Å × 20 Å

Pocket 2 of the 3N40

-15.9 Å, 1.5 Å, 19.7 Å

20 Å × 20 Å × 20 Å

Pocket 1of the 3N42

-21.3 Å, -11.7 Å, -24.9 Å

20 Å × 20 Å × 20 Å

Pocket 2 of the 3N42

-22.4 Å, -4.2 Å, -11.9 Å

20 Å × 20 Å × 20 Å

Pocket 3 of the 3N42

-5.7 Å, 31.2 Å, -8.9 Å

20 Å × 20 Å × 20 Å

Pocket 4 of the 3N42

-44.7 Å, -39.8 Å, -38.2 Å

20 Å × 20 Å × 20 Å

Blind docking
(at the centre of the 3N40)
Blind docking
(at the centre of the 3N42)

6.2 MOLECULAR DYNAMICS SIMULATIONS
The program NAMD265 was used for MD simulations to investigate the stability and
flexibility of the hit-target complexes and study their interactions. In this study, a
general strategy for MD simulations was performed as followings (Figure 5.2):
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Generation of
parameter and

Energy
minimization

Heating

Equilibration

Production

topology files
Figure 6.2. A general scheme for MD simulations.
It includes the following steps:
Step 1: Generation of the force field parameters (including the parameter and topology
files) for simulation for protein and ligand. The protein atoms were treated with the
CHARMM22 force field257 and the corresponding parameters for the ligands were
generated with AmberTools.262
Step 2: The systems were solvated in a cubic box of TIP3P water molecules that
extends 10 Å from the edge. Sodium counterions were added to neutralize the system by
randomly replacing the water molecules to mimic the physiological concentration of
0.15 M NaCl. All simulations were run under the periodic boundary conditions.
Step 3: Energy minimization for the system was conducted using a conjugate gradient
method to remove the bad contacts.
Step 4: The system was subjected to a heating procedure. The temperature was set to
298.15 K, and the pressure to 1 atm. The Langevin algorithm was used to maintain the
temperature and pressure coupling. The PME algorithm was used to compute long range
electrostatic interactions.269 The cutoff distance for vdW interactions was set at 12 Å,
and the pair-list distance was 13.5 Å.
Step 5: Running equilibrium and production simulations. The equilibrium phase with
weak harmonic restraints on heavy atoms for 3 ns was carried out. This brings the
system to equilibration state when the calculated average temperature, pressure, and
energies were converged or stabilized. The production phase of the simulation was run
subsequently and results of MD simulations were analysed based on the production phase.

All of the simulations were run on the high performance computation (HPC) clusters.
The HPC cluster is comprised of large compute nodes (Model Dell PowerEdge C6145)
with 16 core-processors, and 256 GB memory. System software provided includes
Linux or Mac OS client and Windows system operating system. The clusters are
connected with Interconnect technology from the Linux OS or MS Windows or DOS.
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Time for running depends on system size. For the nsP3 macrodomain and its
complexes: 12 simulations were run, including one simulation of apo protein and 11 for
the complexes of nsP3 and ligands. For the nsP2 protease and its complexes: the
number of systems was 14 including one simulation of apo protein and 13 for the
complexes of nsP2 enzyme and ligands. For envelope glycoprotein complexes: due to
the large sizes of these glycoproteins complexes, the simulations for these complexes
could not be done in this study.

Analysis of simulations: The trajectories for analysis were saved every 10 ps. To
determine the system stability, the value of RMSD of the heavy atoms over 50 ns was
calculated with respect to the starting structure versus the simulation time. The RMSF
of Cα atoms during the MD simulations was measured to obtain information on the
local flexibility of the system. The resulting trajectories such as hydrogen bonding and
hydrophobic contact interactions were analyzed by the CHARMM22263 and VMD
(version 1.9.1).276 A hydrogen bond was defined as the distance between proton donor
(D) and acceptor (A) atoms was ≤ 3.5 Å, and the angle D − H ⋯ A was ≥ 120°.70 If

occupancy of HBs was more than 75%, they were considered as strong HBs whereas

HBs occupations of less than 50%, were designated as medium.70 The hydrophobic
contacts were also monitored based on a cutoff distance between the carbon atoms of
non-polar parts of residues of proteins and of ligand of 4.0 Å.277-278 The Clustering
Plugin in VMD is applied for clustering analysis for the snapshots from the trajectories.

6.2.1

SIMULATIONS FOR PROTEIN

MD simulations were conducted for the apo protein and the hit-target complexes
obtained from virtual screening.

6.2.1.1 The nsP3 macrodomain

MD simulations were carried out for the apo state (PDB id: 3GPG), and 11 ligand-nsP3
complexes. The total number of atoms (including protein, water, and counterions) in the
CHIKV system was about 18,000; and the size of the initial water box was about 58 Å ×
58 Å × 58 Å.
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6.2.1.2 The nsP2 enzyme

MD simulations were conducted for the apo state (PDB id: 3TRK), the 13 complexes of
the nsP2 protease, and hit compounds obtained from virtual screening. The total number
of atoms of protein, water, and counterions in the CHIKV system was about 70,000; and
the dimension of the initial water box was about 90 Å × 90 Å × 90 Å.

6.2.2

SIMULATIONS FOR LIGANDS

Additional simulations of ligands in water were conducted to calculate the binding free
energies with the LIE method, described in 5.3 section. The other parameters of setting
up MD simulations were the same as previously used for protein.

6.3 BINDING FREE ENERGY CALCULATIONS
There have been different approaches developed over the years to calculate the ligand
binding free energies such as free energy perturbation, thermodynamic integration, and
LIE.316, 328 In this study, an LIE approach was applied to calculate the absolute binding
free energies for ligands in complexes with the protein targets, the nsP3 macrodomain
and the nsP2 enzyme. The main reason for this approach is that this method
compromises between speed and accuracy, and so is more practically feasible for large
ligands. In addition, we can utilize the results of MD simulations of proteins. Derived
from the linear response theory, the binding free energies is approximated as
vdw
vdw
elec
elec
〉 + β 〈Vbound
〉+γ
∆Gbind = α 〈Vbound
− Vunbound
− Vunbound

(Equation 1.16)

The various van der Waals and electrostatic components can be obtained from two
simulations: one with the ligand in aqueous solution, and the other with the protein
(nsP3 or nsP2)-ligand complex in aqueous solution. The NAMDEnergy plugin in VMD
was utilized to compute the energy components over the frames obtained from the MD
simulations.265, 276
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In Equation 1.16, α, β, and γ are empirical parameters. α is often set to 0.18 for a wide
variety of ligand-protein systems. The β represents a function of the chemical nature of
the ligand, so in principle the value of β can be parameterized from explicit solvent free
energy calculations of different chemical entities. The γ parameter can be set γ = 0 or γ ≠
0 depending on the hydrophobicity of the binding site to estimate absolute free energies
of binding.
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During the past decade, computational approaches have shown their success and power
in assisting drug discovery and development. With the emergence or re-emergence of
some alphaviruses, such as CHIKV, a neglected tropical disease in more than 55
countries in the word, searching for potential inhibitors to combat the virus in efficient
time, and in a cost-effective manner is significantly important. Taking advantage of all
available information on CHIKV, this study examined major potential targets of
CHIKV. The non-structural proteins nsP3 macrodomain and nsP2 protease were used to
target the viral replication and transcription (Chapter 2 and Chapter 3). The envelope
glycoprotein complexes were another potential target as they direct virus entry and
attachment (Chapter 4). A combination of computational tools; including molecular
docking, virtual screening, molecular dynamics simulations, and binding free energy
calculations, were used to identify a number of lead compounds for potential CHIKV
disease treatment. The insights into the CHIKV inhibitors and their complexes, as well
as their interaction energies, were elucidated. Our findings provide a foundation which
would be helpful for further research on rational antiviral drug design, especially the
design of CHIKV inhibitors.

7.1 NSP3 MACRODOMAIN PROTEIN
Chapter 2 described the attempts at drug discovery targeting the nsP3 macrodomain.
The nsP3 is considered a potential target for CHIKV drug discovery because of its
crucial role in the early stages of transcription for viral replication. With the goal of
identifying potential novel inhibitors for the CHIKV, this study utilised the available
crystal structures, nsP3 macrodomain (PDB id: 3GPG) and its complex with ADPribose (PDB id: 3GPO) as a starting point. Initially, reproducing the experimental data
with respect to the co-crystal structure of nsP3-ADP-ribose showed that ligand ADPribose binds tightly into the nsP3 (binding affinity of less than -10 kcal/mol). This
indicated a successful and robust docking protocol with AutoDock Vina. Virtual
screening based on this protocol was conducted with the library database compounds
(NCI Diversity Set II). The top hit compounds and three binding pockets were
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identified. In virtual screening, blind dockings covering the entire protein, followed by
focused dockings to a specific pocket of protein, were a robust strategy to detect
potential binding pockets. An additional strategy used the MetaPocket program to
confirm these pockets, with consistent results. Pocket 1 is the well-characterised
adenine binding pocket, and Pocket 2/Pocket 3 are two additional binding pockets.
Moreover, in terms of binding affinity, Pocket 1 appears to be the most favourable for
ligand binding (binding affinities of less than -10 kcal/mol), while Pocket 3 appears to
be the least favourable one. Some ligands bind to different pockets with the different
conformations. Based on the binding affinities and analysis of interactions, some
ligands showed greater potential than others. They are NCI_61610 (-11.1 kcal/mol),
NCI_345647_a (-10.9 kcal/mol), NCI_25457 (-10.8 kcal/mol), NCI_670283 (-10.6
kcal/mol), NCI_37168 (around -10.0 kcal/mol), NCI_372499_b (-10.3 kcal/mol), and
NCI_324623 (-10.3 kcal/mol). However, the question of ligand selectivity to the pocket
requires more experimental work. Analysis in terms of HBs and hydrophobic
interactions revealed key residues for interactions with the ligands in the nsP3.

Furthermore, equilibrium MD simulations for most of the top docked ligand-nsP3
complexes were carried out to validate the molecular docking results. The stability of
these complexes over 50 ns was reported, and there were subtle structural
rearrangements in the nsP3 observed to better accommodate the ligands. Throughout
analysis of MD simulations and binding free energy calculations, insights into the
interactions between ligands and the protein nsP3 were observed at an atomic level.
Consequently, the compounds to be considered for biological testing, are NCI_61610
(-15.2 kcal/mol), NCI_670283 (-13.2 kcal/mol), NCI_293778 (-12.7 kcal/mol),
NCI_345647_a (-12.1 kcal/mol), NCI_37168 (-12.0 kcal/mol), and NCI_25457 (-10.0
kcal/mol).

Utilizing the simulation results of the nsP3 and its complexes, the LIE approach was
applied to calculate binding free energies for the top hits obtained from docking. The
LIE method is one of the most powerful approaches in the estimation of binding free
energy for a ligand. Given the approximations used in the LIE approach, careful
selection of parameters was provided. The comparison between the top-hit compounds
and the tenth-hit compounds in terms of their binding free energy showed a close
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agreement of docking and simulations in predicting binding affinities. The combination
of the results from docking, MD simulations and binding free energy calculations
provides a list of compounds was proposed for biological testing including NCI_61610,
NCI_345647_a, NCI_25457, NCI_670283, and NCI_37168.

For further work, the identified potential inhibitors should be experimentally tested their
ability to inhibit CHIKV verified by in vivo studies. The key residues for interaction
will be further investigated on their contributions, e.g. through HBs interactions, or the
vdW to probe their influence on the binding process. The results are also useful for
constructing a pharmacophore for future ligand-based drug design to generate the
chemical libraries for novel inhibitors targeting CHIKV. Strategies for the synthesis and
subsequent lead optimization are also a major next consideration.

7.2 NSP2 PROTEASE ENZYME
Drug discovery targeting the nsP2 protease was presented in Chapter 3, using the same
process as described in Chapter 2. The nsP2 protease is a potential target with an
important role in the cleavage of the non-structural polyproteins into non-structural
proteins in the viral replication cycle, and transcription shut-off. This study is the first
instance where molecular modelling using the X-ray structure has been undertaken. Due
to lack of the structural information about the binding between ligands and the nsP2
protease, no information about its potential binding pockets was forthcoming; blind
docking was crucial to discover the possible binding pockets in the enzyme, and to
detect hit compounds which may bind to these sites. Blind dockings were also based on
previously published information, defining the binding site based on a homology model
of the nsP2 protease and its potential inhibitors. In our study, the top hit compounds and
five potential binding pockets of the nsP2 protease were identified. Focused dockings
into these different binding sites offered more hit compounds and provided further
binding modes at these pockets. Pocket 4 in the N-terminal domain of the nsP2 protease
was identified based on structural alignment as the active site (through the presence of
catalytic residues, Cys1013 and His1083) while most of previous studies reported
Pocket 1 as the active site. The results from docking and virtual screenings indicate that
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the potential compounds are NCI_61610 (-10.6 kcal/mol), NCI_293778 (from -9.8 to
around -10.2 kcal/mol), NCI_37553 (-9.6 kcal/mol), NCI_217697 (-9.3 kcal/mol), and
NCI_25457 (-9.0 kcal/mol).

The results of top hit compounds after equilibrium MD simulations for 50 ns indicated
most of the systems were maintained by interactions from hydrophobic contacts rather
than hydrogen bonds. The LIE approach was used to obtain the accurate binding
affinities of different ligands based on their trajectories from MD simulations. The
different binding energies were explained by the contribution of varying numbers of
HBs and hydrophobic contacts. The lead compounds selected were NCI_293778 (from
-9.9 to around -13 kcal/mol), NCI_67436 (-15.5 kcal/mol), and NCI_217697 (-9.0
kcal/mol). The relative ranking of binding free energies of top-hit compounds gave a
good agreement between docking results and MD simulations results.

After combining the results obtained from docking, MD simulations and binding free
energy calculations, proposed compounds for biological testing including NCI_293778,
NCI_217697, and NCI_67436.

Moreover, as there are some potential binding pockets other than the active site in the
structure of nsP2 enzyme, so further experimental work is required to investigate the
effect upon binding to these alternate pockets. More experimental data is also needed to
elucidate the contribution and influence of vdW, and electrostatic energy on ligand
binding. Calculations of interaction energy components from key residues should be
considered. The study opens up a promising approach to rational drug design
(pharmacophore constructing with the generated scaffold) for the design of inhibitors
for CHIKV. Synthesis of the lead compounds followed by lead optimization, is also an
important next step.

7.3 ENVELOPE GLYCOPROTEINS
Envelope glycoproteins are another class attractive targets for inhibition of virus entry
or virus attachment as inhibition of the viral envelope glycoproteins can block the in
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vitro CHIKV infection. Chapter 4 focused on the discovery of inhibitors for CHIKV
targeting the envelope glycoproteins complexes. Computational investigation of the
envelope glycoproteins complexes (the immature and mature forms) has previously
been explored within our group, however a more rigorous exploration based on blind
docking was deemed essential to the full characterization of potential target sites.
Virtual screenings based on blind docking and focused docking explored the potential
binding pockets and inhibitors for both the immature and mature structure of envelope
proteins. Promising hit compounds were identified for two complexes of the envelope
glycoproteins. Pocket 2 was a novel binding pocket in the immature structure. Pocket 2
and Pocket 3 were detected as novel binding sites for the mature complex of the
glycoproteins. The key residues involved in stabilizing the complex or participating in
the fusion process were confirmed. This study also investigated the convergence of
conformational sampling in AutoDock Vina. The results demonstrated that this
parameter affected a searching process for conformations of ligand in docking however
in the current study, the different screening provided a semi-quantitatively consistent
picture. The binding affinities of most of top hits compounds were about -10 to -13
kcal/mol indicating good binding between the ligands and the envelope glycoprotein
complexes. The compounds bound into Pocket 1 and Pocket 4 were expected to be
promising targeting the glycoprotein complexes, as they could interact with the residues
involved in the process of virus attachment and virus entry. Therefore, the potential
compounds proposed for biological testing include NCI_293778 (from -11.4 to around
-13.7 kcal/mol), NCI_61610 (from -11.6 to -12.3 kcal/mol), NCI_37553 (-11.5
kcal/mol), and NCI_156219 (-11.1 kcal/mol).

This work supported the current docking protocol, utilising AutoDock Vina as a robust
strategy, which could be used to identify inhibitors and understand the binding modes.
However, in docking, the protein structure was kept rigid and this might affect both the
docking and scoring process. More accurate binding free energies are expected to be
obtained from explicit solvent based MD simulations, however, due to the larger sizes
of these envelope glycoprotein complexes, this could not be conducted within the time
frame of this work.
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In future work, experimental studies are required to determine the inhibitory effects of
hit compounds on these membrane proteins. It would be useful to investigate the
stability and flexibility of the systems. The mechanism of virus entry and virus
attachment through the envelope glycoproteins would require further MD simulations
experimental data. The binding free energy calculations would be also needed to guide
rational antiviral drug design.
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Appendix 1. Chemical structures of top hit compounds in all dockings for the nsP3
macrodomain, nsP2 protease, and envelope glycoprotein complexes.
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Appendix 2. Interactions analysis for each ligand in the VST1 for the nsP3.
Compound

Binding affinity
(kcal/mol)

1. NCI_25457

-10.8

2. NCI_116702

-10.7

3. NCI_309892

-10.3

4. NCI_109451

-10.2

π-system with Tyr114

5. NCI_127133

-10.2

π-system with Trp148

6. NCI_328101

-10.2

HBs: Val113 (HN)-N, Arg144 (HE)-O
π-system with Trp148

7. NCI_372275_a

-10.2

π-system with Trp148

8. NCI_45545

-10.2

HBs: Val113 (HN)-N, H-Asp31 (O)

9. NCI_84100_b

-10.2

HBs: Val113 (HN)-O
π-system with Tyr114

10. NCI_37168

-10.1

π-system with Trp148

Interactions
HBs: Val113 (HN)-O
π-π interaction with Trp148
HBs: Val113 (HN)-O
π-π interaction with Tyr114
HBs: H-Thr (111)
π-system with Tyr114

Appendix 3. Interactions analysis for each ligand in the VST2 for the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_34567_a

-10.9

Hydrophobic contacts

2. NCI_37553

-10.9

π-π interaction with Trp148

3. NCI_25457

-10.8

Hydrophobic contacts

4. NCI_116702

-10.7

Hydrophobic contacts

5. NCI_58052

-10.6

Hydrophobic contacts

6. NCI_127133

-10.5

Hydrophobic contacts

7. NCI_293778

-10.5

Hydrophobic contacts

8. NCI_670283

-10.5

Hydrophobic contacts

9. NCI_328101

-10.4

Hydrophobic contacts

10. NCI_372499_b

-10.3

π-system with Trp148
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Appendix 4. Interactions analysis for each ligand in the VST3 for the nsP3.
Binding affinity
(kcal/mol)

Interactions

-11.1

HBs: Gly112 (HN)-O
π-π interaction with Trp148, Tyr114

-11.0

Hydrophobic contacts

-10.9

HBs: Gly112 (HN)-O
Thr111 (HG1)-O

4. NCI_25457

-10.8

π-π interaction with Trp148

5. NCI_58052

-10.6

HBs: Gly112 (HN)-N
Thr111 (HG1)-N

6. NCI_127133

-10.5

π-π interaction with Trp148, Tyr114

Compound
1. NCI_61610
2. NCI_293778
3. NCI_345647_a

HBs: Arg144 (HN)-O
Asp145 (HN)-O
π-π interaction with Trp148
HBs: Asp31 (HN)-O
π-π interaction with Trp148

7. NCI_372499_b

-10.3

8. NCI_37553

-10.3

9. NCI_309892

-10.2

HBs: H-Thr111 (O)

10. NCI_37168

-10.2

π-π interaction with Trp148

Appendix 5. Interactions analysis for each ligand in the VST4 for the nsP3.
Compound
1. NCI_61610
2. NCI_37553
3. NCI_345647_a

Binding affinity
(kcal/mol)

Interactions

-11.1

HBs: Val113 (HN)-O
π-π interaction with Trp148

-11.0

π-π interaction with Trp148

-10.9

HBs: Gly112 (HN)-O
Thr111 (HN)-O
H-Thr111 (OG1)
HBs: Val113 (HN)-O
π-π interaction with Trp148, Tyr114

4. NCI_25457

-10.8

5. NCI_293778

-10.8

HBs: Val113 (HN)-N

6. NCI_127133

-10.7

π-π interaction with Trp148, Tyr114
HBs: Val113 (HN)-O
π-π interaction with Tyr114,
π-system with Trp148
HBs: Gly112 (HN)-N, Thr111 (HN)-N
Asp31 (HN)-O

7. NCI_116702

-10.6

8. NCI_58052

-10.6

9. NCI_670283

-10.5

Hydrophobic contacts

10. NCI_324623

-10.3

HBs: Thr111 (HG1)-O

194

Appendix 6. Interactions analysis for each ligand in the VST5 for the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_127133

-8.3

HBs: H-Asp133 (O), H-Thr135 (O)

2. NCI_293778

-8.2

π-system with His-1

3. NCI_338042

-7.6

Hydrophobic contacts

4. NCI_132232

-7.5

HBs: H-Asp133 (O)

5. NCI_310326

-7.5

Hydrophobic contacts

6. NCI_328101

-7.4

HBs: Tyr4 (HH)-F, His-1(HT1)-O

7. NCI_69359_a

-7.3

Hydrophobic contacts

8. NCI_90737

-7.3

Hydrophobic contacts

9. NCI_122819_a

-7.2

HBs: Tyr4 (HN)-O

10. NCI_400976

-7.2

Hydrophobic contacts

Appendix 7. Interactions analysis for each ligand in the VST6 for the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_670283

-10.6

Hydrophobic contacts

2. NCI_319990

-10.2

HBs: Tyr144 (HH)-O

3. NCI_80731

-10.1

HBs: Tyr144 (HH)-O, H-Asp31 (O)

4. NCI_84100_b

-10.1

HBs: H-Tyr114 (OH)

5. NCI_372287_a

-10.0

HBs: Thr111 (HN)-O, Asp31 (HN)-O

6. NCI_84100_a

-9.9

HBs: H-Tyr114 (OH)

7. NCI_97920

-9.6

HBs: H-Asp31 (O)

8. NCI_58052

-9.5

HBs: H-Asp31 (O), Asn75 (HD22)-O

9. NCI_227186_a

-9.4

Hydrophobic contacts

10. NCI_293778

-9.4

HBs: Asp31 (HN)-N
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Appendix 8. SASA’s values (Å2) in the simulations of the apo nsP3 and its complexes with different ligands: A: Ligand NCI_61610, B: Ligand
NCI_25457, C: Ligand NCI_345647, D: Ligand NCI_670283, E: Ligand NCI_127133, F: Ligand NCI_37168vst1, G: Ligand NCI_372499vst2,
H: Ligand NCI_37168vst3, I: Ligand NCI_324623vst4, J: Ligand NCI_400976vst5, K: Ligand NCI_293778vst6.
nsP3

nsP3-A

nsP3-B

Ala22

31.3

36.6

35.6

Pro25

75.5

57.8

Leu28

102.6

108.2

Val33

68.8

81.7

57.4

Pro107

25.9

20.4

25.2

Val113

129.8

146.5

138.8

Tyr114

70.2

63.4

Trp148 84.0
Ile11
12.6

88.4

nsP3-C

nsP3-D

nsP3-E

45.0

nsP3-F
36.9

nsP3-G

nsP3-H
42.3

nsP3-I
41.4

nsP3-J

65.9
113.1

100.8
79.7

58.2

24.1
130.8

69.3

63.8

90.2

95.5

52.9

71.9

75.3

53.7

30.6

28.4

21.9

142.2

138.2

137.8

147.7

140.4

87.4

63.5

55.8

54.8

49.7

95.5

82.9

25.8

Ala36

34.0

Ala1

74.5

81.2

80.6

Pro2

37.9

56.4

62.3

Tyr4

39.2

41.7

50.2

Ala23

10.5

Arg144 172.0
Phe45

14.6

Phe129

17.8

30.0

13.4
185.7
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10.6

172.0
25.3
145.9
202.5

202.8

Thr111 24.3

14.9
27.0

Arg159 129.1
Arg26

nsP3-K
38.4

25.5

Appendix 9. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-5nsa in
the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-11.6

Π-stacking with Tyr114

2. NCI_84100_b

-10.7

Π-stacking with Tyr114

3. NCI_84100_a

-10.6

Π-stacking with Tyr114

4. NCI_80997_b

-10.5

Hydrophobic contacts

5. NCI_37553

-10.4

Hydrophobic contacts

6. NCI_61610

-10.3

Hydrophobic contacts

7. NCI_670283

-10.2

Hydrophobic contacts

8. NCI_59620_a

-10.2

Hydrophobic contacts

9. NCI_308835

-10.2

HBs: Ser110(HN)-O

10. NCI_60785

-10.2

HBs: H-Leu108(O)

Appendix 10. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-10nsa
in the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_37553

-11.1

HBs: Asn24(HD22)-O

2. NCI_293778

-11.1

HBs: Val33(HN)-N

3. NCI_60785_a

-11.0

HBs: H-Thr111(OG1)

4. NCI_59620_a

-10.8

5. NCI_27592_a

-10.7

Hydrophobic contacts

6. NCI_670283

-10.7

Hydrophobic contacts

7. NCI_82802_a

-10.7

HBs: Ile11(HN)-F

8. NCI_328101

-10.5

9. NCI_59620_a

10. NCI_308835

-10.5
-10.5

HBs: Thr111(HN)-O, Leu108(HN)-O,
Asn24(HD22)-O

HBs: Ala22(HN)-F, Ala22(HN)-F,
Asn24(HD22)-O
HBs: Thr111(HN)-O, Leu108(HN)-O,
Asn24(HD22)-O
Hydrophobic contacts
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Appendix 11. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-15nsa
in the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-10.5

Hydrophobic contacts

2. NCI_308835

-10.3

Hydrophobic contacts

3. NCI_37553

-10.3

HBs: Asn24(HD22)-O

4. NCI_97920

-10.0

HBs: H-Asp31(O)

5. NCI_84100_b

-9.9

Hydrophobic contacts

6. NCI_59620_a

-9.8

HBs: Gly112(HN)-O, Asn24(HD22)-O

7. NCI_84100_a

-9.8

Hydrophobic contacts

8. NCI_37627

-9.8

HBs: Gly112(HN)-O

9. NCI_60785_b

-9.7

Hydrophobic contacts

10. NCI_25457

-9.7

HBs: Asp31 (HN)-N

Appendix 12. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-20nsa
in the nsP3.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_37553

-12.1

HBs: Asn24(HD22)-O

2. NCI_61610

-11.9

HBs: Asn24(HD22)-O

3. NCI_670283

-11.7

HBs: Asp31(HN)-O

4. NCI_293778

-11.3

Hydrophobic contacts

5. NCI_60785_a

-11.1

HBs: H-Leu108(O)

6. NCI_63680

-11.1

Hydrophobic contacts

7. NCI_82802_a

-11.0

HBs: H-Thr111(OG1)

8. NCI_219894

-10.8

HBs: Leu108(HN)-O, Ser110(HN)-O

9. NCI_80997_b

-10.7

HBs: H-Leu108(O), Asn24(HD22)-O

10. NCI_328101

-10.7

HBss: Gly70(HN)-F
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Appendix 13. Interactions analysis for each ligand in the nsP2 in VST1a.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_61610

-10.6

HBs: Tyr1177 (HH)-N

2. NCI_293778

-10.3

Hydrophobic contacts

3. NCI_116702

-9.2

HBs: Cys1290 (HG)-N

4. NCI_37553

-9.2

HBs: H-Tyr1079 (OH)

5. NCI_84100_a

-9.2

6. NCI_84100_b

-9.1

HBs: H-Trp1161(O),
Lys1165(HZ2)-O
HBs: H-Trp1161(O),
Lys1165(HZ2)-O

7. NCI_25457

-9.0

HBs: Cys1290(HG)-N

8. NCI_670283

-10.2

9. NCI_97920

-9.0

Hydrophobic contacts

10. NCI_58052

-8.8

HBs: Asn1167(HN)-O

HBs: Lys1045(HZ1)-O,
Lys1239(HZ1)-O

Appendix 14. Interactions analysis for each ligand in the nsP2 in VST2b.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-10.3

π -system with Trp1084

2. NCI_61610

-10.1

π -system with His1151, Phe1225

3. NCI_670283

-9.7

π -system with Tyr1078

4. NCI_116702

-9.2

Hydrophobic contacts

5. NCI_217697

-9.2

Hydrophobic contacts

6. NCI_84100_a

-9.2

π -system with Tyr1177

7. NCI_84100_b

-9.2

π -system with Trp1084

8. NCI_298892_b

-9.1

9. NCI_37553

-9.1

Hydrophobic contacts

10. NCI_25457

-9.0

HBs: Cys1290(HG)-N

HBs: His1222(HN)-O,
Lys1239(HZ1)-N
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Appendix 15. Interactions analysis for each ligand in the nsP2 in VST3a .
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_217697

-9.3

Hydrophobic contacts

2. NCI_60783

-9.3

3. NCI_298892_b

-9.2

4. NCI_328101

-9.2

Hydrophobic contacts

5. NCI_25457

-9.1

Hydrophobic contacts

6. NCI_116702

-9.0

7. NCI_80997_a

-9.0

Hydrophobic contacts

8. NCI_109451

-8.9

Hydrophobic contacts

9. NCI_93427

-8.9

Hydrophobic contacts

10. NCI_127133

-8.8

Hydrophobic contacts

HBs: Lys1045(HZ1)-O,
Lys1239(HZ1)-O
HBs: Lys1045(HZ1)-N,
Lys1239(HZ1)-N, His1222(HN)-O

HBs: Lys1045(HZ1)-N,
Lys1239(HZ1)-N

Appendix 16. Interactions analysis for each ligand in the nsP2 in VST4b.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-9.8

H-bonds: Lys1239(HZ1)-N

2. NCI_37553

-9.7

H-bonds: Lys1045(HZ1)-O

3. NCI_328101

-9.3

Hydrophobic contacts

4. NCI_670283

-9.3

HBs: Lys1239(HZ1)-O, Lys1045(HZ1)-O

5. NCI_25457

-9.2

Hydrophobic contacts

6. NCI_298892_b

-9.2

7. NCI_61610

-9.2

HBs: Lys1239(HZ1)-N, Lys1045(HZ1)-N

8. NCI_84100_a

-9.2

π -system with Tyr1177

9. NCI_84100_b

-9.2

π -system with Tyr1177

10. NCI_217697

-9.1

Hydrophobic contacts

HBs: Lys1239(HZ1)-N, Lys1045(HZ1)-N,
His1222(HN)-O
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Appendix 17. Interactions analysis for each ligand in the nsP2 in VST5c.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-9.8

π -stacking with Tyr1177

2. NCI_37553

-9.4

π -stacking with Tyr1177

3. NCI_269148_a

-8.5

HBs: Lys1155(HZ3)-O, His1222(HD1)-O

4. NCI_146771

-8.3

5. NCI_227186_b

-8.3

6. NCI_308835

-8.3

Hydrophobic contacts

7. NCI_7524_b

-8.3

HBs: Lys1155(HZ3)-O

8. NCI_227186_a

-8.2

HBs: Phe1225(HE22)-O, Tyr1177(HH)-O

9. NCI_328101

10. NCI_362639

-8.2
-8.2

HBs: Gln1232(HE22)-O, Thr1295(HG1)-O,
H-Thr1292(O)
HBs: Tyr1177(HH)-O. Ala1180(HN)-O, HGlu1160(OE2), H-Glu1160(OE1)

HBs: Gln1232(HE22)-O, Phe1225(HN)-N,
Tyr1177(HH)-F
HBs: Phe1225(HN)-O, Thr1295(HG1)-O

Appendix 18. Interactions analysis for each ligand in the nsP2 in VST6d.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_37553

-9.6

Hydrophobic contacts

2. NCI_319990

-9.4

HBs: Asn1167(HN)-N

3. NCI_116702

-9.2

HBs: Cys1290(HG)-N

4. NCI_61610

-9.2

Hydrophobic contacts

5. NCI_25457

-9.0

HBs: Cys190(HG)-N

6. NCI_293778

-9.0

Hydrophobic contacts

7. NCI_97920

-9.0

Hydrophobic contacts

8. NCI_67436

-8.9

HBs: H-Ser1256(OG)

9. NCI_80997_b

-8.9

Hydrophobic contacts

10. NCI_84100_b

-8.9

Hydrophobic contacts
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Appendix 19. Interactions analysis for each ligand in the nsP2 in VST7e.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-10.4

Hydrophobic contacts

2. NCI_670283

-9.7

Hydrophobic contacts

3. NCI_121868_a

-9.3

HBs: Trp1084(HE1)-O

4. NCI_37553

-9.2

Hydrophobic contacts

5. NCI_61610

-9.2

HBs: Tyr1079(HH)-O

6. NCI_319990

-8.9

7. NCI_328101

-8.9

HBs: Ser1048(HG)-F, Lys1091(HZ3)-F

8. NCI_67436

-8.9

HBs: H-Tyr1079(OH)

9. NCI_227186_a

-8.8

HBs: H-Leu1205(O)

10. NCI_122819_b

-8.7

HBs: Trp1084(HE1)-O, Lys1091(HZ3)-O

HBs: Trp1084(HE1)-O, H-Leu1205(O),
Tyr1079(HH)-O

Appendix 20. Interactions analysis for each ligand in the nsP2 in VST8f.
Compound
1. NCI_293778

Binding affinity
(kcal/mol)
-10.2

Interactions
Hydrophobic contacts
HBs: H—Glu1270(OE1), H-

2. NCI_80734

-9.2

Glu1270(OE2), Phe1070(HN)-N,
Arg1271(HH21)-O
HBs: Arg1142(HH21)-O, H-

3. NCI_61610

-9.1

4. NCI_37553

-9.0

5. NCI_80735

-8.7

6. NCI_80997_a

-8.4

HBs: H-Glu1270(OE1)

7. NCI_345845

-8.1

HBs: H-Ser1067(O), H-Ala1099(O)

8. NCI_5157

-8.1

HBs: H-Asp1066(O), Ag1142(HH21)-O

9. NCI_58052

-8.1

HBs: H-Asp1066(O), Ag1140(HH21)-O

10. NCI_67436

-8.1

Hydrophobic contacts

Thr1313(OG1)
Hydrophobic contacts
HBs: H-Glu1270(OE1), Arg1271(HH21)O
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Appendix 21. Sequences alignment of three crystal structures, namely the nsP2
protease of CHIKV (PDB id: 3TRK), the nsP2 protease of VEEV (PDB id: 2HWK)
and the nsP2 protein of SINV (PDB id: 4GUA). The catalytic cysteine and histidine
are highlighted with *.
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Appendix 22. SASA’s values (Å2) in the simulations of the apo nsP2 and its complexes with different ligands: A: Ligand NCI_61610, B: Ligand
NCI_217697, C: Ligand NCI_37553, D: Ligand NCI_293778vst4, E: Ligand NCI_293778vst5, F: Ligand NCI_293778vst2, G: Ligand
NCI_293778vst7, H: Ligand NCI_293778vst8, I: Ligand NCI_217697w, J: Ligand NCI_25457w, K: Ligand NCI_362639, L: Ligand
NCI_84100_b, M: Ligand NCI_67436.
nsP3

nsP3-A

nsP3-B

Lys1045

89.6

90.6

89.8

Gly1176

42.6

Pro1191

43.4

59.0

45.8

Val1194

46.1

50.3

45.8

Leu1203

21.5

27.2

22.6

Glu1204

35.9

69.9

110.1

67.7

Ile1221

27.5

46.4

36.5

38.1

41.2

Met1238

17.3

29.3

30.6

44.5

Lys1239

49.1

68.8

90.2

85.3

Met1242

51.6

Leu1243

46.2
2.6

Tyr1047

24.7

Trp1161

140.8

137.0

144.6

142.3

Leu1162

25.1

27.9

29.3

24.9

Lys1165

170.7

168.6

175.2

182.3

Ile1166

24.8

26.1

Ser1282

57.8

53.6

Ser1283

33.6

19.1

Arg1284

123.8

132.7

Leu1286

37.5

39.7

33.9

Pro1288

22.4

20.2

25.9
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nsP3-C

nsP3-D

nsP3-E

nsP3-F

115.4

nsP3-G

nsP3-H

nsP3-I

nsP3-J

nsP3-K

nsP3-L

96.5

40.0

11.0

34.3

24.4

31.0
75.1

56.7
10.8

16.3

35.4

13.5
21.4

25.8

22.0

nsP3M

Pro1289

77.6

101.4

100.4

Leu1300

20.5

32.0

Ser1302

27.6

31.6

Ala1046

24.9

54.4

Hsd1222

95.2

95.9

Thr1223

11.4

32.4

Pro1224

94.1

117.5

25.6
42.7

43.1

64.3

99.4

106.3

Hsd1236

8.1

14.6

Met1242
Lys1155

46.2
205.1

56.7

Gly1156

50.0

66.7

Glu1157

90.5

87.5

Arg1158

152.8

152.4

Met1159

10.8

64.0

Gly1176
Tyr1177

42.6

38.3

115.5

84.6

Leu1179

-15.3

21.5

Thr1292

73.8

42.6

Ser1048

21.2

27.5

Tyr1078

88.6

79.5

Tyr1079

114.2

129.2

Asn1082

121.9

138.2

Trp1084

59.4

63.6

49.2

Leu1205

109.2

110.9

129.2

Val1077

6.9

Ile1102

103.9

105.2

Leu1103

25.8

31.8
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95.2

210.6
94.0

90.1

51.9

129.8

11.3

Pro1191

43.2

43.2

Leu1192

116.0

115.5

Gly1193

67.0

76.2

Val1194

46.6

46.1

Ser1293

5.4

Asp1066

93.8

79.3

Ser1067

28.6

37.5

5.8

Asn1140

63.4

69.0

Arg1141

46.0

47.8

Arg1142

211.6
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Pro1144

38.7

34.0

His1145

11.7

10.9

Glu1270

45.6

37.6

Arg1271

127.2

122.0

Cys1274

40.8

31.7

Val1275

67.4

72.2
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Appendix 23. Interactions analysis for each ligand in the nsP2 in VST-10ns.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-8.6

Hydrophobic contacts

2. NCI_37553

-8.5

Hydrophobic contacts

3. NCI_59620

-8.4

HBs: Thr308(HN)-O

4. NCI_7524_b

-8.3

Hydrophobic contacts

5. NCI_308835

-8.2

Hydrophobic contacts

6. NCI_227186_a

-8.0

7. NCI_328101

-8.0

HBs: Thr308(HN)-N, Thr308(HN)-O

8. NCI_339161

-7.8

HBs: Thr308(HG1)-O

9. NCI_270738_b

-7.8

HBs: Asn135(HD22)-O

10. NCI_58052

-7.8

HBs: N-Thr308(OG1), Asn135(HD22)-O

HBs: Thr308(HN)-O, His309(HE2)-O,
Arg137(HN)-O

Appendix 24. Interactions analysis for each ligand in the nsP2 in VST-20ns.
Compound

Binding affinity
(kcal/mol)

Interactions
HBs: Lys101(HZ1)-O, H-Asp59(OD2),

1. NCI_345647_a

-9.0

2. NCI_338042

-8.8

Hydrophobic contacts

3. NCI_293778

-8.7

HBs: Thr308(HG1)-N

4. NCI_67436

-8.3

HBs: H-Asn135(O), Arg137(HH11)-O

5. NCI_80997_a

-8.3

HBs: Lys101(HZ1)-O

6. NCI_338963

-8.2

Hydrophobic contacts

7. NCI_319990

-8.2

HBs: His309(HD1)-N

8. NCI_25457

-8.0

Hydrophobic contacts

9. NCI_670283

-7.9

Hydrophobic contacts

10. NCI_326182

-7.9

Hydrophobic contacts

Arg136(HH12)-O
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Appendix 25. Interactions analysis for each ligand in the nsP2 in VST-30ns.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-8.3

Hydrophobic contacts

2. NCI_3045647_a

-8.0

Hydrophobic contacts

3. NCI_97920

-8.0

Hydrophobic contacts

4. NCI_327702

-7.9

HBs: Gln236(HE22)-N

5. NCI_156516

-7.9

Hydrophobic contacts

6. NCI_80313

-7.8

HBs: Gln236(HE22)-O, Gln236(HE21)-N

7. NCI_116709_b

-7.8

Hydrophobic contacts

8. NCI_37553

-7.8

HBs: Arg266(HH12)-O

9. NCI_326757

-7.6

HBs: H-Val270(O)

10. NCI_154585

-7.6

HBs: H-Gln236(O)

Appendix 26. Interactions analysis for each ligand in the nsP2 in VST-40ns.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-8.5

Hydrophobic contacts

2. NCI_61610

-7.9

Hydrophobic contacts

3. NCI_122819_b

-7.7

HBs: H-Thr307(OG1), Thr308(HN)-O

4. NCI_671136

-7.6

HBs: Thr308(HN)-O

5. NCI_19990_a

-7.6

6. NCI_37641_b

-7.5

HBs: H-Thr307(OG1), His309(HD1)-O, HGlu265(OE2), Arg137(HN)-O
HBs: Thr308(HN)-O, H-Thr307(OG1),
His309(HN)-O
HBs: H-Arg137(O), Thr308(HN)-O, H-

7. NCI_269148_b

-7.4

Thr307(OG1), H-Asn305(OD1),
Arg273(HH22)-O

8. NCI_319990

-7.4

HBs: Arg137(HN)-N, H-Arg137(O),
H-Thr137(OG1)
HBs: H-Thr302(OG1), Thr308(HN)-O, H-

9. NCI_156219_b

-7.4

Thr308(OG1), Asn312(HD21)-O,
His309(HN)-O

10. NCI_59620_b

-7.3

HBs: Thr308(HG1)-O
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Appendix 27. Interactions analysis for each ligand in the nsP2 in VST-50ns.
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_61610

-8.2

HBs: H-Thr308(OG1)

2. NCI_84100_a

-7.2

HBs: Thr308(HN)-O, H-Thr308(OG1)

3. NCI_146771

-7.2

Hydrophobic contacts

4. NCI_84100_b

-7.1

HBs: Thr308(HN)-O, H-Thr308(OG1)

5. NCI_25457

-7.0

Hydrophobic contacts

6. NCI_116702

-7.0

Hydrophobic contacts

7. NCI_37553

-7.0

Hydrophobic contacts

8. NCI_80731

-7.0

HBs: His309(HD1)-O, H-Glu265(OE1)

9. NCI_35691

-7.0

HBs: H-Leu138(O)

10. NCI_332670

-7.0

HBs: Asn312(HD21)-O
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Appendix 28. Binding sites identified in the immature form (PDB id: 3N40) using
receptor cavities tools in Accelerys Discovery Studio software. The binding site
detected is based on X, Y, Z coordinates; volume; and a set of points (point count).
Pocket location

X

Y

Z
24.9

Volume
(Å3)
131.8

Point
count
1054

Between E1 domain II and E2 domain C
(Pocket 1)
Between E1 domain II and the E2 β-ribbon
(Pocket 1)
At the E2 β-ribbon (Pocket 2)
Behind the fusion loop, between E3, E2
domain A, E2 domain B (Pocket 4)
Between E1 domain I-domain III and E2
domain C (Pocket 3)
Between E1 domain II-E3
Between E1 domain I-E1 domain III
Between E1 domain II-near E2 β-ribbon
Between E1 domain II-E1 domain I
Between E1 domain I and E2 domain C
Between E1 domain I-E1 domain III
Between E1 domain II-E2 domain A and E3
Between E2 domain B-E3
Between E2 domain C
Between E2 domain A and E2 β-ribbon

-25.6

21.1

-13.8

-4.7

19.7

352.3

2818

-22.4
-9.6

-0.2
-7.3

8.9
8.2

123.5
26.8

988
214

-11.1

-58.4

19.7

42.3

338

-34.1
-11.1
-26.6
-6.9
-2.9
-4.9
-33.1
-54.4
-9.6
-17.6

21.1
-58.4
-4.4
-23.9
-25.2
-37.4
33.3
32.1
-7.3
7.3

39.4
19.7
25.2
33.7
19.4
12.9
25.2
29.4
8.2
8.2

49.0
42.3
38.8
36.1
32.8
31.8
27.6
27.1
26.8
23.4

392
338
310
289
262
254
221
217
214
187

Appendix 29. Binding sites identified in the mature form (PDB id: 3N42) using
receptor cavities tools in Accelerys Discovery Studio software. The binding site
detected is based on X, Y, Z coordinates; volume; and a set of points (point count).
Pocket location

X

Y

Z
-19.9

Volume
(Å3)
621.2

Point
count
4970

Between E1 domain II and E2 domain C
(Pocket 1)
At the E2 β-ribbon (Pocket 2)
Behind the fusion loop, between E3, E2
domain A, E2 domain B (Pocket 4)
Between E1 domain I-domain III and E2
domain C (Pocket 3)
Between E1 domain II, E2 β-ribbon
E2 domain A
Between E1 domain I-E1 domain III
Between E1 domain I-E1 domain II and
E2 domain C
Between E2 domain A-E3
Between E2 domain B-E2 domain A
E1 domain I
E2 domain C
E2 domain A
E3

-16.7

2.0

-19.7
-33.4

-2.9
-14.2

-9.9
-34.9

156.0
523.0

1248
4184

-6.4

24.3

-26.2

129.6

1037

-16.7
-43.4
-6.4
-6.4

2.0
-28.7
37.8
24.8

-19.9
-22.9
-13.4
-26.2

621.2
143.5
139.7
129.6

4970
1148
1118
1037

-46.7
-53.2
-16.2
-10.7
-47.2
-47.2

-14.7
-31.2
51.3
7.8
-12.9
-12.9

-22.9
-27.7
-22.4
-0.9
-12.2
-12.2

100.5
35.8
25.4
25.2
23.5
23.5

804
283
203
202
188
178
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Appendix 30. Interactions analysis for each ligand in blind docking in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.2

π-system with Tyr51

2. NCI_61610

-12.2

HBs: H-Glu99(O)

3. NCI_37553

-11.7

Hydrophobic contacts

4. NCI_156219_b

-11.5

HBs: H-Ile101(O)

5. NCI_84100_b

-10.9

HBs: H-Tyr233(OH)

6. NCI_84100_a

-10.9

HBs: H-Tyr233(OH)

7. NCI_116702

-10.8

HBs: H-Tyr233(OH)

8. NCI_19990_a

-10.8

Hydrophobic contacts

9. NCI_227186_a

-10.7

10. NCI_227186_b

-10.6

HBs: Ser238(HN)-O, H-Thr53(O),
Tyr301(HH)-O, H-Tyr301(OH)
HBs: Ile55(HN)-O, Thr53(HN)-O, HTyr51(O)

Appendix 31. Interactions analysis for each ligand in blind docking in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

π-system with Tyr129

2. NCI_37553

-11.4

Hydrophobic contacts

3. NCI_61610

-11.2

HBs: H-Pro128(O), Ile55(HN)-O

4. NCI_156219_b

-11.1

HBs: H-Glu50(OE2)

5. NCI_84100_a

-11.0

π-system with Tyr242, Pro237

6. NCI_227186_b

-10.9

HBs: Ser238(HN)-O, H-G;u50(OE2)

7. NCI_84100_b

-10.9

HBs: H-Asp43(OD2)

8. NCI_7524_a

-10.9

9. NCI_116702

-10.8

π-stacking with Pro133

10. NCI_308835

-10.8

Hydrophobic contacts

HBs: H-Glu50(OE2), Thr53(HN)-O,
Arg36(HH12)-O, Lys52(HZ1)-O
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Appendix 32. Interactions analysis for each ligand in VST3a in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

π-system with Tyr51

2. NCI_61610

-11.9

Hydrophobic contacts

3. NCI_37553

-11.7

Hydrophobic contacts

4. NCI_156219_b

-11.5

HBs: H-Ile101(O)

5. NCI_84100_b

-10.9

π-system with Pro216

6. NCI_84100_a

-10.9

HBs: H-Tyr233(OH)

7. NCI_116702

-10.8

HBs: Arg100(HE)-N

8. NCI_19990_a

-10.8

Hydrophobic contacts

9. NCI_227186_a

-10.7

10. NCI_227186_b

-10.7

HBs: Ser238(HN)-O, H-Thr53(O),
H-Asn103(OD1)
HBs: Ser238(HN)-O

Appendix 33. Interactions analysis for each ligand in VST4b in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

π-system with Tyr233

2. NCI_61610

-12.3

HBs: H-Glu99(O)

3. NCI_156219_b

-11.5

Hydrophobic contacts

4. NCI_308835

-11.0

Hydrophobic contacts

5. NCI_84100_a

-10.9

HBs: H-Tyr233(OH)

6. NCI_84100_b

-10.9

HBs: H-Tyr233(OH)

7. NCI_37553

-10.8

Hydrophobic contacts

8. NCI_116702

-10.8

HBs: Arg100(HE)-N

9. NCI_67436

-10.6

Hydrophobic contacts

10. NCI_227186_b

-10.6

HBs: Ser238(HN)-O
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Appendix 34. Interactions analysis for each ligand in VST5c in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

Hydrophobic contacts

2. NCI_61610

-12.3

HBs: H-Glu99(O)

3. NCI_37553

-11.7

Hydrophobic contacts

4. NCI_156219_b

-11.5

HBs: H-Pro192(O), H-Tyr51(O)

5. NCI_260594

-11.4

Hydrophobic contacts

6. NCI_308835

-11.1

Hydrophobic contacts

7. NCI_84100_a

-11.0

Hydrophobic contacts

8. NCI_84100_b

-10.9

Hydrophobic contacts

9. NCI_227186_a

-10.9

HBs: Tyr301(HH)-O, Asn103(HD22)-O

10. NCI_19990_a

-10.8

HBs: H-Tyr233(OH)

Appendix 35. Interactions analysis for each ligand in VST6d in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

Hydrophobic contacts

2. NCI_61610

-12.3

HBs: H-Glu99(O)

3. NCI_37553

-11.7

Hydrophobic contacts

4. NCI_156219_b

-11.5

HBs: H-Pro192(O), H-Ile101(O)

5. NCI_260594

-11.4

Hydrophobic contacts

6. NCI_308835

-11.4

Hydrophobic contacts

7. NCI_84100_a

-11.0

Hydrophobic contacts

8. NCI_84100_b

-10.9

Hydrophobic contacts

9. NCI_227186_a

-10.9

10. NCI_19990_a

-10.8

HBs: H-Thr53(O), Ser238(HN)-O, HAsn103(OD1)
Hydrophobic contacts
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Appendix 36. Interactions analysis for each ligand in VST7e in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

Hydrophobic contacts

2. NCI_61610

-12.3

HBs: H-Glu99(O)

3. NCI_37553

-11.7

Hydrophobic contacts

4. NCI_156219_b

-11.5

Hydrophobic contacts

5. NCI_260594

-11.5

Hydrophobic contacts

6. NCI_308835

-11.4

Hydrophobic contacts

7. NCI_84100_a

-11.0

Hydrophobic contacts

8. NCI_84100_b

-11.0

HBs: H-Glu50(OE2)

9. NCI_227186_a

-10.9

10. NCI_19990_a

-10.9

HBs: H-Thr53(O), Ser238(HN)-O,
Tyr301(HH)-O, Asn103(HD22)-O
Hydrophobic contacts

Appendix 37. Interactions analysis for each ligand in VST8f in the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.0

Hydrophobic contacts

2. NCI_37553

-11.7

Hydrophobic contacts

3. NCI_37553

-11.5

Hydrophobic contacts

4. NCI_156219_b

-11.4

Hydrophobic contacts

5. NCI_260594

-11.4

Hydrophobic contacts

6. NCI_308835

-10.9

7. NCI_84100_a

-10.8

HBs: H-Tyr233(OH), H-Thr53(O)

8. NCI_84100_b

-10.8

HBs: Arg247(HH21)-O

9. NCI_227186_a

-10.8

HBs: Arg100(HE)-N

10. NCI_19990_a

-10.7

HBs: Arg168(HH21)-O

HBs: Asn103(HD22)-O, Ser238(HN)-O,
Tyr301(HH)-O
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Appendix 38. Interactions analysis for each ligand in VST3a in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

π-system with Pro128, Pro129

2. NCI_37553

-11.5

Hydrophobic contacts

3. NCI_61610

-11.3

HBs: H-Pro128(O), Ile55(HN)-O

4. NCI_156219_b

-11.1

HBs: H-Glu50(OE2)

5. NCI_84100_a

-11.0

Hydrophobic contacts

6. NCI_7524_a

-10.9

HBs: Ser238(HN)-O

7. NCI_84100_b

-10.9

HBs: H-Asp43(OD2)

8. NCI_25457

-10.8

9. NCI_116702

-10.8

Hydrophobic contacts

10. NCI_122819

-10.7

Hydrophobic contacts

HBs: Thr53(HN)-O, Arg36(HH12)-O,
Lys52(HZ1)-O

Appendix 39. Interactions analysis for each ligand in VST4b in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_37553

-11.5

Hydrophobic contacts

3. NCI_61610

-11.4

π-stacking with Tyr390

4. NCI_156219_b

-11.1

HBs: H-Tyr51(O)

5. NCI_227186_b

-10.9

HBs: Ser238(HN)-O

6. NCI_84100_a

-10.9

Hydrophobic contacts

7. NCI_7524_a

-10.9

HBs: Arg36(HH11)-O, Thr53(HN)-O

8. NCI_84100_b

-10.9

Hydrophobic contacts

9. NCI_308835

-10.8

Hydrophobic contacts

10. NCI_116702

-10.8

Hydrophobic contacts
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Appendix 40. Interactions analysis for each ligand in VST5c in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_61610

-11.5

π-stacking with Tyr390

3. NCI_37553

-11.4

Hydrophobic contacts

4. NCI_156219_b

-11.1

5. NCI_84100_a

-11.0

Hydrophobic contacts

6. NCI_227186_b

-10.9

HBs: Ser238(HN)-O, H-Glu50(OE2)

7. NCI_7524_a

-10.9

8. NCI_84100_b

-10.9

HBs: H-Asp43(OD2)

9. NCI_308835

-10.8

Hydrophobic contacts

10. NCI_25457

-10.8

Hydrophobic contacts

HBs: H-Pro128(O), π-system with
His127

HBs: Arg36(HH11)-O, Thr53(HN)-O,
Lys52(HZ1)-O

Appendix 41. Interactions analysis for each ligand in VST6d in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_61610

-11.6

Hydrophobic contacts

3. NCI_37553

-11.4

Hydrophobic contacts

4. NCI_156219_b

-11.1

HBs: H-Glu50(OE2)

5. NCI_84100_a

-11.0

Hydrophobic contacts

6. NCI_84100_b

-10.9

7. NCI_7524_a

-10.9

HBs: Ser238(HN)-O

8. NCI_227186_b

-10.9

HBs: H-Asp43(OD2)

9. NCI_116702

-10.8

HBs: H-Glu50(OE2)

10. NCI_308835

-10.8

Hydrophobic contacts

HBs: Arg36(HH11)-O, Thr53(HN)-O,
Lys52(HZ1)-O, H-Tyr51(OH)
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Appendix 42. Interactions analysis for each ligand in VST7e in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_61610

-11.6

Hydrophobic contacts

3. NCI_37553

-11.5

Hydrophobic contacts

4. NCI_156219_b

-11.1

HBs: H-Pro128(O)

5. NCI_84100_a

-11.0

Hydrophobic contacts

6. NCI_84100_b

-10.9

HBs: H-Asp43(OD2)

7. NCI_7524_a

-10.9

8. NCI_227186_b

-10.9

HBs: Ser238(HN)-O, H-G;u50(OE2)

9. NCI_116702

-10.8

Hydrophobic contacts

10. NCI_308835

-10.8

Hydrophobic contacts

HBs: Arg36(HH11)-O, Thr53(HN)-O, HTyr51(OH)

Appendix 43. Interactions analysis for each ligand in VST8f in the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_37553

-11.5

Hydrophobic contacts

3. NCI_156219_b

-11.1

Hydrophobic contacts

4. NCI_25457

-10.8

Hydrophobic contacts

5. NCI_121868

-10.8

Hydrophobic contacts

6. NCI_308835

-10.8

Hydrophobic contacts

7. NCI_116702

-10.8

Hydrophobic contacts

8. NCI_122819

-10.7

9. NCI_156219

-10.7

HBs: Ile37(HN)-O, His230(HD1)-O

10. NCI_227186_b

-10.7

HBs: H-Ile55(O), Ser238(HN)-O

HBs: Val231(HN)-O, Ile37(HN)-O,
His230(HD1)-O
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Appendix 44. Interactions analysis for each ligand in VST1a in focused docking in
the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.1

Hydrophobic contacts

2. NCI_37553

-11.4

Hydrophobic contacts

3. NCI_156219_b

-11.3

HBs: H-Ile101(O)

4. NCI_19990_a

-10.9

HBs: H-Thr53(O)

5. NCI_84100_b

-10.8

Hydrophobic contacts

6. NCI_84100_a

-10.8

Hydrophobic contacts

7. NCI_116702

-10.7

HBs: Arg100(HE)-N

8. NCI_60785_b

-10.5

Hydrophobic contacts

9. NCI_308835

-10.5

Hydrophobic contacts

10. NCI_227186_b

-10.4

HBs: H-Thr53(O)

Appendix 45. Interactions analysis for each ligand in VST2a in focused docking in
the 3N40
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-11.4

HBs: Ile200(HN)-S

2. NCI_37641_b

-10.7

HBs: Arg168(HH21)-O

3. NCI_37553

-10.0

HBs: Arg168(HH22)-O

4. NCI_328101

-10.0

HBs: Arg168(HH21)-F

5. NCI_116702

-9.9

Hydrophobic contacts

6. NCI_37641_a

-9.9

HBs: H-Pro197(O), Arg168(HH21)-O

7. NCI_121868_a

-9.8

Hydrophobic contacts

8. NCI_308835

-9.7

HBs: Arg168(HH21)-O

9. NCI_24951_a

-9.5

HBs: O-Pro197(O)

10. NCI_127133

-9.5

Hydrophobic contacts
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Appendix 46. Interactions analysis for each ligand in VST1b in focused docking in
the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_293778

-13.7

Hydrophobic contacts

2. NCI_37553

-11.4

Hydrophobic contacts

3. NCI_61610

-11.3

HBs: H-Glu35(O)

4. NCI_25457

-10.8

Hydrophobic contacts

5. NCI_116702

-10.8

Hydrophobic contacts

6. NCI_308835

-10.7

Hydrophobic contacts

7. NCI_97920

-10.6

Hydrophobic contacts

8. NCI_7524_b

-10.4

Hydrophobic contacts

9. NCI_671136

-10.3

Hydrophobic contacts

10. NCI_84100_a

-10.2

Hydrophobic contacts

Appendix 47. Interactions analysis for each ligand in VST2b in focused docking in
the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_61610

-11.6

π-π interaction with Phe141

2. NCI_37553

-11.1

HBs: Arg144(HE)-O, H-Cys266(SG)

3. NCI_308835

-11.1

HBs: Arg104(HH12)-O

4. NCI_84100_b

-10.9

HBs: H-Asp43(OD2)

5. NCI_84100_a

-10.8

Hydrophobic contacts

6. NCI_82802

-10.7

Hydrophobic contacts

7. NCI_670283

-10.5

Hydrophobic contacts

8. NCI_7524_b

-10.4

HBs: Arg144(HE)-O

9. NCI_293778

-10.4

HBs: His142(HE2)-N

10. NCI_328101

-10.3

HBs: Arg267(HN)-F
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Appendix 48. Interactions analysis for each ligand in VST3b in focused docking in
the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_61610

-11.5

π-stacking with Phe312, Tyr15

2. NCI_293778

-11.0

π-stacking with Phe312, Tyr15

3. NCI_37553

-9.9

HBs: H-Gly12(O)

4. NCI_670283

-9.4

Hydrophobic contacts

5. NCI_332670

-9.4

Hydrophobic contacts

6. NCI_328101

-9.3

HBs: Lys16(HZ3)-F

7. NCI_60785_a

-9.2

Hydrophobic contacts

8. NCI_50648

-9.2

Hydrophobic contacts

9. NCI_60785_b

-9.2

Hydrophobic contacts

10. NCI_308835

-9.1

Hydrophobic contacts

Appendix 49. Interactions analysis for each ligand in VST4b in focused docking in
the 3N42
Compound

Binding affinity
(kcal/mol)

Interactions

1. NCI_121868_a

-10.7

HBs: Lys61(HZ2)-O

2. NCI_24951_b

-10.6

Hydrophobic contacts

3. NCI_24951_a

-10.2

HBs: Lys200(HZ2)-O

4. NCI_332186

-9.7

HBs: H-Tyr93(O)

5. NCI_332670

-9.6

Hydrophobic contacts

6. NCI_3391_a

-9.6

HBs: Lys61(HZ2)-O

7. NCI_80313

-9.5

HBs: Lys200(HZ2)-N

8. NCI_310326

-9.3

Hydrophobic contacts

9. NCI_645330

-9.3

Hydrophobic contacts

10. NCI_97920

-9.2

Hydrophobic contacts

220

